focus
impactCorporate Social Responsibility
Report 2021

Illumina

Patient

Community

Environment

PeopleIntegrity

We are dedicated to making a positive
impact on humanity, not just through ourtechnology, but through our actions.
By doing so, we aim to help shape a moresustainable and equitable future for all.

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

07

Focus on Illumina

15

Focus on Patient Access

27

Focus on Community

38

Focus on Environment

49

Focus on People

67

Focus on Integrity81

ESG Appendix

This report reflects upon the progress we have made, and is a lookto the future on our continued commitment to deepen our impact onhuman health by serving as a champion for patients, our people,
and our planet.
This is our second annual Corporate Social Responsibility Report,
which describes the evolution of our program from January 1, 2020
to December 31, 2020.

RECOGNITION 2020

America’s
Most Responsible
Companies2

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Message From Our CEO
Francis deSouza
In January 2020, the World HealthOrganization initiated an emergency
response to a notification from the Wuhan
Municipal Health Commission of a cluster ofviral pneumonia of unknown cause. By March,
we were in a global pandemic. For the firsttime in modern history, the whole world
was focused on solving a single problem.
The COVID-19 pandemic is a watershed
event of our time, straining health systems,
revealing unconscionable inequalities, andpermanently changing the way we workand live.
Throughout our history, Illumina’s relentless
focus has been to unlock the power of the
genome. At the intersection of biology andtechnology, genomics enables discoveries
that were unimaginable even a few years ago.
That has never been clearer than in responseto the global pandemic. The first SARS-CoV-2
genome was sequenced on an Illumina
sequencer in early January and a mere
42 days later, Moderna shipped the firstbatch of its messenger RNA vaccine,developed from that viral genome data.
Genomic technology has been on the front
lines of diagnostics, research, vaccines,
therapy development, and surveillance.
Genomic research has given valuable insights
into COVID-19 susceptibility and precision
treatments. Genomic surveillance has
detected SARS-CoV-2 variants developing
around the world.

In addition to scientific highlights, we
added exciting business acquisitions andstrategic partnerships to our portfolio.

Access to genomics is advanced throughphilanthropy efforts, expanded insurance
coverage, and education.

Illumina acquired Enancio and BlueBee tofurther expand our informatic and datacompression capabilities. Our partnershipwith Roche will bring accelerated availabilityof Next-Generation Sequencing (NGS)-basedin vitro diagnostic tests. This partnership will
also include collaboration to complement ourcomprehensive pan-cancer therapy selection
assay TruSight Oncology 500 (TSO500) withnew companion diagnostic claims.

Our philanthropic contributions to accelerateaccess and increase the diversity of genomic
data represented included a $20 million
commitment to support the Africa Centres
for Disease Control and Prevention (CDC)
launching the Africa Pathogen Genomics
Initiative. We saw expanded insurance
coverage and broadened access in the US
when the American College of Obstetricians
and Gynecologists recommended NonInvasive Prenatal Testing be made available
to all pregnant women, regardless of maternal
age or baseline risk.

In 2019, we aligned our Corporate Social
Responsibility (CSR) strategy to reflect ashared value approach that creates lasting
impact for both our company and society.
As good corporate citizens, we do businessin a way that reflects the very best of Illumina
and honors the trust that our employees,
patients, customers, community, andshareholders put in us. We remain focused on
supporting the United Nations Sustainable
Development Goals (SDGs) and on measuring
our impact with transparency.
Our CSR focus areas include: Accessto Genomics, Our Community, andEnvironmental Sustainability, which are
underpinned by the foundational pillars of Our
People and Our Integrity.

Continued on next pageThe opportunities to drive
the progress of genomics
and make it more
impactful for patients,
our communities, and ourplanet are boundless.”3

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

4

Message From Our CEO continued
Sustainability to reduce the environmental
footprint of our facilities, our supply chain,and our products.
We recognize the links between thehealth of our planet and the health ofhumanity. Our work on climate action
continued with energy-reduction initiatives
and increased renewables. Our transition
to more sustainable packaging and new
products, such as the ambient ship flow cell,
enabled improved recycling of sequencing
cartridges and was very well received
by customers.
Empowering our community to quickly
respond to the pandemic, natural disasters,
and racial inequality demonstrated our
corporate citizenship.
2020 provided the opportunity to put
our corporate citizenship into action. We
supported the global community with over
$10.5 million in charitable donations related to
COVID-19 response from in-kind donations,direct giving, and the Illumina Corporate
Foundation. We launched the Illumina
Genomics Discoveries STEM education
initiative and invested $500,000 in a new
nonprofit that will target increasing diversity
in STEM in San Diego. Our employees
continued to give back by adjusting theirvolunteer efforts virtually and giving tophilanthropic causes.

Illumina is committed to taking further actions
to drive diversity, inclusion, and respect for
all—principles which have always been partof Illumina’s DNA. Our response to racialinequalities included almost $1 million incharitable contributions. This year, I joined
over 1,500 other CEOs in the pledge to act
on supporting a more diverse and inclusive
workplace for employees. In addition, we
created a new role and hired a Vice President
dedicated to Diversity and Inclusion.
While the pandemic brought suffering andtrauma around the globe and exposed major
global healthcare issues, it also inspired us.
Despite the challenges of 2020, I am
optimistic about the opportunity to harness
the positive impact of science, technology,
and the unprecedented possibilities thatcan be brought to life through genomics.
I am inspired by the selfless dedication ofhealthcare professionals, frontline essential
workers, scientists, and researchers
around the world. When we collaborate
across borders and industries, we seea radical acceleration of science andtechnologies—from years to months
and weeks.

In this, our second CSR report, we
will share progress toward our 2030
targets and reflect on our achievements
and opportunities.

The opportunities to drive the progress ofgenomics and make it more impactful forpatients, our communities, and our planet
are boundless.

It is my pleasure to introduce the second
Illumina Corporate Social Responsibility
Report. It reflects the ways in which wehave worked to positively impact the lives ofpatients, our employees, our communities,
and the planet during this challenging year.

In this report, you will see the data andexamples that describe our approach tofulfilling that aspiration. We will continue
to strive to be the best employer, thebest environmental steward, and the best
corporate citizen we can possibly be.

In 2020, we received recognition from the
Dow Jones Sustainability Indices, Bloomberg
Gender-Equality Index, HRC Corporate
Equality Index, Most Just Companies,
America’s Most Responsible Companies, and
FTSE4Good to name a few.

Many thanks to our employees for helping
Illumina thrive, and for tirelessly working
to unlock the power of the genome toimprove human health, especially during thisunprecedented year. I am optimistic about theopportunity to rebuild and define the world
we want to live in.

Recognizing increased interest fromour stakeholders about climate change
management and material links toour business, we have expanded
the frameworks of reference for our
CSR reporting.
In addition to our current application of
the Global Reporting Initiative, we have
expanded our disclosure to be in line withthe recommendations of the Task Forceon Climate-related Financial Disclosures
and with the Sustainable AccountingStandards Board.

Francis deSouza, CEOIllumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

52020 Highlights
Focus on Patient Access
We Break Through Barriers

Achieved another milestone
toward our goal of the$100 genome, with therelease of the NovaSeqTM
6000 v1.5 Reagent Kit
Contributions from theIllumina iHope Network
continued to provide wholegenome sequencing tounderserved families
Committed $20 million overfour years to help launch the
Africa Pathogen Genomics
Initiative (APGI), expanding
genomics-based publichealth pathogen surveillance
Non-Invasive Prenatal Testing(NIPT) was recommended
to be offered to all pregnant
women, regardless ofmaternal age or baselinerisk, by the American
College of Obstetricians
and Gynecologists (ACOG),
helping to expand coverageand broaden access

Focus on Community
We Are Stronger Together

Illumina, Inc. and the Illumina
Corporate Foundation
made donations totaling$13.8 million
Over 195,000 teachersand students participatedin our STEM Education
and Genomic Literacy
programming withemphasis on support forunderrepresented minorities
Our COVID-related
philanthropy directed over
$10.5 million (see Tackling
COVID-19)

Focus on Environment
We Tread Carefully

Reduced electricity
consumption by 23,228 MWh
Increased use of renewablesolar power by 113%
from baseline
Launched three
innovative sustainable
packaging initiatives

Focus on People

We Nurture a Culture of Care

Focus on Integrity

We Do Business Responsibly

Employee pulse survey
reported 94% are proud
to work at Illumina

100% of our employees
certified to our Codeof Conduct

Number of women in leaderroles has increased 13%
over three years in the UK
and globally the number ofwomen in senior leader roles
has increased 5%

Code of Conduct andSupplier Code of Conduct
updated to reflect ouradvancing CSR commitments
and supplier expectations

Maintained a zero net
pay gap again for 2020
reporting yearIllumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Tackling COVID-19
When COVID-19 hit, Illumina
reacted quickly, offering support
for our people, our customers,
and our communities.

Employee Support
Provided funding, ergonomic
equipment and training for
remote working
Distributed $1,000 COVID Carecash allowances to help addressunanticipated financial needs
Maintained full workforce with zero
furloughs or COVID-related reductions
Provided pay continuity for
employees self-isolating
Offered flexible and remote work
Increased emergency and back-up
childcare program offerings
Offered paid leave for employees
under our Compassion andCare Time Off (CCTO) program
Implemented on-site
safety enhancements
Expanded paid time off withadditional week for on-site hourly
production teams

Customer Support
Our technology helped power the
heroes working around the globe toprovide diagnostic support, tracktransmission, conduct surveillance,and develop vaccines
Worked closely with supply chain
to prevent delays, and provided
sustained support for customer
essential services
Collaborated financially and in
partnership with research-related
efforts across the globe to better
understand the pandemic

Community Support
Addressed the greater good aroundthe world through collaborations,partnerships and philanthropy
Donated a total of $10.5 million
through in-kind products, direct
grants, employee giving andmatched contributions
Offered more than 40 global
virtual volunteer opportunities
Illumina teams came together tocreate personal protective equipment(PPE), including plexiglass shields forfrontline healthcare workers using
Illumina 3D printing machines,
and formulation of hand sanitizers
for donation
Employees volunteered their time tocontinue connecting virtually withstudents around the world6Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

what we do …
and why we
do it
From diagnosing rare disease to understanding
biodiversity in our ecosystems, we are helping to
unlock the power of the genome.

Focus on Illumina
In this section:
08
09
10
11
12
13
14

Q&A With Our Chief Financial Officer
About Illumina
Illumina At a Glance
Business Overview
CSR Framework and Governance
Our Strategy: Creating Unique Impact
Connecting CSR to Our Business7

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

8

Q&A With Sam Samad
Chief Financial Officer

Stewardship of our fiduciary
responsibility includes a strongemphasis on managing risk,
driving performance, and ensuringbusiness integrity. CSR provides
a lens through which to evaluatebusiness opportunities and toensure decisions benefit all our
stakeholders—not just investors,
but also employees, customers,
suppliers, the environment, and thecommunities in which operate.”

Q. What kind of feedback did you receivefrom the inaugural CSR Report?

Q. How has this feedback influenced
your follow-up report?

Q. How has the pandemic affected
Illumina’s portfolio?

A. The feedback was very positive. We
initially chose the Global Reporting Initiative(GRI) as our reporting framework because
it was the most comprehensive. We felt
this would appeal to the variety of our
stakeholders, facilitating data transparency
and enabling us to share the stories that bringour program to life for reviewers.

A. We have expanded our reporting
framework to include GRI plus therecommendations from the Sustainability
Accounting Standards Board (SASB) andthe Task Force on Climate-related Financial
Disclosures (TCFD). We believe thisapproach will enable us to further provide
an integrated, comprehensive view of ouractivities and our progress on commitments
related to sustainability, climate action, andsocial responsibility.

A. There is much to be optimistic about inthe global recovery path and the role ofgenomics in general. While some labs are still
not operating at their pre-pandemic levels,
we see very positive signs that our businessis trending in the right direction. We saw afaster recovery than expected, in both clinicaland research customers, leading to a strong
rebound in our business by the second halfof the year.

We heard from our investor community that
we could go into greater detail about thepotential financial impacts of sustainability
on our business and how we assessed
opportunities and risk associated withclimate change.

We recognize that stewardship of our
fiduciary responsibility includes a strongemphasis on managing risk, driving
performance, and ensuring business integrity.
CSR provides a lens through which toevaluate business opportunities and to ensure
decisions benefit all our stakeholders—not
just investors, but also employees, customers,
suppliers, the environment, and thecommunities in which we operate.

Despite the many challenges of 2020,
we still had several ground-breaking
activities. We launched NextSeqTM 2000
and NextSeqTM 1000, as well as theP3 flow cells. In addition, we rolled out
the NovaSeqTM 1.5 reagents, and launched
COVIDSeqTM, the first NGS-based test toreceive Emergency Use Authorization (EUA)
from the FDA. Our research and development(R&D) investments grew both sequentiallyand year-over-year.
We contributed to some remarkable scientificand medical genomic breakthroughs thisyear, and witnessed continued adoptionof NGS in cancer treatment. We also saw
expanded coverage and access to NIPT for
all pregnant women, regardless of risk. Finally,
there is a greater appreciation of the need forgenomic surveillance of COVID-19 for tracking
the emergence of new strains and raised
awareness of the critical role sequencing canplay with infectious disease. I am confident
that our portfolio is stronger than ever.

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

About Illumina
We aim to drive progress inthe transformative power ofgenomics for all.
We are an applied genomics technology
company and the global leader in DNA
sequencing and array-based technologies.
At the intersection of biology and technology,
genomics is having a transformative effectacross everything from healthcare andsustainable agriculture to data storage.
Our first products enabled researchers
to explore DNA on an entirely new scale.
This helped to create the first map of genevariations associated with health, disease,and drug response. This set the groundworkfor many other discoveries in the future.

OUR MISSION:

Improve
Human Healthby Unlocking thePower of the
GenomeWe are striving to continue opening up
unprecedented access to the incredible
potential of genomics. During the first chapter
of genomics, we pioneered technology thathas the capacity to see into the genome.
Since then, we have endeavored to makethe genome more accessible to ensure thatthe extraordinary potential of these scientificbreakthroughs has a truly global reach.

OUR VALUES

Illumina is ready to embark on the next
chapter of genomic applications. This will
involve further empowering our partners
and helping them to predict and prevent a
wider range of diseases, making personalized
medicine a reality.

Innovation isin our DNA

With progress in this field, we believe
genomic advances should be applied
responsibly, diligently, and, above
all, ethically.
Urgency is paramount. Today’s discoveries
offer new treatments and fresh hope tothe patients of tomorrow. We are working
tirelessly to create the leading-edge
technology required to enable clinicians
and researchers to not only understand the
genome, but also fully tap into its power.

We are relentlessin the creation ofgreat products

We move fast andembrace change

We collaborate
deeplyWe areopen

WHO WE SERVE
Our focus is helping professionals in the fields of:Genetic
healthOncology

Research

Reproductive
healthAgriculture

Population
genomics

Direct-toconsumer
products

9Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Illumina At a Glance
2020

$3.2B
revenue

Headquarters
San Diego, CA

100%

employees
certified to
Code of Conduct

7,828

employees 43% women 57% men

OUR LOCATIONS

850

Americas
Baltimore, MD, USA 4
Foster City, CA, USA 3, 4, 6
Hayward, CA, USA 2, 4
Madison, WI, USA 2, 4, 6
San Diego, CA, USA 1, 2, 3, 4, 5, 6
São Paulo, Brazil 4

iHope cases$681M
R&D investment

21%of revenue$13.8M
donated64

average hours training
per person per year

EMEA
Berlin, Germany 4
Cambridge, UK 4, 5, 6
Eindhoven, Netherlands 4, 5
Evry, France 4
Mechelen, Belgium 4
Moscow, Russia 4
Rennes, France 4

1 Headquarters, 2 Manufacturing, 3 Clinical, 4 Commercial, 5 Distribution Center, 6 R&D

17,000active sequencing
systems installed

7,300

global customers

Greater China
Beijing, China 4
Shanghai, China 4
Asia Pacific
Melbourne, Australia 4
Osaka, Japan 4
Seoul, South Korea 4
Singapore 2, 4, 5, 6
Tokyo, Japan 4

10Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Business Overview

Illumina Corporate Social Responsibility Report 2021

OUR SEQUENCING INSTRUMENTS
We are striving to advance genomics through purposeful innovation

Illumina revenue comprises:
Consumables, Instruments, and Service & OtherLOW THROUGHPUT

FY20 Revenue

FY16

$2.3B
$2.7B

FY17

iSeqTM

FY18

MiniSeqTM

MiSeqTM

MiSeq DxTM

$3.3B

FY19

MID THROUGHPUT$3.5B$3.2B 8% 5-year CAGR

FY20

14% 10-year CAGR

71%

16%

13%

Consumables
These include library prep andproprietary sequencing kits,such as flow cells andreagents, for our sequencing
and microarray instruments.

Service & Other
We provide warranties andmaintenance contracts for oursystems, and undertake services
at our in-house labs. Furthermore,
we receive revenue from
intellectual property (IP) fees,in vitro diagnostic (IVD) licensing
and milestones, and informatics.

Instruments
Our range of sequencing
systems spans the full range
of applications. In addition, weoffer a microarray instrument tosupport genotyping.

NextSeqTM 550

NextSeqTM 550Dx

NextSeqTM 1000 & 2000

HIGH THROUGHPUT

NovaSeqTM is a major leap in termsof output capacity and reducing
the cost per read.”
Thomas Volkert, Genome Coreat Whitehead Institute

NovaSeq

TM

Links to Proxy statement, 10-K Report, and Illumina Source Book

6000

1st

sequencer to exceed$1 billion annual revenue

11Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

CSR Framework and Governance
At Illumina, CSR is governed at the executive level with the Board of
Directors and is increasingly embedded into all areas of our business.

CSR LEADERSHIP

Board
of Directors

CEO & CEOStaff
The Board provides oversight and receives
updates on current performance andfuture strategic plans at least annually(or more frequently if material changes
occur). The complete Board of Directors
provides guidance and direction on
environmental, social, and governance issues
and opportunities that have potential impact
on reputation and long-term economic
viability, including climate action.
Illumina’s Executive CSR Steering
Committee, chaired by the Chief Financial
Officer (CFO), is comprised of a teamof senior leaders drawn from across theorganization that provide guidance on
strategic plans, and review progress on aquarterly basis.

The CSR Functional Group reports directly
to the CFO. The Functional Group is
responsible for program management,
recommendations for program evolution,and program reporting. The CSR programs
are embedded into our business throughseveral supporting working groups,
including the Diversity & Inclusion Council;
Environment, Health & Safety Steering
Committee; Quality Council; Public Policy
Committee; Illumina Cares Champions;Sustainability Green Teams; and employee
resource groups (ERGs).
Giving governance for Illumina, Inc. is led
by the Corporate Citizenship Steering
Committee. Giving from our nonprofit entity
the Illumina Corporate Foundation is led
by senior leaders including the CEO, CFO,
General Counsel, Chief Medical Officer,
and Chief People Officer.

CSR Executive Steering
Committee

CSR FunctionalGroup

Supporting CSR Working
Groups & Related Teams

GivingGovernance12Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

13

Our Strategy: Creating Unique Impact
We invest in sustainable solutions
across our facilities, supply chain,and products.

We strive to remove barriersof access and increase
representation of global
diversity to expand thetransformative benefits ofgenomics for all.

R
r CS

s Are
as

Empower
Our Communities

y

ss

to

Ou

no

rC

mic

SR Focus AreassEm

u n i ti e s
rC

Ou

ce

Ge

We share our time, talent,
and technology with thecommunities where we live
and work.

om mDeepening our impact
on human health byserving as a champion
for patients, thecommunity, andour planete l e r a t e Ac

We support the 17 United Nations Sustainable
Development Goals (SDGs). Our priorities andtargets are aligned to focus on the sevengoals we can most uniquely impact:Ou

Our CSR
VisionAc c

We have identified three focus areas
for our CSR activities: Accelerating Accessto Genomics, Empowering Our Communities,
and Environmental Sustainability. These
are underpinned by Our People, andGovernance & Ethics.

nv

ental Sustaina
nm
bil
o
ir
it
Focu

er

We are dedicated to positively impacting
humanity through both our technology
and actions.

Environmental Sustainability

Accelerate Accessto Genomics

E

Our CSR strategy focuses on
our most significant and material
issues, our stakeholders, andthe areas where we can uniquely
impact the global community.

pow

Governance & Ethics

ur

Et

hi

O

cs

Our People

We cultivate an agile,
innovative workplace,and a culture fueled bycollaboration, diversity,
inclusion, and fairness.

Pe

op

le

Sup

p or ted by

two foundational ele

men

ts

rn
ve
Go

an

ce

&

We align our businessprinciples with our core values,
ethical responsibilities, andlegal obligations.

GUIDING PRINCIPLE
We believe that pursuing our mission to improve human health extends beyond bringing innovative technologies to market.
We have a responsibility to ensure that everyone can benefit from unlocking the power of the genome.
It is in our DNA to lead with sustainable, responsible, and proactive corporate citizenship.

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Connecting CSR to Our BusinessTo inform our CSR strategy, we engaged with a wide rangeof stakeholders. Our internal engagement encompassed allorganizational levels, while our external engagement included
representatives from global, national, and local interests.

Materiality Assessment
We assessed our material issues on the importance to our businessand the ability to create impact across the categories of:Environment Community Product Employee Governance

Co
pa m
rt

Em
pl

s

Suppliers

Philanthropy

ity
un
m ers
n

ee
oy

re
lthca
Hea v i d e r sorpVolunteerism

Genomic Literacy
STEM Education

Data Privacy
and Securitynnel
C ha n e rs
t
p ar

Custo
mer
s

Waste Minimization

ut or

CSR
groupeerps

Distrib

We engagewith a wide rangeof stakeholders

Diversity and Inclusion

Employee Safety

Water Management

 roduction
P
and Packaging

Transparency

Sourcing

Delivery

Employee Engagement

Equitable Rewards

Product Design
and Development

its

Product Quality

pr
of

s

G
an overnm
d reegulat nt
io ns

tr y
Ind us rs
d
a
le e

No

n

This report is aligned with the following industry
benchmarks and reporting frameworks:
Dow Jones Sustainability Indices; CDP; Gender-Equality Index;
Corporate Equality Index; GRI; SDGs; UN Global Compact; SASB; TCFD;
Science Based Targets initiative (SBTi) methodology; ISO 14001 and ISO 45001

Ability to Create Impact

s
ve
In

Pro Bono Genomic
Testing for Patients

Energy ManagementstorCorporate Ethics
and ComplianceGovernanceHealth andLifestyle Benefits

Importance to Illumina BusinessNote: In this report, we use the terms “material” and “materiality” to refer to topics that reflect Illumina’s meaningful environmental, social, and governanceimpact. The use of such terms shall not be deemed to constitute an admission as to the materiality of any information in this report for purposes of applicablesecurities laws or any other laws of the United States, nor are we using them as they are used in the context of financial statements and financial reporting.

14

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

webreak throughbarriers
Focus on Patient AccessIn this section:
16	Q&A With Our Chief Medical Officer
17
Focus on Access to Genomics: Overview
18
Enabling Innovation
19
Bringing Hope to Patients
20
Championing Patients
21
Creating an Impact
22
Expanding Genomic Literacy
23
Catalyzing Genomics Startups
24
Nurturing the Genomics Ecosystem
26
Magnifying Impact Through Partnerships

We are relentless in our pursuit to improve human health.
We recognize that a key component of our work ismaking genomic technology more accessible to people
and places around the world. Through our programs andpartnerships, we aim to remove barriers of access andincrease equity of representation to expand the benefitsof genomics for all.

15

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

16

Q&A With Phil Febbo, MD
Chief Medical Officer
Q: How has Next-Generation Sequencing(NGS) played a role in COVID-19?
A: NGS has played a critical role ineverything from identification of the virus
to understanding transmission routes, viralmutation rates, and genome evolution, andhas served as a foundation for vaccine
development and therapies. NGS is a criticalpart of predicting and preventing future
outbreaks. One of the primary advantages
NGS provides over other methods of analysis
is that it is an effective and high-throughput
solution for screening multiple samples
and detecting viruses and other pathogens
without prior knowledge of an infectious
agent. Once an organism is identified, NGS
workflows can be used to detect a pathogen,perform surveillance and epidemiologicalstudies, track mutational changes in thepathogen’s genome, enable unbiased
discovery of co-infections, and analyze
potential susceptibility and human response
to infection.
Five main ways sequencing-based surveillancehas been used to fight SARS-CoV-2 are:1. Identified the virus causing the respiratory
illnesses in Wuhan, China
2. Tracks transmission routes globally
3. Determines how quickly the virus isadapting as it spreads
4. Identifies host genetics associated withsevere disease
5. Guides repurposing and/or developmentof effective therapies and vaccine

Q: What lessons from COVID-19 can beapplied to the future of infectious disease
and NGS or genomics in general?
A: NGS is contributing significantly to theglobal response to SARS-CoV-2 and will help
the world to prepare for future pandemics.
The COVID-19 pandemic has underscored theneed for tools to detect and monitor emerging
pathogens like SARS-CoV-2. We saw the useof sequencing to resolve epidemiologicaluncertainties by linking ambiguous caseswith established transmission pathways
and separate local transmission events fromthose that were imported from a different
region. In addition, we simply would not haveeffective and authorized vaccines without thewidespread use of NGS.
We know the routine use of genomics will bea required part of global surveillance systems
to spot potential threats earlier and faster.
These systems require local capabilities
to collect and analyze samples as well asmechanisms to aggregate pathogen genomes
across national boundaries to rapidly identify
emerging threats.
This pandemic has highlighted the increased
threat of infectious disease in a world thatis so interconnected. Genomics can help
us respond faster and more efficiently, andleverage the strength of working together.

Q: How has Illumina’s approach toincreasing access evolved in 2020?
A: On several levels, 2020 has further
highlighted the inequities of vulnerable
populations, underrepresented groups andgeographies. There are still tremendous
gaps in access to genomic technology,
personalized medicine, and evenrepresentative data to understand genomes
in the context of global diversity. While
we are working to increase access togenomics through innovation, education for
healthcare professionals, and collaborations
to improve market access, we are also
focused on removing barriers through ourphilanthropic contributions.
COVID-19 added challenges for the alreadyvulnerable population of children and theirfamilies seeking help for undiagnosed andrare disease. We continued to support
patients through iHope this year, and added aclinic in Africa to the network. We are hopefulthat as we recover from the pandemic, we
can continue to grow the number of patients
we can impact with this program.
We grew our philanthropic program tomagnify our impact supporting projects
around the globe that are enabling
broader access and more equitable
representation, such as the New YorkGenome Center Polyethnic-1000 project,
the GINGER fellowship at the Broad
Institute, and the launch of the Africa
Pathogen Genomics Initiative (APGI).
We will continue to seek opportunities
to champion patients and access.

NGS has played a critical role ineverything from identificationof the virus to understandingtransmission routes, viral mutation
rates, and genome evolution,and has served as a foundationfor vaccine development andtherapies. NGS is a critical partof predicting and preventing
future outbreaks.”

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

17

Focus on Access to Genomics: Overview
Our Commitment

Our Objectives

Our Why

We are committed to drive
positive progress in genomics
for the benefit of all.

We aim to remove barriers of accessand increase equity of representation
to expand the transformative benefitsof genomics for all through:

There is urgency to our mission because
we understand that today’s discoveries havethe potential to help tomorrow’s patients.
We recognize that our efforts to improve
human health can be magnified if all
people and places have access togenomic technology.

 nabling innovation and reducingE
the cost per genome
In progress

Bringing hope through philanthropic
efforts and patient support
In progress

Expanding genomic literacy
In progress

Catalyzing the creation of
breakthrough genomics startups
In progress urturing the genomic ecosystemNthrough community collaborations,market access efforts, and partnerships
In progress

Genomics is a transformational field of
science. Having been integrated into clinicalpractice at a faster rate than almost any
innovation in the history of medicine, it istoday creating a path toward personalized
medicine and inspiring hope worldwide.
This implementation has, however, been
almost entirely restricted to more developed
nations. There is a vital need to makegenomic technology and precision medicine
available to all, regardless of their social
status, income, or geographic location.
To ensure that genomes can be interpreted in
the appropriate context of global diversity, we
aim to increase the equity of representation in
genomic data.

Cutting-edge technologies help patients tobe diagnosed quicker and more accurately.
This reduces the delay, which is often
referred to as a “diagnostic odyssey.” While
we are driving down the cost of sequencing
with innovation and advocating for increased
coverage and reimbursement througheducation, obstacles still exist in terms ofvarying adoption rates around the globe.
Through innovation, philanthropy, education,and collaboration, we will break down barriersand continue to seek new ways to drive
progress in the adoption of genomics for all.

Achievements in 2020
$600 genome
28 philanthropic clinical iHope
network sites$20M committed to help launch
the Africa Pathogen Genomics
Initiative (APGI) with Africa CDC
23 professional healthcare
education programs launched

Early stages
In progress
Achieved and continuingIllumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Enabling Innovation
The Human Genome Project:
Enabling Innovation
Thirty years ago, the Human Genome
Project sparked a revolution in technology
and genomic understanding that continues
to advance at great speed. The project hasgiven us profound insights into biology bydemonstrating that everyone has virtually
identical genomes, and has become anincredible tool for understanding thesignificance of even the smallest variationsin individuals’ DNA.
The genomics revolution has enabled theuse of Non-Invasive Prenatal Testing (NIPT)
and helped thousands of patients with raredisease receive a diagnosis in weeks rather
than years. Research is continuing to help
us learn more about human health, to better
understand the population and biomes inwhich we live, and to provide insights that
improve our understanding about how we canutilize the world’s natural resources in a moresustainable way.
Thousands of scientists worked for decades
to sequence the first genome. Today, thanks
to the power, efficiency, and throughput of
our NovaSeqTM sequencing systems, thesame feat can be accomplished in a day, andat a fraction of the original cost.

In 2003, The Human Genome Projectcompleted a composite sequence of thefull human genome at a cost of almost$3 billion. Since then, the cost to decodea genome has been decreasing fast—from
hundreds of thousands of dollars per person
to approximately $1,000 in 2014. In 2017,
we launched the NovaSeqTM and madesignificant progress toward realizing the$100 genome. This year, another significant
step forward was achieved with the releaseof the NovaSeqTM 6000 v1.5 Reagent
Kit, which further reduced the cost to$600 per genome.
We are proud that Illumina’s technology is
helping scientists to make major discoveries
by enabling whole genome sequencing to beaccessible and affordable for labs of all sizes.
Our pioneering technology and leading-edge
advancements have allowed researchers touncover the genome’s potential, enabling
life-impacting science on everything fromCOVID-19 and infectious disease to cancer
and sustainable agriculture.
We will continue to innovate and develop
technology that provides unprecedented
access to the genome, with more dataprocessing power, more efficiency, andgreater affordability.

The Human Genome Project
was a unique opportunity tointerrogate life’s software:DNA. It was a legacy projectthat will continue to light theway for generations to come.
At Illumina, we have the greathonor of continuing that legacy,
providing new insights into thegenetic code, which are having
a profound impact on scientificresearch and healthcare.”

COST PER GENOME
2003$3,000,000,000

2006$20,000,000

2007$2,000,000

2008$200,0002010$10,000

Susan Tousi, SVP,
Chief Product Officer

2014$1,000

Launch of our NovaSeqTM
6000 v1.5 Reagent Kit

2020

$600

$100

18

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Bringing Hope to Patients
iHope is a philanthropic
consortium that provides
whole genome sequencing tounderserved families aroundthe globe.
Over 350 million people worldwide have agenetic disease; more than half of thoseaffected are young people. Families ofchildren with undiagnosed genetic diseases
often face an uncertain and unpredictable
future. These diagnostic odysseys averageseven years and often include multiple
inconclusive tests, surgeries, and procedures.
The iHope Program was created in2017, bringing together a wide range oforganizations from around the world. Its aim
is twofold: to shorten the diagnostic odyssey;
and to inspire hope by increasing access togenomics for all.
iHope website

28

iHope clinical sites worldwide>850

patients since program inception

250

iHope patients in 2020

400

iHope patient 2021 target

40%–70%patients who receive
a diagnosis after cWGS

50+%

change managementthat occured after cWGS

We have a moral imperative to remove barriers of access andhelp find solutions for those in need. The global health inequities
highlighted in 2020 only served to magnify the urgency of bringing
the power of genomic testing to all in need.”
Ryan Taft, VP Scientific Research

OUR STORIES OF IMPACT

LIFE-CHANGING TREATMENT THROUGH cWGS IN PERU
Eleven-year-old José was referred to the iHope Program by the Instituto Nacional deCiencias Neurológicas in Peru due to early onset movements in his arms and legs, whichcaused pain and cramping, greatly limiting his ability to walk and perform daily activities.
After having received normal brain MRI and muscle biopsy results, Jose’s clinical teamdiagnosed him as suffering from generalized dystonia. He was then put on a course ofa central nervous system muscle relaxant called Baclofen, which unfortunately brought
no relief.
Jose’s DNA sample was submitted to the Illumina Clinical Services team for clinicalwhole genome sequencing (cWGS), which revealed an anomaly that impacted a numberof genes. Following the return of the result, Jose was referred to a neurologist andplaced on low doses of a levodopa/decarboxylase inhibitor. In addition, his family was
also counseled about the respective reproductive screening and testing options thatwere available.
The confirmation of diagnosis afforded by cWGS was highly successful from a clinicalperspective, and has proved life changing for Jose, who has since experienced a
90% reduction in debilitating movements thanks to the iHope Program.

19

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Championing PatientsOUR STORIES OF IMPACT

Watch film

Patient Ambassador Program
The Rare and Undiagnosed Genetic Disease(RUGD) Patient Ambassadors are a coalitionof patients and family members dedicatedto increasing awareness of the importanceof early detection of rare disease throughgenetic testing.
Connecting families to a wider community ofpeople with similar experiences helps provide
support and strength during the search
for a diagnosis, and can improve care andmanagement. By sharing personal stories
about their rare disease journey, the groupis able to educate and motivate an entire
ecosystem of support.

These families are empoweredto help others in theircommunity find answers
through genomic testing.”
Carolyn Dumond, Patient Ambassador
Program Manager

Watch filmAward-Winning Short Film:
Journey of Hope
Journey of Hope is a short film createdby not-for-profit Same but Different incollaboration with Illumina. It offers a touching
glimpse into the lives of rare disease patientsand their families. Meet children, like Iggy,
who often receive a rare genomic diagnosis
after many years of not knowing what waswrong, or what treatment was needed.
The film highlights the reality of the search
for a diagnosis, the impact of the diagnostic
moment, and how the power of genomics
provides a different kind of hope for hundredsof millions of people worldwide.

To be heard, and for Iggy to
be seen, was empoweringand therapeutic—and scary,as absolutely our raw truth isout there.”
Sarah, Iggy’s Mom

LOVE AND CARE IS NEVER RARE:A MESSAGE OF HOPE FOR THE RARE DISEASE COMMUNITY DURING COVID-19
Patients are a constant source of inspiration to fulfill our mission to unlock the power ofthe genome, and this sense of purpose has only increased during the pandemic. Illumina
recognizes the added challenges COVID-19 has presented to those in the vulnerable raredisease community. We continue to advocate for the best clinical care for patients acrossthe globe in these unprecedented times, actively engaging with medical organizations
and governments to ensure that the rare disease community has not only hope but alsoa voice.
Even at times of great challenge and sadness during a global pandemic, unexpected
moments of optimism still exist. From individuals to communities, from companies
to countries, people are finding ways to support one another and address the
pandemic together. We as a company have been very active: working tirelessly todevelop technology that will support sequencing-based surveillance capabilities andempower public health officials as they track the disease and raise funds for raredisease organizations.
Learn more.

20

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Creating an Impact
Our philanthropic efforts
associated with accelerating
access to genomics include
removing financial barriers andsupporting efforts to increase
the diversity of data.
These are ensuring a more equitable
representation of our global population,
and would mean that genomes can beinterpreted in the appropriate context ofglobal diversity.

Magnifying Our Impact byEmpowering More Equitable Access
Democratizing sequencing can enablefamilies, communities, and whole countries
to harness the benefits of Next-Generation
Sequencing (NGS).
In geographies where specialists are limited
and clinical resources sparse, there is animperative to close the genomic medicine
gap, and advance to next-generation care.
In addition to our philanthropic cWGS program
iHope, we offer charitable contributions toorganizations that are working to accelerateaccess to genomics. By doing so we canhelp to expand the genomics infrastructurein underserved areas, and support thediversification of data.

Support for Polyethnic Project to Study
Inequities in Underserved Populations
Illumina, Inc. donated $2.4 million of in-kindproduct to support research at the New YorkGenome Center’s Polyethnic-1000 project.
Researchers will collaborate with academic
health centers and community hospitals in
the New York City area to recruit patientsand perform whole-genome and RNA
sequencing on cancers and normal tissues.
This will help to identify differences between
ethnicities that may account for disparities
in occurrence, response to treatment, andsurvival for different cancer types. The
program is designed to study cancer careinequities in underserved populations,with the objective of democratizing andbroadening access to the power and potentialof cancer therapies.
Funding for Research on the Barriers ofAccess and Challenges of Diagnosis
The Illumina Corporate Foundation provided
a $50,000 grant to the nonprofit Global Genes
to support its research into understanding
the diagnosis landscape for underserved
communities, and, by determining resource
needs, help mitigate barriers and reducetime to diagnosis.

Enabling Genomics Across Africa
The African genome is the oldest humangenome, with Africa containing moregenetic diversity than any other continent.
It is estimated, however, that fewer than
3% of analyzed genomes come fromAfricans, making it a very rich potential
source of new genetic information
for health and diagnostic researchand development.
Illumina joined a cross-sector partnership
through the Africa Centres for Disease
Control and Prevention (CDC) to support
the launch of the Africa Pathogen
Genomics Initiative (APGI). The initiative
will expand access to NGS tools andexpertise with the goal of strengthening
pathogen capacity across the continent.
The focus will be to build a continent-wide
disease-surveillance network to informpublic health responses to COVID-19, in
addition to other epidemic threats such as
AIDS, tuberculosis, malaria, cholera, andother infectious diseases.
We have committed more than $20 millionof charitable donations over the next four
years, to include NGS platforms, reagents,
and training support. The initiative aims toaccelerate the sustainable implementationof NGS for pathogen surveillance, and tohelp ensure capabilities are maintained.

OUR STORIES OF IMPACTENHANCING GENETIC RESEARCH
THROUGH VIRTUAL CLASSROOMSIN AFRICA
The Illumina Corporate Foundation provided
a $50,000 grant to the Global Initiative
for Neuropsychiatric Genetics Education
in Research (GINGER). GINGER is part of
the NeuroGAP program, supported by the
Stanley Center for Psychiatric Research at
the Broad Institute, in partnership with theHarvard T.H. Chan School of Public Health.
The project’s objective is to enhance
genetics research capacity in Africa
using virtual classrooms and help train a
new generation of genetics researchers
by making the courses available online.
Demand for this competitive programis high, with places filled by research
fellows from Ethiopia, Kenya, South Africa,and Uganda.
As a way of boosting global capacity for
genetics research, the grant will curate
virtual classroom content and enable it tobe videotaped, edited, and translated into
other languages. This virtual connection will
provide continuity of programming throughthe pandemic response and recovery.

21

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

22

Expanding Genomic Literacy
Illumina is committed to increasing
the awareness of genomics inhealthcare and the advancementof precision medicine.
Our work in education can be divided
into two key areas—supporting existing
healthcare professionals and inspiring thenext generation of scientists, innovators,
and researchers. Learn more about our
STEM education efforts in the Focus on
Community chapter.

The time has come todemocratize DNA sequencing
technology by enabling morelabs around the world to haveaccess to it, as well as make thetechnology simpler, faster, andmore affordable so patients can
be closer to the treatment theyneed when they need it andphysicians know how they
can apply it.”
Karen Gutekunst
VP, Regulatory Affairs

Education for Healthcare Professionals
Illumina plays an important role in providing
accurate, unbiased, and balanced information
to healthcare professionals (HCPs). Our
education begins with basic genetic
concepts, and encompasses specific areas offocus such as reproductive health, oncology,
genetic health, and infectious disease. With
our educational activities tailored for nongenetics HCPs and patient advocates, thiswork also supports our efforts to reduce thenon-financial barriers of access to genomics.

We provide a range of educational grants
for HCPs that align with our clinical areasof focus to support accredited and nonaccredited educational activities. All grant
proposals are reviewed for compliance with
our policies and relevant legal and industry
requirements, including guidelines set out
by the Accreditation Council for Continuing
Medical Education (ACCME).

NCC: Genetics Training
The National Coordinating Center (NCC) for
the Regional Genetics Networks is part of theAmerican College of Medical Genetics andGenomics. Grants from the Illumina Corporate
Foundation supported two programs: MOC4
Primary Care Physician Genetics Training and
Healthcare Interpreter Train the Trainer.
ISONG: Cancer Genomics Course
The Illumina Corporate Foundation
provided a grant to develop an online course
on Cancer Genomics specifically for theInternational Society of Nurses in
Genetics (ISONG).
ASHG: Online Professional Education
We are helping fund the development ofan online professional education programby the American Society of Human
Genetics (ASHG).

12,000+

8

23

+83%

60%

59%

Participants

Programs in progressor launched

Learners from GENOM project
said they would make changes
in their practiceCountries represented

Learners from ASHG program
stated satisfaction with program

Programs supported
directly through key local or
national societies

GENOM: Foundational Understandingof Genomics
A grant from the Illumina Corporate
Foundation helped support the Genomics
Essentials in Hematologic Malignancies(GENOM) project via the American Society of
Hematology, the Leukemia and Lymphoma
Society, and the France Foundation. The goal
is to provide clinicians with an introductoryunderstanding of genomics, current
applications, and practical strategies to apply.

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Catalyzing Genomics Startups
Genomics startups are playing
an increasingly important roleinternationally in the expansion of
the genomic ecosystem. For thisreason, Illumina aims to catalyze
this growth by supporting
the Illumina Accelerator andIllumina Ventures.

Illumina for Startups
Illumina for Startups is our way of accelerating
innovation in the entrepreneurial community
by partnering with leading venture capital
investors and entrepreneurs to create, launch,and grow genomics startups. Illumina for
Startups initiatives include Illumina Accelerator,
founded in 2014, and Sequoia Capital ChinaIntelligent Healthcare Genomics Incubator,
Powered by Illumina, launching fall 2021.

Important agriculture and foodinnovations to feed more with lessIllumina Accelerator is an engine for creatingcompanies co-located with Illumina researchand development sites in the San Francisco Bay
Area and Cambridge, UK. Illumina Accelerator
provides select startups with access to seed
investment, business guidance, Illumina’s
sequencing systems and reagent, and fully
operational lab space during each six-monthfunding cycle.

New synthetic biology approaches
for a more sustainable future

The Illumina Accelerator in 2020

The scope of these programs includes:
Novel drug discoveries totreat patients
Impactful diagnostics to detect andprevent diseases

Software and tools to further enable
new insights
Consumer-driven applications to help
us better understand ourselves
The dramatic innovations emerging fromthese startups are helping to drive down
costs, and unlocking new areas of biology
and market use.
Illumina Ventures website
Accelerator website

7

early-stage companies joined
the first global cohort; 3 from boththe US and UK, and 1 from India

45

genomic startups invested
in from around the globe~$600M

raised in venture capital funding

Illumina Ventures
We are further supporting early-stage
companies through Illumina Ventures,
an independently managed firm foundedin 2016. It is focused on assisting startups
that are pioneering genomic applications
and enabling precision medicine.
In addition to providing the initial seedmoney, Illumina also provides strategic
counsel to Illumina Ventures, and accessto the wealth of experience and expertiseof the world’s leading genomics solutions
provider. Companies supported by Illumina
Ventures are pioneering everything fromnew applications for advancing humanhealth through genomics to applications
that leverage genomics for sustainability,
biodiversity, climate change research, foodscarcity, and agrigenomics.

As we navigate the current
global pandemic, there is aneven stronger urgency to create
breakthrough genomics startups
that will transform human health.”
Amanda Cashin, Co-founder andGlobal Head, Illumina Accelerator

23

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Nurturing the Genomics Ecosystem
We want more communities tohave greater access to genomic
testing. Illumina actively finds
partners that can help us achieve
this aim.
Beyond Coverage
In 2018, Illumina announced a partnershipwith the Blue Cross Blue Shield Association(BCBS), a federation of the largest
commercial health insurers in the US, serving
more than 100 million customers. The
collaboration and subsequent publication also
included the Personalized Medicine Coalition(PMC) and Concert Genetics.
In order to expand access to personalized
medicine, we began mapping the national
availability of DNA sequencing technologies,
genetic testing and precision medicine.
The BCBS study findings were publishedin 2020:• Utilization rates of medically appropriate
genomic testing are inconsistentacross states• Payer genomic testing coverage policies
vary considerably and are inconsistent,
although coverage has grown over time
• Favorable policies do not always correlatewith higher utilization rates

Inconsistent coverage and reimbursement
policies remain barriers to testing access,but do not entirely explain the inconsistentutilization. Other access barriers must be
addressed, such as socioeconomic factors,
in addition to a lack of awareness about
genomics and precision medicine in thehealthcare system.

OUR STORIES OF IMPACT

Increased adoption takes more thanfavorable policies. Illumina is committed
to enabling broader access to genomics
through innovation, philanthropy, education,community outreach, collaborations, andkey partnerships.

It’s very rare to be able touse the most advanced andinnovative technology that
medical science offers toboth improve a child’s lifeand save money, yet
Project Baby Bear proved
it’s possible.”
Stephen Kingsmore, President
and CEO, Rady Children’s Institutefor Genomic Medicine

PROJECT BABY BEAR: GENETIC TESTING FOR BABIES“Project Baby Bear” is the nickname for
the $2 million Medi-Cal pilot program
developed to provide genetic testing forbabies in intensive care. The successful
18-month trial was the first state-funded
quality improvement project of rapid Whole
Genome Sequencing (rWGS) in neonatal
and pediatric intensive care units in the US.
As part of the pilot, Illumina teamed up with
the Rady Children’s Institute for Genomic
Medicine. In a group of 178 babies, thestudy reported a 43% diagnostic yield,with 31% experiencing a change in care
attributed to rWGS. The project also
generated $2.5 million of healthcaresavings, attributed to 513 fewer daysin hospital and 27 fewer surgeries orinvasive procedures.

The project’s final report, published inJune 2020, showed that using rWGS
or cWGS can provide fast, precise,and often life-changing answers to
medical mysteries, producing better
health outcomes while saving millions inhealthcare costs.
The project highlighted the readinessof rWGS as the new standard of care,
supporting Illumina’s efforts to make wholegenome sequencing a covered benefit
for all infants with rare and undiagnosed
diseases and inspiring similar projects
around the globe such as Project Baby
Gazelle in Israel, Project Baby Deer inMichigan, and many others.

24Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

25

Nurturing the Genomics Ecosystem continued
Expanded Coverage for Genetic
Disease and NIPTOUR STORIES OF IMPACT

Over the last four years, there has been a 100% increase inlives affected by Next-Generation Sequencing (NGS) coveredby insurance. This year we saw significant gains toward
full equity of access in the US through Medicaid coverage,
accounting for nearly 50% of US pregnancies.

100%
increase incovered lives
in last 4 years

54+40+6G 66+1420G 12+5137G
UNITED STATES NGS COVERAGE OUTLOOK
2%

54%

Non-Invasive
Prenatal
Testing(NIPT)

20%

14%

66%

Somatic
Mutation
Panels(Oncology)

44%

Total insured lives: 257M

IMPROVING ACCESS TO NON-INVASIVE PRENATAL TESTING (NIPT)
2020 saw significant gains in coverage
across the US for Non-Invasive Prenatal
Testing (NIPT), which analyzes DNA froman expectant mother’s blood to screen
for chromosomal conditions in her baby.
It is the most sensitive and specificscreening test for chromosomal changes,
and can help prevent the need for moreinvasive procedures.
In August 2020, the American College ofObstetricians and Gynecologists (ACOG)
recommended NIPT be made available

to all pregnant women, regardless ofmaternal age or baseline risk. ACOG’sendorsement helped expand insurance
coverage and broaden access to NIPT.
By the end of 2020, some of the largest
US insurance providers, including
United Healthcare, Aetna, Humana,
Centene, Harvard Pilgrim, Anthem,and most Blue Cross Blue Shield plans,
expanded coverage for NIPT to all
pregnant women, instead of only those atrisk or over the age of 35—a significant
win for expectant parents.

Atlantic Information Services Directory of Health Plans for number of lives data. Coverage policies through Policy Reporter update December 20, 2020.

37%

12%

Whole Exomeand Genome(RUGD)

51%

Total insured lives: 310M

Total insured lives: 257M

All pregnancies covered 138M

All panel sizes covered 205M

WES & WGS covered 31M

Only high risk covered 113M

Only targeted panels 44M

Only WES covered 130M

Not covered 5M

Not covered 61M

Not covered 96M

WES: Whole exome sequencing WGS: Whole genome sequencing CGP: Comprehensive genomic profiling

OUTSIDE UNITED STATES HIGHLIGHTS
Decision to remove priorauthorization to WGS/WES
and CGP in Germany

Creation of reimbursement
for CGP in the Netherlands,
Switzerland and Israel

NIPT now covered in mostof Western Europe
with more developments
expected including
increasing focus on accessin developing countries

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

26

Magnifying Impact Through Partnerships
In order to accelerate accessto genomics, we participate
in several partnerships
and coalitions.
Harvard Pilgrim Health Careand Illumina PartnershipThis partnership aims to make whole genome
sequencing (WGS) available to members
for faster diagnoses of genetic diseases
in children.
International Consortiumon Acute Leukemia (ICAL)
Next-Generation Sequencing (NGS) has
revolutionized the diagnosis and treatment of
acute myeloid leukemia (AML) through moreaccurate testing, classification, and the ability
to take advantage of precision medicine. Our
work with ICAL is bringing this cutting-edge
technology to Latin America.
DNA Data Storage Alliance
Illumina partnered with 14 other techbased companies and institutions, including
Microsoft, Western Digital, and Twist
Bioscience Data Storage, to establish
standards for this new field. DNA data
storage and readability will depend on
Illumina’s innovative sequencing technology.

10

full-length movies1 could be written
into a DNA molecule and packed tothe size of a grain of salt.

Microsoft, Illumina, and Twist Bioscience estimate

1

ACCELERATE ACCESS TO GENOMICS

Increase diversity andequity of representation in
genomic data

Ensure genomes can beinterpreted in the appropriate
context of global diversity

The Melbourne Genomics Hub
By combining Illumina’s industry expertisewith the University of Melbourne’s researchand student body (with support fromthe Victorian Government in Australia),
this partnership aims to improve publichealth outcomes.
The Shanghai Public Health ClinicalCenter (SPHCC)-Illumina Microorganism
Sequencing Research and Application
Demonstration Center
The center accelerates pathogenic
microorganism research and clinical testing.
Illumina provides technical support andtraining, and facilitates academic exchanges.

Close the gap
in underrepresented
communities

Illumina to Collaborate with Weill Cornell
Medicine and New York-Presbyterian
Hospital’s cWGS Initiative
As the largest US cWGS partnership, patients
can integrate genomics into their medicalcare by having their genomes sequenced
using Illumina technology. This initiative
will examine the feasibility of large-scale
cWGS implementation in one of the largest
metropolitan healthcare systems in the US.
Access to Comprehensive Genomic
Profiling (ACGP) Coalition
The coalition advocates for broad US
coverage of CGP for patients living withadvanced cancer.

Ensure everyone has access tolifesaving treatments tailored totheir individual health needs

Other partnerships• Blood Profiling Atlas in Cancer (BloodPAC)• Coalition for Access to Prenatal
Screening (CAPS)• Medical Genome Initiative (MGI)• European Confederation of Pharmaceutical
Entrepreneurs (EUCOPE)• German National Action League for People
with Rare Diseases (NAMSE)• Genomic Medicine Sweden (GMS) for WGS
in acute leukemia• GE-MED Germany WGS rare disease project• WIDE Study of WGS in partnership with the
Netherlands Cancer InstituteIllumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

weare stronger
together
By sharing our time, talent, and technology, we aim to
inspire, support, and empower our communities, ouremployees, and the next generation.

Focus on Community
In this section:
28
29
30
31
32
34
35

Q&A With Our Global CSR Lead
Focus on Community: Overview
Giving Back Is in Our DNA
Corporate Citizenship in Action: Illumina Cares
Employees Making a Difference
Empowering Our Communities During the Pandemic
Educating Future Generations

27

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

28

Q&A With Sharon Vidal
Global Lead Corporate Social Responsibility

While remote work createdchallenges for in-person
volunteering, it also unlockeda tremendous opportunity toengage virtually, regardlessof location.”

Q: Tell us how Illumina’s CSR focus
areas guided your response to the many
challenges of 2020.
A: When the impact of the global pandemic
started to unfold, we were able to leverage
our CSR framework and respond in acomprehensive way. It was key to apply ourrisk-based approach to protecting employees,
ensuring business continuity for our supply
chain and maintaining our culture of giving fordisaster response and employee engagement.
Q: How did your CSR efforts support
Illumina’s response to addressing
racial inequity?
A: Embedding diversity, inclusion, andfairness in everything we do has always
been a foundational priority. In 2020, social
inequities and systemic racism were brought
to the forefront of the global conversationand demonstrated a need for more urgent
and broader action. We re-examined ourprograms to identify additional ways to lift
community partners and bring our employees
into the conversation. We created a special
200% match campaign supporting Equal
Justice Initiative, Public Allies, NAACP, ACLU,
and the Innocence Project.

Their mission of creating a more just andequitable society resonated with our
employees, leading to an unprecedented levelof engagement in record time.
We also championed a new nonprofit
called SD2, or San Diego STEM Diversity,
which aims to support diversity in science,technology, engineering, and mathematics(STEM) education.
Q: In response to COVID-19, most of yourworkforce shifted to a remote setting. How
did you pivot your volunteer program tocontinue to support local communities?
A: While remote working created challenges
for in-person volunteering, it also unlocked atremendous opportunity to engage virtually,
regardless of location. Previously, a sitebased activity would only reach the local
workforce, whereas in 2020 our virtual givingback campaigns were able to touch every
region. We completed a virtual Walk the Worldfor Rare Disease charity fitness challengewith more participation than any previous
fitness campaign. We are also deeplycommitted to creating equitable access to
STEM education for all students and we felt
it was imperative to continue this during
the pandemic.

We strongly believe that igniting interestin genomics can empower students tosee themselves as future scientists andinnovators. We were able to continue hosting
career panels around the globe through thenonprofit Skype a Scientist and converted ourprograms from the classroom to the home.
We also successfully piloted a skills-based
volunteer program for our interns. This
resulted in over 1,000 volunteer hours that
supported nonprofits around the world,and created a positive proof of concept toroll out company wide in the future.

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Focus on Community: Overview
Our Commitment

Our Objectives

Our Why

We are committed to being good
corporate citizens. It is about
more than simply giving back.
We believe it is about creating
shared value through our businessand seeking opportunities tocontribute to a more equitable
and sustainable future.

By sharing our time, talent, and technology,
we aim to inspire, support, and empower
our communities, our employees, and thenext generation.

We are proud to have a purpose-driven
business strategy and mission. With the aim
to bring the positive progress of genomics
to all, we believe community engagement
on a local and global level is critical to thefoundation of a better world.

Deepen the impact of our genomic literacy
efforts and double our STEM reachIn progress

Drive meaningful employee engagement
opportunities to support a culture ofcommunity outreachIn progress

Partner with nonprofits to address unmet
needs locally and globally in support of our
CSR focus areas
In progress

Create opportunities for employees to giveback to the community and feel connected
to our mission
Achieved and continuing

Fostering a culture that emboldens our
employees to give back is integral toconnecting to our mission. We recognizethat as the leader in genomics, we have aunique responsibility to use our resources
for the greater good. Every day, we strive toprovide easy and meaningful opportunities
for employees to engage in their communities
and connect with organizations that mattermost to them.
Our corporate giving connects to our CSR
focus areas with the themes of access togenomics, diversity of genomic data, patient
support, independent medical education,
disaster response, and diversity.

2020 was a year of unprecedented
global challenges
Our CSR framework enabled us
to focus our community response
toward the global health crisis andto racial inequality. Our employees
and our company came together withthe staunch belief that collectively
we are stronger together. We canembrace this opportunity to rebuild amore just, equitable, and sustainable
future together.

Achievements in 2020
Inclusion on Newsweek
America’s Most
Responsible Companies
Wall Street Journal Top 250
Management Index with 5 outof 5 stars in the corporate
responsibility category$13.8M in philanthropic
donationsOver 5,000 volunteer hours

Early stages
In progress
Achieved and continuing

29Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Giving Back Is in Our DNA
We put our principles of corporate
citizenship into action throughour corporate giving, Foundation
giving, and our employee program,
Illumina Cares.
Illumina, Inc.
Strategic giving, supporting
key CSR areas with grants andin-kind donations
Illumina Corporate Foundation
Supports our CSR focus areas andthe employee match program
Illumina Cares
Supports volunteering by employees
and the causes about which they
are passionate

29

countries
reached775
causessupported$6.7M
Illumina Corporate
Foundation

55+45+G$13.8M
Donations$7.1M
Illumina, Inc.

$721K

Total matched by Foundation(including special 200% matches)

2,078

employees participatedin giving or volunteering• $573K employee donations$10.5M

Total COVID-19 response• $53K employee donations• $103K Illumina Corporate
Foundation match• $3.3M Illumina Corporate
Foundation direct grants• $7M Illumina, Inc. in-kindproduct donations

5,532

employee + internvolunteer hours$762K

Global racial equity response• $211K employee donations• $391K Illumina Corporate
Foundation match• $160K direct grants from
Illumina Corporate Foundation30

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

31

Corporate Citizenship in Action: Illumina Cares
As a company we are proud
and fortunate to have so many
employees that enhance ourcommunities through theirgenerous contributions andvolunteer efforts.
Illumina Cares
Illumina Cares defines and governs thework Illumina does in the community. By
providing giving opportunities, we encourage
employees to make a difference locally.
We match employee donations, offer paid
volunteer time off, and support a volunteer
rewards program to earn giving dollars foreach hour of volunteer work. To establish
our culture of giving right from the start,each new hire receives seed money to their
Illumina giving account to donate to the causeof their choice.

Skills-Based VolunteeringiAspire, our internship program, includes
programming to support Illumina Cares. In
2020, we held the intern program virtually,
with our interns facilitating the pilot of our
first skills-based volunteer program.
2030 Targets
50% employee participation(giving + volunteering)
In progress

Current Status

24% employee participation

70

interns volunteered over 1,200
hours helping 12 organizationsin 2020

Employee

Donation matching program$500

Our $250 match giving cap
will be doubled in 2021

Volunteerrewards program (Dollars
for Doers) $10/hour volunteered

EMPLOYEE PARTICIPATION IN GIVING AND VOLUNTEER PROGRAMS
Although volunteering was hit by the pandemic in 2020, giving increased from 19% to 21%.
Volunteering(employees + interns)$25

New hire seed
donation deposit

16 hours

40%

Skills-Based20%

Accessto giving portal to search forpre-approved organizationsand volunteer opportunities

Total Participation(giving and volunteering)

50%

Paid volunteer time off (VTO) per
year, and for 2020 we increased
paid VTO from 2 to 10 days
per employee

Volunteering

Giving

30%

10%
0

2017

2018

2019

2020

In order to be included in the Causes Database, an organization must meet their country’s NGO guidelines. Organizations
are then evaluated against 1,200 watchlists and a number of National Taxonomy of Exempt Entities Codes (NTEE) that arealso excluded from matching eligibility. Illumina currently blocks the Southern Poverty Law Center hate list from search,matching and volunteering; this comprises charitable organizations that have been found to discriminate against a specificrace, religion, ethnicity, sexual orientation, or gender identity.

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Employees Making a Difference
Acting as Ambassadors
Our corporate citizenship team helps patients,
engages employees in the powerful work we
do as a company, and connects our teammembers with impactful ways to give backto the community.
Doing Things Differently in the Pandemic
September’s Childhood Cancer AwarenessMonth was a time to highlight the importantcause of childhood cancer and join together
to make a difference. In 2020, due to thepandemic, we celebrated Childhood Cancer
Awareness Month virtually, and asked
employees to support September Go Goldby posting photos and spreading awareness.
For each photo, the Illumina Corporate
Foundation made a donation to Rady
Children’s Hospital in San Diego.

OUR STORIES OF IMPACT

Personal Connections
Our employees often have a very personalconnection to our mission. Vanessa Light,
Illumina Corporate Citizenship Program
Manager, became a patient family member
when her 7-year-old nephew, Carter, wasdiagnosed with B-cell acute lymphoblastic
leukemia. Through genetic testing, doctors
were able to identify an extra X chromosome
in his DNA that provided insight and change
management to his treatment regimen. “I got
to see firsthand how our technology impacts
patients, and how our giving back efforts
support the community,” said Vanessa.

PEDAL THE CAUSE
Every year, our employees participate in Pedal the Cause activities. Teams raise funds,
make superhero capes for children, and ride, run, or walk to support the cause. In 2020,
the St. Louis Illumina Pedal Team Captain and Field Employee Walter Bass was diagnosed
with stage 4 prostate cancer. After four years leading the Illumina Team’s efforts to giveback in the community, he became a patient. Even while undergoing treatment at Siteman
Cancer Center, one of the very sites for which the team had previously raised funds, heremained focused on raising money to give back to the community. COVID-19 proved
no barrier, with employees jumping in from California to Australia and riding virtually insupport of Walter Bass and his St. Louis team, raising close to $25,000.
Walter’s brave battle with cancer ended in December 2020. We will honor his legacy
through our mission to improve human health, and by continuing to champion patientsand our community.

32

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Employees Making a Difference continued
Rare Disease Day: Employee Impact
February 2020: Decked in Denim for
Rare Disease Day
Our employees are passionate about the raredisease community. They understand thepower of genomics to help end a patient’s
diagnostic odyssey and support theircare management.
Since 2008, Rare Disease Day events havetaken place around the world on the last
day of February to raise awareness about
rare disease, and highlight its impact onpatients’ lives. To mark Rare Disease Day,
we encourage employees to post photos ofthemselves decked in denim for the Jeansfor Genes (#JeansForGenes) fundraising
campaign. For every photo posted, theIllumina Corporate Foundation donates tothe chosen charities for the year.
In 2020, we collectively raised over $35,000.
These funds were distributed to charities
across our communities, including Rare
Disorders Society (Singapore) (RDSS);
Findacure; Illness Challenge Foundation; andthe National Organization for Rare Disorders.

RARE DISEASES CURRENTLY AFFECT BETWEEN
4% AND 6% OF THE POPULATION WORLDWIDE
Some 300 million people worldwide are living with one or more of theover 6,000 identified rare diseases.1

72%
90%

of employees surveyed feel support
to give back to the community inways to connect our mission.
1 rarediseaseday.org

of rare diseases are genetic
While some rare diseases may only
affect a handful of people aroundthe world, taken as a whole thenumber of people directly affectedexceeds the population of the US,
the third most populous country in
the world.

70%

of genetic rare diseases
start in childhood
Others are the result of infections(bacterial or viral), allergies andenvironmental causes, or aredegenerative and proliferative.

Illumina Corporate Social Responsibility Report 2021

33

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

34

Empowering Our Communities During the Pandemic
To create a holistic responseto the pandemic, we applied
all three elements of ourcorporate citizenship program:direct corporate giving, Illumina
Corporate Foundation giving,and employee engagement.
As a key component of our giving response
to COVID, we asked our employees toassist in identifying the most impactful local
opportunities to help, particularly the localorganizations in their regions about which
they were most passionate. We allocated a
total of $2 million to our regions to distribute.
Over 1,200 employees participated in thisselection process, engaging with more than
20 different nonprofits from around the globe.
Fighting COVID-19 in Our Communities
To support the vital mobilization of initial
response efforts, the Illumina Foundation
donated $1 million to the CDC Foundation
Emergency Response Fund.

OUR STORIES OF IMPACT

Our COVID-19 Response­—
Supporting Education Throughthe Pandemic
During the pandemic, shifting to distancelearning for school children exacerbated the
problems of equity and exposed a growing
digital divide for vulnerable students.

TESTING AT SCALE
Illumina, Inc. donated $2.5 million to
support the critical work undertaken
during the pandemic by nonprofit
Testing for America, which bothsupported the response to the
COVID-19 testing crisis in the US, andhelped to ensure the safe reopeningof historically black colleges anduniversities (HBCUs).

The Illumina Corporate
Foundation’s generous donation
will have a significant and positive
impact on fighting the coronavirus
in communities across theUnited States.”

What Testing for America haslaunched is demonstrating that
testing at scale can be done
successfully, and we are proud
to be part of the solution.”

Judy Monroe, MD, President and CEOof the CDC Foundation

Francis deSouza, CEO
Illumina

Support for Distance Learning
To support efforts to ensure that school
children had what they needed to continue
their studies and pursue their dreams, we
provided a $1 million donation to the San
Diego Foundation COVID-19 Community
Response Fund. These funds were directed
to help bridge the digital divide and provide
access to technology and connectivity tostudents in our most immediate community—
San Diego, home of our headquarters.

In San Diego, we funded 100 scholarships
through a $27,000 donation to the Fleet
Science Center Distance Learning Hubs,
which provide safe spaces for children to
make use of their school’s online learningfacilities while their parents are at work.
We also provided a $25,000 contribution to
Scripps Birch Aquarium to enable them toengage virtually with students in after-school
projects that bring together ocean science,
conservation, and genomics.
In our Asia Pacific region, we donated$85,000 to Singapore’s Children’s Wishing
Well to help children access e-learning
resources during the pandemic, and $35,000
to Save the Children Korea, which was utilized
to provide computers and other resources tounderprivileged children.

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

35

Educating Future Generations
We are committed to equitable
access to STEM education for
all, with the goal of empowering
students to envision themselves
as future scientists, innovators,
and trailblazers. Our approach
includes partnerships, direct
programming, philanthropy, andemployee engagement.

ENHANCING GENOMIC LITERACY
Examples of programs that we support:
DNA Decoded

A partnership between the Illumina Corporate Foundation andDiscovery Education, DNA Decoded provides ready-to-go,
standards-aligned lessons and activities for teachers and students
to explore the ways in which they can see genomics being used ineveryday life. Explore DNA Decoded

Career Profile Videos

By showing what it is like to work at Illumina, we are able
to introduce students to the diverse range of careers, bothscience and non-science related, our growing industry offers.
Meet our Employees

Genomics 101

We support our employees volunteering in the classroom, andsince launching the program in 2018, 170 employees haveconnected with classrooms around the world. We now haveconnected employees volunteering.

Skype a Scientist

This enables students and members of the general public toconnect directly with thousands of scientists around the world,
helping to take the mystery out of genomics.

I Am A Scientist

Through our partnership with I Am A Scientist, we support building
a collection of educational resources designed to challenge public
misconceptions and inspire the next generation of STEM leaders.

Illumina
Genomic Discoveries

We have launched Illumina Genomic Discoveries with the Biocom
Institute, a 501(c)(3) nonprofit that supports life science innovation
by strengthening the workforce and creating the leaders of
tomorrow. The program offers a series of programs to inspire,educate, and prepare students, and aims to increase teacher
participation from Title 1 schools. Illumina Genomic Discoveries

STEM atHome Microsite

We dedicated a special section of our website to genomic-focused
activities and resources for both young people and their teachers,
providing lessons and activities to keep children busy at home whenschools were forced to close.

Increasing Genomic Literacy
Our mission to improve human healthcommences with fostering a passion for
science. We aim to inspire our youth topursue STEM careers, at the same time
supporting educators to bring genomics
into the classroom and remove barriers
for underrepresented groups.

195,000

teachers and students
engaged in Illumina STEM
programs in 2020

>600,000
STEM participants a yearby 2030This year, I volunteered virtuallyfor the Skype a Scientist program,and had a great time chatting witha classroom of young people who
were really keen to find out more
about what scientists do and how
I started my career at Illumina. I
was thrilled to be able to continue
connecting STEM education forstudents even during COVID withthis virtual option.”
Clarisse Betancourt Roman,
Field Applications Scientist

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Educating Future Generations continued
DNA Day
Employees’ children from around the world
chatted with Phil Febbo MD, our Chief
Medical Officer, as part of a fun day ofactivities to celebrate DNA Day 2020 and avirtual Bring Your Kid to Work event.

OUR STORIES OF IMPACTSAN DIEGO FESTIVAL OF SCIENCE& ENGINEERINGIn March 2020, over 170 employees
volunteered at the San Diego Festivalof Science & Engineering. More than
23,000 children, parents, and STEM
enthusiasts attended the event,which was an ideal opportunity tohelp children discover the magic of
the genome.

36

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

37

Educating Future Generations continued
STEM for All
As a leader in an industry at the intersectionof biology and technology, we aim to curate
a diverse and inclusive workforce today
and for the future by collaborating with ourcommunity partners to reach and inspire
students of all backgrounds.

OUR STORIES OF IMPACT

In 2020, the Illumina Corporate Foundation
made donations specifically designed toaddress the issue of racial inequality found ineducation and STEM studies. We are deeplycommitted to creating equitable access to
STEM education. This year we supported
the following:

Our volunteers joined virtual sessions
held entirely in Spanish and supportedby the Bostonia Language Academy.
The sessions showcased careers ingenomics and encouraged young people
to consider different options for the future,demonstrating to students of all backgrounds
that a viable path exists if they wish to
pursue a career in the STEM industries.

• $30,000 grant to enroll 50 students
from underrepresented backgrounds in a
training program as part of a project run
by the education organization MILRD andmentoring program the Minds of Initiative• $10,000 annual commitment to support
high school scholarships in STEM subjects
for students from San Diego’s black and
Latinx communities• $500,000 over the next three years to
San Diego STEM Diversity (SD2), a new
nonprofit launched in 2020 that focuseson introducing underrepresented groups
to STEM• $10,000 a year in grants to black STEM
educators in San Diego

Championing Careers in Genomics
A key element of our work in 2020 was
supporting virtual career fairs to inspireyoung STEM students. In celebration of
Hispanic Heritage Month, we held internaland external careers panels with schools
based in communities where English was
primarily a second language.

RESEARCHING ETHNIC DISPARITIES IN COVID-19
In 2020, we provided a $130,000 grant to support Future Kings, a nonprofit thatteaches advanced skills in genomics research to young people from underserved groups.
The grant will support a research project that uses DNA science to understand why someindividuals are more resilient to COVID-19 than others. This will contribute to importantresearch into the ethnic disparities observed during the pandemic in the US and provide
real-life science experience for the students.

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

we
tread
carefully
Human health and the health of our environment
are intertwined, connecting our company mission to
improve human health with our commitment to operate
responsibly and sustainably. By understanding the marvelsof nature, the power of the genetic code, and collective
action, we can protect the planet that sustains us all.

Focus on Environment
In this section:
39
Q&A With Our Chief Product Officer and Chief Operations Officer
40	Focus on Environment: Overview
41
Creating Sustainable Facilities
45
Developing Sustainable Products
48
The Power of Genomics Beyond Human Health38

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Q&A With Susan Tousi

Q&A With Bob Ragusa

Chief Product Officer

Chief Operations Officer

Q: How has the pandemic created
innovation opportunities in product design?
A: Genomics offers insights that are changing
our world. The current COVID-19 pandemic
has underscored the need for tools to detectand monitor emerging pathogens. In responseto this we launched COVIDSeq™, the first
Next-Generation Sequencing (NGS) test
issued an EUA by the FDA. This decodes
the virus’s full genetic material. Additionally,
we launched the Illumina SARS-CoV-2
NGS Data Toolkit as a free collection of
informatic resources powered by DRAGEN
that accelerate sequencing data analysis
and mutation detection, simplify global
sample tracking, and make it easier for
scientists to contribute to and access public
databases. Looking to 2021 and beyond, we
will continue to deliver products that enablefamilies to grow, people to stay healthy, andscientists to understand and conquer disease.

Q: How does Illumina develop products
in line with the Design for Environment(DfE) approach?
A: Relational design-led innovation issomething we believe in and foster
across Illumina. The relationship between
technology, people, product, and our planet
truly motivates our scientists and engineers
every day. Their focus on integrating Designfor Environment is a practice that creates
new opportunities for product innovation.
We are proud to connect our ground-breaking
innovations to our sustainability goals andlead the way for our industry.
Q: You mentioned more efficient dataprocessing. Have the recent acquisitions
impacted this workflow? How does thatconnect to your Design for Environment
sustainability initiatives?
A: With the expanding body of genomics
data, new challenges arise with data
analysis and informatics. The acquisitionsof Edico, Enancio, and BlueBee positioned
us to respond to this bottleneck as well as
improve the environmental footprint. The
sustainability savings can be seen with aclear trend of improved power efficiency fordata transmission. The Enancio compression
provides power-consumption savings per
run, with power savings directly scaling with
output capacity. For NovaSeqTM 6000, we
saw a 20.4 kWh power saving per run! Our
innovation is not only helping customers withnew scientific insights, it is also contributing
to sustainability enhancements throughout
our value chain.

39

Q: Illumina’s role in responding to theglobal pandemic classified us as criticalinfrastructure. How did you manage tomaintain operations and meet customer
needs to support the response?

Q: How are your Facilities and Environment,
Health & Safety (EHS) teams applying
the sustainability goals related to climatechange and emission reduction into
your operations?

A: Illumina qualified as an exempt healthcare
operation with critical infrastructure
designation. Our top priority was the healthand safety of our employees. Our next
priority was to ensure that our customers
and our internal labs could continue efforts
researching and responding to the pandemic
using our technology. We applied multiple
layers of safety measures on campus,
including facility modifications, temperaturescreening, daily health check-ins, density
limits in the labs, increased air exchange
rates, workforce segregation, and enhanced
sanitization to name a few. We applied ourbusiness continuity planning and engaged
our supply chain and transportation partners
to ensure a variety of options were available
to continue meeting the needs of ourcustomers. The operations teams aroundthe globe adjusted to keep our employees
safe, our product quality protected, and ourcustomers enabled.

A: We have operationalized the 2030
strategic environmental targets into site-levelgoals. Our functional groups are working
through a pipeline of energy-conservation
projects and incorporating green design into
our new construction. We brought the Foster
City, California, solar power system online andcompleted the first full year of operation forour 3.5MW fuel cell installation in San Diego,
California. Our commitment to climate action
remains just as strong despite the challengesof the global pandemic. Even with reduced
team members on-site, we completed a
project in our San Diego region to convert our
shuttles to electric power and continue ourpath to reduce our environmental footprint.

Our top priority was the health and safety of
our employees. Our next priority was to ensurethat our customers and our internal labs could
continue efforts researching and responding
to the pandemic using our technology.”Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Focus on Environment: Overview
Our Commitment

Our Objectives

Our Why

We are committed to integrating
environmental stewardship into
the fabric of how we operate. We
recognize the importance of theenvironment in creating a healthy,
sustainable future for our business,patients, and communities.

We have organized our approach toenvironmental sustainability by prioritizing theimplementation of sustainable solutions in ourfacilities, our supply chain, and our products.

With human health at the heart of ourbusiness, we will continue to seek
opportunities for environmental protection
and take action on the climate crisis.

Facilities

By focusing on environmental sustainability,
we foster employee engagement and drive
innovation. We do this by challenging ourscientists and engineers to design new
products and packaging that lower ourenvironmental impact while unlocking thetransformative power of genomics.

We view sustainability through thelens of continuous improvement,
knowing there will always be more
opportunities for us to protect ourplanet and do our part.

• Green building designs• Reduce CO2 emissions• Increase renewable energy• Reduce water footprint• Reduce waste to landfill
In progress

Supply Chain• Supplier commitments• Supplier diversity
In progress

Product• Design for Environment• Packaging and dry ice reduction
In progress

We are responding to climate change risksuch as increased severe weather events,
potential policy changes, and reputationalharm by investing in more renewable energy,
integrating green design principles into ourfacilities and products, and continuing todrive innovation. Opportunities to support
climate action through genomics research
can create additional positive impacts. We areproud to see our products being used aroundthe world to study climate change impact,conservation biology, and influence moresustainable agriculture practices.

More information on climate change
risk and opportunities is included in the
ESG Appendix, using the TCFD and
CDP framework.

Achievements in 2020
Foster City site
solar activation
San Diego site shuttles
converted to electric
Foam cooler replacedwith sustainable andrecyclable packaging
Sustainable supplierassessments initiatedRecipient of SD Green
Commuter Program Awardfor third year in a row

Early stages
In progress
Achieved and continuing

40Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Creating Sustainable Facilities
As part of our environmental
commitment, we incorporate
green building design into new
construction projects and seek new
ways to incorporate the natural
world. For our existing buildings,
we seek initiatives to reduce ourenvironmental footprint.
2030 Targets
All new construction will integrate
green design principles with Leadershipin Energy and Environmental Design(LEED) certification elements orregional equivalent
Early stages

Current Status

are LEED certified, spanning
9 b3 uildingsof our main locations

250+

free electric car charging stations
installed around the globe

SCOPE 3 COMMITMENT
In 2021, we plan to conduct anassessment to evaluate our Scope 3
emissions. In our 2022 CSR Report,
we will share targets for our holistic
environmental footprint reduction.

Green Building Design
We design our buildings to minimize ourenvironmental footprint, including:

OUR STORIES OF IMPACT

Installing green roofs
Using sustainablebuilding materials
Sourcing furniture madefrom recycled content
Incorporating energy-conservation
techniques wherever possible

We Support
The Intergovernmental Panel on
Climate Change (IPCC) findings andthe elements agreed upon in the Paris
Agreement established to keep global
average temperature increases well
below 2°C
The implementation of UN SDG 13:
Take urgent action to combat climatechange and its impacts
Aligning carbon emission reduction
efforts with the Science Based Targets
initiative (SBTi) methodology

BOOSTING BIODIVERSITY
We believe the natural spaces in and around our sites are an extension of our working
environment. We work with experts to reduce the risk of impacting local biodiversity,
closely managing protected spaces.
For example, at the San Diego headquarters we have a dedicated conservation spacespanning 2.5 acres, housing an endangered species of fairy shrimp. Our employees canparticipate in walking tours to learn more about the ecology of the surrounding naturalareas and our role in protecting these spaces.
This work is not limited to our headquarters. More than 50% of the landscape at our
Madison site is new prairie restoration, including three water-retention ponds forstormwater deferral and trees native to the oak savannah.

41

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

42

Creating Sustainable Facilities continued
EnergyEach of our sites has a pipeline of energy
projects to contribute to reducing ourCO2 emissions.
2030 Targets1

PORTFOLIO TRENDS
Total Electricity Consumption (MWh)80k
71,56960k

30% reduction in Scope 1 & 2 emissions2

48,341

40k

Early stages

Current Status

36,573 MT CO2e6% above baseline
3

20k
0

2019

2020

50% increase in renewable energy
Achieved and continuing

Current Status

926 MWh energy from renewables
113% increase from 2019As a result of COVID-19 and somebuildings being left unoccupied witha remote workforce, we adjusted ourequipment to optimize energy efficiency.
This resulted in a 42% decreaseat our SD i3 location.

Improved
efficiency

with Tesla battery storage system4

700,000 kWh
and 56,000 therms reduced
annually through lab energy
management program

367,500 kWh

Reducing Our San Diego Footprint
Our headquarter’s footprint accounts forover 60% of our energy portfolio, so we
focus heavily on creating an impact here.
A few examples of measures implemented
to support our sustainability goals are:• Installed a 3.5-megawatt fuel cell system.
Developed by Bloom Energy, it uses solidoxide fuel cell technology to convert natural
gas into electricity through a combustionfree electrochemical process. In 2020,
this technology enabled us to reduce
our electricity by 80% but increased our
natural gas by 111%. The emission factors
associated with an increasingly cleaner
California grid resulted in a net increaseof our emissions at the site. We hope toconvert the fuel cell to a renewable biofuelas innovation in the field evolves and theprice of this commodity reduces to supporta reasonable ROI• Conserved energy through optimization of
the central plant and chilled water retrocommissioning, LED lighting, and roomoccupancy controls for lighting and HVAC
• Increased efficiency with Tesla battery
storage system to capture and store energy
when demand is low, and discharge during
peak times

saved through the two-year
SEM initiative

1 Renewable energy and emission targets are based on 2019 data as baseline.
2 Scope 1 and 2 greenhouse gas emission inventory boundary defined as: sites >30,000 square feet or that contain manufacturing, distribution, or significant R&D activities. These sites
represent our jurisdictional control plus material locations. This scope accounts for 96% of our total estimated footprint. Data reported for Scope 1 and 2 comes from direct utility sources.
Where direct data was unavailable, industry standards were applied as estimates to capture total impact (ie, shared tenant spaces)
3 Energy and emission baseline year definitions have been updated from 2018 to 2019 after identifying that 2019 is the earliest reliable and representative data set for our portfolio.
4 Tesla battery storage improves the efficiency of electrical grid use and reduces the SD HQ electricity bill by 5%.

• Utilized the Aircuity lab management
system to continuously monitor air quality
throughout the day, providing demandbased ventilation to meet safety protocols.
Through more efficient ventilation
procedures, this system reduces electricity
use by 700,000 kilowatt hours and56,000 therms annually• Participated in a two-year Strategic
Energy Management (SEM) program with
the California Public Utilities Commission(CPUC) and our local utility provider.
Activities included treasure hunts with ourenergy champion volunteers and audits
with the Facilities and EHS teams, resulting
in more than 100 low- (or no-)cost energysaving projects. The projects were mostly
focused on operational and maintenanceopportunities and resulted in 367,495 kWh/year savedIllumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Creating Sustainable Facilities continued

Water Stewardship
Even though our industry is in general
not water-intensive, by managing
our water use, we can reduce ourenvironmental impact and operationalcost, and address potential risk thatwater scarcity may present.

2030 Target

MADISON

10% reduction in water footprint2

By embracing the natural local
ecosystem, we minimized theneed for irrigation

Early stages

Current Status

401 megaliters 33% increase

We assessed our water usage bycomparing the locations of our sites
with the baseline water stress risk
ranking according to the World Resource
Institute and its Aqueduct atlas1.
For those identified as operatingin water-stressed regions, we arecommitted to focusing additional efforts
on water management planning.
ILLUMINA SITES
Beijing, China

Rennes, France

Mechelen, Belgium

Tokyo, Japan

Moscow, Russia

Madison, WI

San Diego, CA

Osaka, Japan

Berlin, Germany

Baltimore, MDEindhoven, Netherlands

Cambridge, UK

Evry, France

Foster City, CA

Melbourne, Australia

Hayward, CA

São Paulo, Brazil

Singapore

Shanghai, China

Water risk assessment
High

Low-Medium

Low

50%

of thewater used in our San
Diego locations is fromrecycled sources

Seoul, South Korea

Extremely HighSAN DIEGO

Medium-High

SINGAPORE
Our Sustainability and EHS
teams ran water conservation
awareness campaigns on
World Water Day

1 World Resources Institute water stress and the Aqueduct Project.
2 Water targets are applied to main campus locations and normalized for intensity across square feet.

43Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

44

Creating Sustainable Facilities continued
Reducing Waste
We aim to be a catalyst for positive change byaddressing waste at our facilities and in our
products, and encouraging our supply chain
to adopt responsible policies. Our approach
to non-hazardous waste management
utilizes a hierarchy where source reductionis the most preferable option, and landfill is
the least preferable. Our hazardous waste
management hierarchy is designed tominimize impact and manage materials in themost environmentally responsible manner,
following the hierarchy: reclamation/reuse,recycle, waste to energy recovery, fuelblending, wastewater treatment, incineration,
autoclave, and landfill when other alternatives
are not available.

Producer Responsibility:
Product Take Back and Recycling
We participate in required complianceschemes for producer responsibility to ensure
proper collection, management, and disposal.
This includes the recycling of packaging,batteries, and waste electrical and electronicequipment (WEEE). Under the EU’s Batteries
and Accumulators Directive and Packaging andPackaging Waste Directive, and regulations
in several EU member states, we comply withrequirements to finance the collection andrecycling of batteries and packaging suppliedwith our products at end of life.

OUR STORIES OF IMPACT

100% of strategic suppliers to commit tominimizing their environmental footprint
Early stages

Current Status

75%

Growing production levels and new sites
have generated increased waste, which we
continuously seek to reduce.

In progress

TACKLING WASTE
Avoid or Reduce
Minimize materials bound for waste
stream: smaller, less material,
gauge reduction

Current Status

49%

Re-UseReturn materials for reuse

Our EMEA and Singapore sites
have already achieved greaterthan 90% landfill diversion

RecycleUtilize materials with appropriate
recycle streams or support curbside
compostable. Recycling streams often
require development

We are actively working with
our US sites on projects toincrease their diversion rate

1 Main site locations currently include:
San Diego (i3, HQ, DC), Foster City, Hayward, Madison,
UK Illumina Centre, Netherlands, Singapore Woodlands.

SUSTAINABILITY GREEN TEAMS

Most preferable

Incinerate
Burn waste materials withenergy recovery; only route forhazardous materials
Landfill
Collaborate with waste haulers toensure targeted ideal material streams

Least preferable

Sustainability is a strategic priority forthe company, and Illumina is committed
to working with suppliers that recognize
the value and importance of minimizing
environmental footprint.
2030 Target

2030 Target
90% landfill diversion at all main sites1

Sustainable Supply Chain

Our Sustainability Green Teams operate
at all our major sites, and represent an
important and effective means to both
engage with employees and enhance
the sustainability of our business. For
example, our Madison team led theimplementation of a project to recycle
non-hazardous lab waste by glove
and garment recycling through theKimberly-Clark RightCycleTM Program.
In San Diego, the team removed plastic
liners from the office recycle container
bin to reduce plastic bag usage. In
EMEA, the Sustainability team led
virtual climate change “lunch n’ learn”
sessions, and the Singapore teamhosted an Earth Day Fair.

Supply Chain: Engaging Our Suppliers
Illumina considers it a business imperative
to work with suppliers who share our goal ofbeing a good corporate citizen.
We are committed to minimizing ourenvironmental footprint in our supply chain
by focusing on requirements upstream
for our strategic suppliers and maximizing
opportunities for small, diverse, andlocal suppliers. By extending our efforts
to minimize our environmental footprint
throughout our value chain, we can magnify
the impact for greater results.
Our Supply Chain

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Developing Sustainable Products
We are committed to respecting
and protecting the environment
as we develop new products,
technologies, and solutions.
We will apply the principles ofenvironmental stewardship to
address impact throughout the
product life cycle.

EnergySequencing Instruments
Increased processing efficiency,translating to decreased power
consumption per gigabase (Gb)
Introduced dynamic power
management for new highthroughput sequencers, as wellas efficient HVAC design

2030 Targets

Design for Environment

Integrate Design for Environment (DfE)

Design for Environment (DfE) is anapproach to incorporate sustainability
and lower the environmental impact of
products through design. Through DfE, weapply environmental criteria to resource
selection, design, packaging, energy use,
data processing efficiency, and end-oflife management.

In progress

Optimize sequencer power consumption
and processing efficiency
In progress

Reduce amount of plastic in new
product designs
In progress

Replace use of chemicals of concern
wherever possible with greener alternatives
In progress

Introduced efficient instrument
system thermal design forreagent temperature cycling
Investigating more power-efficient
alternatives to CPU architecture
NEXTSEQTM• Ambient shipping of sequencing flowcells

DfE in Action in 2020

• 75% decrease in waste footprint

Greener Reagents• Replaced formamide with safer,
plant‑based chemistry in microarray• >50% consumable cartridge plastics
designed to be recyclable• Reduced Triton usage in SBS reagents tounder 1%, complying with EU requirements
Waste Reduction• Increased shelf life from three to twelve
months on NovaSeqTM 6000 v1.5 RUO kit
Material Right Sizing• Re-configured reagent kits for highthroughput customers, shifting fromindividual tubes supporting 96 samples pertube to bottles that contain 1,152 samples

1 NextSeqTM 2000 compared to NextSeqTM 550

OUR STORIES OF IMPACT• 4x reduction in reagent kit size1
NOVASEQTM• Shifted crate material to a recyclable
alternative, reducing weightby 100 lbs• 80% reduction in hazardous reagent use• 50% reduction in label use• Carton inserts that are 100%
biodegradable and consumable• Innovative data compression resulting
in a reduction of 20.4 kWh per run

OPTIMIZING RECYCLING
We developed a tool for safe and easy
disassembly of the NextSeqTM 1000 and2000 sequencer cartridges. The tool
enables part segregation to optimize
and increase recycling options forreagent cartridges.

45Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Developing Sustainable Products continued
Sustainable Packaging

Optimizing Packaging Achievements

By integrating DfE elements, our focus ison both optimizing packaging for materials
currently on the market and incorporating
sustainable packaging design into ourprocess for development of new products.

• Enhanced packaging of NextSeqTM
1000/2000, with reduction of double barrier
pouch around cartridge to single barrierbag, while maintaining product quality

To help us evaluate differences inenvironmental impacts between packaging
options, we have implemented a simplified
life-cycle assessment (LCA) tool whichenables us to make informed and evidencebased decisions about packaging materials
and designs.
Many of our products are temperaturesensitive, which creates uniquerequirements for packaging, shipping,and storage.

2030 Targets
75% reduction in packaging
In progress

50% recyclable primary packaging
In progress

90% recyclable or reusable secondary& tertiary
In progress

90% reduction in use of dry ice
In progress

OUR STORIES OF IMPACT• Optimized shipping for bulk transit on
TruSight Oncology (TSO), resulting in 54%
volume reduction• Improved the original launch of the
packaging associated with our COVID-19
commercial application COVIDSeq™ Test.
Packaging improvements were implemented
to shift from an eight-box kit to afour-box kit• Transitioned from tertiary corrugatedpackaging to 100% recycled content
in North America, with plans for future
global implementation• Shifted to bulk packaging for shipments to
China, including a new molded pulp tray
made from more environmentally friendly
materials, and optimized packaging design
to increase the quantity of units shipped
per pallet while protecting sensitive
components of the cartridges

TRUSIGHT PACKAGING REDUCTION
Improved packaging configurations of the TruSight Oncology 72- and 144-sample kits,consolidating 21 boxes down to six. This reduced volume by over 50%, with fewer barrierbags and shipping containers.

• Refrigerated shipment gel packs consist of
biodegradable gel and recyclable wrapper

The change to recyclable packaging by Illumina has beentransformational and much easier to manage!”Charlie Johnson, PhD
Executive Director Genomics and Bioinformatics Service at Texas A&M AgriLife Research46

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

47

Developing Sustainable Products continued
Returning and Reusing
Our Packaging
Illumina has implemented a variety of
projects to bring enhanced sustainability
to our existing product portfolio.

250,000 ft3
diverted from landfills per
100,000 containers

34 kg

diverted from landfill for every
reusable returned

100%

Returnable Insulated Containers
Insulated containers used for refrigerated
and frozen in vitro diagnostic product (IVD)
product shipments can be returned to us
for reuse.

80 kg

reduction in dry ice per frozen
pallet via advanced material types

Launched a container reuseprogram where returned containers
are inspected, sterilized, reworked,
and used again

Elimination

At full implementation, thesecontainers reduce emissions by
1.43 metric tons each monthpaper packaging made of recycled
and recyclable materialof bubble wrap—replaced withdunnage paper

Recyclable Insulated Containers
A move to plant-based paper insulated
containers results in a solution whichis recyclable.

Reusable Bulk Sustainable Solutions
New insulated pallet shippers are validated
for multiple uses and returnable forrefurbishment and reuse.

100% curbside recyclable andcompostable using standard paperrecycling streams

Supplier return facilities inspect
and refurbish for return shipment
to Illumina

The insulated containers for frozen
shipping are made with plant-based
renewable materials, which requires
less energy and diverts from landfill

Pallets are modular and break down
flat for easy return of multiple units
via land or ocean

Implementation completed in AMR
in 2020, with roll out to EMEA in 2021
and APAC in 2022

Supports internal movement networkand customer bulk orders

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

The Power of Genomics Beyond Human Health
The health of the environment and humanhealth are intertwined and connect ourcompany mission with our commitment
to operate responsibly and sustainably.
Our technology is being used to directly
support sustainability, understand climatechange, study conservation, and evaluate
environmental DNA. The positive powerof genomics beyond human health is
helping to solve some of humankind’s mostchallenging issues.
Greater Good Initiative
The Illumina Agricultural Greater Good
Initiative grants, launched in 2011, are awarded
annually. This program spurs critically needed
research that will increase the sustainability,
productivity, and nutritional density ofagriculturally important crop and livestock
species. Grant recipients receive donationsof Illumina products to support their projects.
This year, the grant was awarded to a projectfocused on bee health. Pollinators are at
the apex of long-term sustainability in foodproduction, as 90% of wild plants and 75% ofcrop species are dependent on bees and otherpollinators. This project will leverage genomics
to further understand genetically controlled
behavioral differences between honeybees
and secure the survival of pollinationdependent species, including humans.
Illumina Agricultural Greater Good

Earth BioGenome Project
The Earth BioGenome Project (EBP)
is a network of partner organizations
and affiliated projects with the sharedgoal of sequencing and annotating the
genomes of all 1.5 million known species
over a 10-year period.

OUR STORIES OF IMPACT

Launched in 2018, the EBP aims tocreate a digital backbone of sequencesthat will serve as critical infrastructure
for biology, conservation, agriculture,
medicine, and the growing global
bioeconomy. EBP aims to help withbiodiversity and responsibly stewarding
its resources.
Illumina is providing 100 referencequality genomes and also participatingin the development of technology forthe sequencing of genomes from singlecell and small multicellular organisms.

COMPARATIVE GENOMICS AND LEMUR CONSERVATION
Through iConserve, a philanthropic initiative that brings the community together toaccelerate wildlife conservation, the Illumina team is partnering with the San Diego Zoo,
the University of Antananarivo in Madagascar, and the Universitat Pompeu Fabra in Spainto help preserve the future of several endangered creatures.
Lemurs are mammals native only to the island of Madagascar in the Indian Ocean. At
least 17 lemur species have become extinct during the last 2,000 years, and species thatstill survive are threatened due to significant habitat loss, hunting, and illegal logging.
The effects of widespread poverty and political instability also hinder and undermine
conservation efforts. As a result, the International Union for Conservation of Nature(IUCN) considers lemurs to be among the world’s most endangered mammals, andestimates that 90% of all lemur species are facing extinction. Lemurs are important
for research as their mix of ancestral characteristics and traits shared with anthropoid
primates could yield insights into the evolution of humans and other primates.
The iConserve work will consist of research into the comparative genomics of lemurs,
which will provide structure to cataloging biodiversity in wild and captive populations.
This will ultimately support decisions around species conservation and management.

48

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

we nurturea cultureof careFocus on People
In this section:
50
51
52
53
58
60
61
62
64

Q&A With Our Chief People Officer
Focus on People: Overview
Our People
Diversity, Inclusion & Fairness
Caring for Our Employees
COVID Care for Our Employees
Supporting Early in Career and Beyond
Investing in Developing Our People
Committed to Health & Safety in the Workplace

Our aim is to embody a culture of care that is fueledby collaboration, diversity, inclusion, and fairness.
To continue as a leader in genomics we will need toharness the world’s best talent, and give them theopportunity to thrive.

49

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

50

Q&A With Aimee Hoyt
Chief People Officer

Cultivating an inclusive, diverse
workforce is foundationalto enabling everyone to
fully contribute to our
mission of improving humanhealth and unleashing theircomplete potential.”

Q: How has Illumina continued to takecare of its global workforce during
the pandemic?

they have extended to one another. Like our
employees, I am confident we will emerge
even stronger than before.

A: We are fortunate to have a culture atIllumina, much like our company mission, thatis focused on care and support. Our cultureof care has served as our foundation and has
been built upon the principles of employee
trust, flexibility, transparency, and well-being.
This foundation enabled us to provide an
immediate level of support to our employees,
while also enabling us to quickly adapt toour employees’ changing needs and unique
circumstances as the pandemic evolved.

Q: How have employees reacted to thecompany’s response to COVID-19?

In practical terms, this has meant focusing
our efforts on providing our global workforce
with pay continuity and stability, incremental“COVID Care” cash payments (to help addressunanticipated financial needs), flexible
working arrangements and time off, 30 days’
paid leave for emotionally significant events
under our Compassion & Care Time Off
program, and increased emergency backup
childcare. Our employees have been handlingso much this past year, personally andprofessionally, and every individual situationis unique. This is why we have strived—even
before the start of the global pandemic—tocontinually provide a progressive, flexible
suite of programs and benefits for our global
workforce. While we never anticipated acrisis of this nature or scale—of a global
pandemic—our culture of care foundation
has been built to respond to crises as theyarise. I am extremely proud of the resilience
our employees have shown and the kindness

A: Employees have shared very positive
feedback about our response to COVID-19,
which entailed increased communication,
leadership engagement, employee benefits,
and faith in the future of the company. We
have worked hard throughout the pandemic
to provide a variety of platforms to listen
to colleagues and adjust based off theirdirect feedback.
We increased our all-company meetings totwice a month, launched a twice-monthly
forum with our Chief Medical Officer,
and created dedicated internal channels
for COVID-19 support and updates. We
continue to keep a very close pulse on theoverall health of our organization, employee
engagement, and employee trust throughquarterly employee surveys—allowing us touncover insights and challenges early on inhopes we can proactively address them inmeaningful ways.
Q: What initiatives has Illumina undertaken
to address racial inequity and create a fairand inclusive working environment?
A: Cultivating an inclusive, diverse workforce
is foundational to enabling everyone to fully
contribute to our mission and unleash theircomplete potential. Heading into 2020,
we strived to embed diversity, inclusion,and fairness (DIF) in all we do across theorganization. This included elements ofcultural competence, equal opportunity, pay
equity, inclusive benefits, employee resourcegroups, supplier diversity, and community
engagement. Our efforts also reflected
the labor principles within the UN Global
Compact. Although our DIF efforts are notnew, the horrific racial and social injusticeevents of 2020 emphasized a clear need formore urgent, purposeful action.
As we considered how to continue ourcommitment to DIF in new and meaningful
ways, we recognized the need for a
dedicated leader who could help elevate
our efforts, our thinking, and our diversity
practices across the organization. Dr. Lisa
Toppin joined us in the fall as Vice Presidentof Diversity & Inclusion. In addition, we
became a proud signatory of the CEO
Action for Diversity & Inclusion, created a
new employee resource group called “BEGREAT” (Black Employees Guiding Racial
Empowerment and Trust) dedicated toblack employees and allies, hosted diversity
dialogue through company meetings,
workshops, leadership forums, and guest
speakers, promoted virtual courses on
diversity, unconscious bias, and emotional
intelligence, and increased efforts torecruit from historically black colleges anduniversities (HBCU).
While there is still much work to be done, weare committed to this journey of fostering a
global culture that is more equitable and more
representative of the diverse world we live in.

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

51

Focus on People: Overview
Our Commitment

Our Objectives

Our Why

We are committed to nurturing
a culture of care, delivering
practices and programs thatare as progressive as the
products we are innovating. By
attracting, retaining, developing,and supporting our people, we
can enable everyone to fully
contribute to our mission anddeliver on the transformative
power of genomics. Our aim isto help build a more equitable,
inclusive, and sustainable world.

We strive to promote an inclusive andinnovative workplace, powered by passionate
people, to help drive the positive progress ofgenomics for all. To achieve this we:With an extraordinary mission comes theneed for extraordinary people and leaders
at every level. Every day at Illumina, wehave the chance to do once-in-a-lifetime
work, transforming human health and driving
scientific innovation. We know the best
ideas will come from a diverse, inclusive
environment where everyone feels safe,
respected, and supported.

 oster an environment where people feelF
Illumina is a great place to work for everyone
Achieved and continuing

Embed diversity, inclusion, and fairness
in all that we do
In progress

Offer employees the resources and support
they need to bring their personal best every
day and reinforce our culture of care
In progress

Acquire and grow extraordinary talent andteams to create a deep and diverse pipeline
In progress

Steward our employee safety and wellness
In progress

Focusing on inclusion means amplifying
our value of collaboration and building
community. Fostering an inclusive andhealthy workforce is a foundational
principle and essential for innovation. To
enable that environment, we offer flexible
work conditions, and invest in developing
employees throughout the various stagesof their careers, including helping toenhance their technical, professional, andleadership skills.
A strong culture of safety, belonging, andwellness leads to more engaged employees,
allowing our workforce to offer their best
work to our mission. We provide a portfolioof benefits and wellness programs to be themost compelling, in order to recruit top talent,to care for our employees through life events,
and to support the variety of their personalneeds. We aim to create an environmentthat will reflect and represent the diverse
communities we serve around the globe.

There is still much work to do to build a more
equitable, inclusive, and sustainable world.
We will continue our efforts to build towardthat future in our workplace, in our supply
chain, and in our communities.

Achievements in 2020
Inclusion on the Bloomberg
Gender-Equality Index
Earned 100% on the Human
Rights Campaign Corporate
Equality Index and designatedas Best Place to Work for
LGBTQ Equality
Joined CEO Action for
Diversity & Inclusion
Included in America’s Most Just
Companies and received thehighest score for our industry
in the category of workers
Singapore Workplace
Safety Award

Early stages
In progress
Achieved and continuingIllumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

52

Our People
Making genomics useful for all is our purpose and our promise—to thepeople who work toward this every day and to the lives it touches.
Who We Are

7,828

Employee Age Distribution

Total Global Employees (FTE)67%

Listening to Our Employees
We regularly ask our employees to complete
our iPulse survey. In 2020, we increased thefrequency from two times a year to quarterly.
This helps us gauge how they feel about
the business and how we are performing. In
turn, these insights help leaders, at all levels,
to better understand and respond to ouremployees’ needs.

Diversity, inclusion, and fairness—in all that we do and at every
level of our organization—is vitalto harness the full power of all
our people and build a more
equitable future.”

In the face of a year like no other, we arepleased that employee trust remained strongin 2020.

Sue Siegel
Illumina Board of Directors

30–50

16%

17%

Over 50

Under 30

43%

Regional Employee Distribution

Female63%
AMR Region

13%
EMEA Region

24%
APAC Region

57%
Male

Trust and Engagement

85% Trust & Confidence Indexonfidence
in Illumina’s continued
88% Cgrowthand success
81% Engagement Index

What Our Employees Think About Illumina
llumina really cares about my
88% Iwell-being

94% Iam proud to work for Illumina

wouldgladly recommend Illumina
85% Iasa great place to work to people
I know and respect

87% Ifeel like I belong at Illumina

Diversity, Inclusion, and Fairness
f employees feel that Illumina
90% ovalues
diversity
Illumina’s COVID-19 Response
verall satisfaction with93% oour
company’s response to
the pandemic

f employees
indicated Illumina
81% owill
emerge stronger postcrisisIllumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Diversity, Inclusion & Fairness

Dr. Lisa Toppin, VP, Diversity & Inclusion

Employees

Culture• Equal opportunity• Diversity training and programming• Pay equity• Added new company holiday torecognize MLK Day• Gender-neutral parental leaveesyeCommunity
it y

lie

pp

• Support for local businessrs

Co• Employee surveys to regularly
assess diversity index• Employee resource groups

Our
Four Focus
Elements

Suppliers• Supplier Diversity program

Cu
lt

e
ur

• Flexible work options, including
flexible and paid time off without
accrued limits

Su

Although our DIF efforts did not begin in
2020, we recognized the need for moreurgent action. The violence and acts of racial
injustice committed against black people in2020 highlighted the stark and continuing
disparities in economics, education, wealth,and access to equitable healthcare. We aremaking progress, but much remains to be
done. We recognize that change will not be
quick or easy.

At this critical time in our society, diversity and a true
sense of belonging have never been more important.”un

We strive to foster an inclusive and diverse
culture in which all employees feel valued
and appreciated. This culture helps people
engage at their best, knowing they havean equal opportunity to grow and succeed
based on their performance, regardless of
individual differences. We invest equally in
our employees and work to create a culturethat encourages all our employees to share
their unique perspectives and experiences,learn from one another, and contribute. An
inclusive, diverse workforce also reflects
our global business and customer base andwill lead to continuous improvements asan organization.

As we aim to embed diversity, inclusion, andfairness in all we do, our response to evolve
our DIF strategy is integrated across theareas of our employees, our culture, oursuppliers, and our community. It includes
setting new targets, investing in programs
to drive improvements, and expandingtransparency of our diversity data. We believethat creating an environment that reflects
and represents the diverse communities that
we serve around the globe makes us
a stronger and better company.

Em
pl
o

The collective talent, diversity, and dedicationof our employees supports our mission
to improve human health. We celebrate
our employees’ unique life experiences,backgrounds, talents, passions, andcontributions to innovation.

mm• Equitable access to STEM
education programming• Grants for black STEM educators• Scholarships for underrepresented
students entering STEM fields• Philanthropic offer of treatment (cWGS)

53

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Diversity, Inclusion & Fairness continued
Employees

We aim to attract, develop, andretain a diverse workforce thatreflects our global community.

Based on the current demographics of US
workforce representation, we are focusing
our efforts on increasing the representationof BIPOC (Black, Indigenous and People ofColor), Latinx, and multi-racial groups.

We are committed to equal opportunity andproviding employment and advancement
opportunities to individuals based on
merit. Our policies prohibit discrimination
based on race, color, age, gender, sexual
orientation, marital status, gender identityand expression, ethnicity, religion, physical ormental disability, medical condition, genetic
information, veteran status, national origin, or
any protected class.

The following programs and initiatives will
support our path to progress on diversity
recruitment, retention, and advancement:• Screening job descriptions andadvertisements for gender andethnicity bias

• Implement practices to promote diverse
interview panels• Achieve diverse intern cohort by gender,
race, and ethnicity
We will also continue to monitor the followinginternal key performance indicators:• Turnover and promotion rate acrosseach Equal Employment Opportunity
Commission (EEOC) category and level ofthe organization• Conversion rate of diverse applicant
pool vs. % BIPOC and women hired• Encouraging applications via
targeted communities• Promotion rate for equitable representation
across all groups• Increasing recruitment from HBCUs

US MINORITY DATA 2020 % BY LEVEL1

Support to Entry Professional
Intermediate to Senior Professional
Manager to Associate Director
Director and Above
0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

White/CaucasianAmerican Indian/Native Alaskan

Hispanic/Latino

2 or More

Native Hawaiian/Other Pacific Islander

AsianBlack/African American

Not Disclosed

1 For additional data points on EEOC, refer to ESG Appendix

Flexible
workplace policies

Gender-neutral policies

49%

Diverse workforce (US)54

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Diversity, Inclusion & Fairness continued
2030 Targets
Gender Representation (Global)
Increase representation of
women in senior leadership1

Pay Equity
Our revolutionary work in genomics
demands outstanding and diverse talent.
To support this, we strive to offer meaningful
development opportunities and rewards for
impact, performance, and potential.

Zero Net Pay Gap2
Achieved and continuing

In progress

2020

Zero Net Pay Gap

2020

34%
Workforce Diversity (US)Increase participation of disabled peoplein our workforce

Increase participation of veteransin our workforce
In progress

In progress

2020

2020

3% Veterans

5% Disabled people

Increase underrepresented workforce(% Black, Latinx & multi-racial)

Elevate racial and ethnic minority
representation3 in senior leadership1

In progress

In progress

2020

2020

16%

25% Director and above
GENDER DATA(%)

Female30

Board ofDirectors

36

SVP/C
Suite

63

37

VP

64

36

Director &Sr. Director

5942Supervisor
to Associate
Director

Intermediate
to SeniorProfessional

57+43+G
7,828
Employees

57%

FemaleMale

1 Senior leadership defined as Director and above.

2 Zero net gap in pay means no statistically significant
difference in pay for the same or similar work, regardlessof gender, ethnicity, or race.
3 Based on summary of all non-Caucasian.
4 Equal pay refers to paying a woman and man equally forthe same or similar work. ​5 A pay gap is the difference in average pay between
women and men in an organization. ​6 UK leader represents manager and above.

53

58

41

Nonetheless, when we examine the average
pay5 of women and men in our organization,
we recognize opportunities still exist to
improve. More senior positions at ourcompany are held by men than women, which
increases the average overall pay for men.

47

Supportto Entry
Professional

13%

Increase in women in leader6 roles in the
UK over last 3 years

55

43%

Male

70
64

Our pay policies and practices are designed
to compensate employees based on factors
such as job performance, expertise, andexperience relevant to individual geography.
We believe no one should be paid differently
due to their gender, race, age, ethnicity,
sexual orientation, or national origin. For thisreason, we monitor our pay equity status andmarket competitiveness on an annual basis toensure we offer equal pay.4 Our 2020 global
compensation cycle once again confirmed azero net gap2 in pay.

Illumina Corporate Social Responsibility Report 2021

5%

Increase in women in senior leader1 roles
globally over last 3 years

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Diversity, Inclusion & Fairness continued
Working with our business partners and the global community,
we can create a more equitable and just world.
Our ERGs include:

SHADES: Employees of color fromdiverse backgrounds and allies

iPride: Employees of the LGBTQIA+
community and allies

CultureOur employee resource groups (ERG) are
key to fostering a respectful workplace anda more inclusive environment. By connecting
individuals with their peers, ERGs enablegroups to develop a collective voice onshared issues and promote internal andexternal diversity initiatives.
We will monitor our regular employee
iPulse surveys across diversity categories
to ensure equitable experience and culture.
We aim to provide robust diversity, inclusion,and fairness training and programming
beyond the minimum required content.
We are working to create a culture where
employees choose to participate in these
supplemental opportunities.

iServed: Employees who servedor currently serve in the military and allies

Horizons: Employees early in theircareers and allies

WIN: Women at all levels and stagesof their careers and allies

BE GREAT: Dedicated to Black/African
American employees and allies

THE CEO ACTION PLEDGE
In 2020, our CEO, Francis deSouza, signed the CEO Action pledge, the largest
CEO-driven business commitment to advance diversity and inclusion within theworkplace. The pledge recognizes the importance of companies truly representing thecommunities they serve, which results in improved economy, corporate performance, andemployee engagement. By working together toward diversity and inclusion within our
workplaces, industries, and the broader business community, we can cultivate meaningfulchange for our society.

56

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

57

Diversity, Inclusion & Fairness continued
Suppliers
Establishing collaborative partnerships withqualified small and diverse suppliers is acommitment we take very seriously. We understandhow important it is that our supply base reflects
the diversity of the communities in which welive, work, and serve. Moreover, we recognizethat a diverse supply base offers a competitive
advantage by harnessing suppliers’ uniqueexperiences, creativity, and innovative solutions.

OUR STORIES OF IMPACT

We must confront ignorancewith knowledge, hatred with love,and complacency with action
for equality. Every voice raised
against racism chips away atits power.”
Francis deSouza, CEO Illumina,
in a letter to all employees

Our program, overseen by a Supplier Diversity
Governance Committee, promotes partnership
opportunities for suppliers in the US that are atleast 51% owned, managed, and controlled by aqualifying diverse group. These include but are notlimited to: woman-owned, minority-owned, veteranowned, disabled person–owned, LGBTQ-owned, or
socially and economically disadvantaged-owned
businesses. Furthermore, we are expanding these
supplier diversity principles to our international
locations. We encourage the use of local businesses
wherever possible to support the economies where
our employees work and live.

Community
We will continue to promote diversity
and inclusion activities and action,
giving back to our communities.
Additional information on our community
engagement can be read in our Accessand Community chapters.

2030 Targets

We aim to magnify our impact by extending these
efforts throughout our value chain.

Maintain annual commitment to UN
Global Compact with submission ofcommunication of progress

2030 Target

Achieved and continuing

Achieve and maintain at least 20% spend
with diverse suppliers (US), and globally,
support local businesses wherever possible

Scale philanthropic cWGS to increase
impact in underserved communities
In progress

In progress2020 Progress

16%

Read more about our
Supplier Diversity Program

STANDING WITH OUR BLACK AND AFRICAN AMERICAN COMMUNITIESIn 2020, we supported organizations such as The National Association for the
Advancement of Colored People (NAACP), American Civil Liberties Union (ACLU), theInnocence Project, Public Allies, and the Equal Justice Initiative. Our cumulative impact
to organizations fighting inequalities resulted in over $800,000 in donations.

Increase programming that supports
equitable access to STEM education
In progressIllumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

58

Caring for Our Employees
Building the world’s best teamstarts with caring for our
employees and putting theirwelfare at the heart of all we do.

Reproductive Health Benefits
Employees, their spouses, and domestic
partners may be eligible for companysponsored reproductive health financial
support, including:

We offer a world-class portfolio of employee
benefits and wellness programs, care forour employees through life events, support
their diverse personal needs, and offer all ourbenefits to employees, spouses, domestic
partners, and dependents.

• In vitro fertilization (IVF)

Workplace Genomics Program
Through our partner, Genome Medical, we
provide access to genetic experts who canprovide guidance and facilitate testing for
employees and their families. In addition,
we offer financial support for cancer tests,
reproductive health tests, and clinical wholegenome sequencing (cWGS) for rare andundiagnosed diseases.

• Non-Invasive Prenatal Testing (NIPT)
Through Progyny, we offer a comprehensive
fertility benefit program that provides
coverage for fertility preservation, providing
equitable access to care for all of our diverse
employees, including those pursuing
non-traditional paths to parenthood.
Parental Leave
Following the birth of a child or placement ofa child for adoption or foster care, we provide
100% pay continuity to eligible US-based
employees for up to six weeks to help ensure
peace of mind during this essential time. Ourparental leave policies in the other locations
where we operate either meet or exceed local
legal entitlements.
The Extra Benefits of Working
at Illumina1
Our employee benefits program recognizes
the tremendous value our people bring to ourbusiness. While benefits vary by country andregion, we provide all our employees with anarray of different programs.

Fostering Wellness Inside and Out

Providing Time to Recharge

Medical, dental, visionF lexible time off

Flexible spending accounts

Minimum 20 days’ paid time off for
non-exempt employees

Heath savings accounts
Employee Assistance program (EAP)W
 ellness program and rooms fornursing, meditation, and prayer
Travel medical insuranceGym access or membership n-site health screenings, bloodO
pressure monitoring, and flu shots
 ffices equipped with ergonomicOworkstations, abundant natural light,
and opportunities to work outdoors
 afeterias offer sustainable, healthy foodCoptions, including vegetarian choices
Genetic counseling and screening
Virgin Pulse digital wellness platform
Supporting Growing Families
Up to six weeks of paid parental leave
Bring Your Kid to Work Day
Back-up care with Bright Horizons
for child and elder care
Flexible work schedules
and remote working opportunities
Gender-neutral parental leave policies

 wo days of paid volunteer time offT(increased to 10 during 2020 as part of
COVID response)
Minimum 10 days of holiday paid time off
Investing for the FutureEmployee stock purchase program401K savings plan
Life insurance
Short- and long-term disability insurancePensionIndependent financial advice
 uition assistance and student
Tloan repayment
Additional Perks and Benefits ite amenities, including car
Swashing, dry cleaning, mobile hairsalons, food service, mindfulness,and self-improvement courses
Employee referral programDonation matching programLegal assistanceS pecial interest clubsC ommuter support

1 Benefits vary by country and region.

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Caring for Our Employees continued
Wellness Programs

OUR STORIES OF IMPACT

We recognize the importance of promoting
a holistic approach to wellness. To help our
employees thrive, we undertake a numberof activities to help meet their physical andmental health needs.
Our digital wellness platform is free toall full-time employees, enabling them totrack wellness-related activities, as well as
participate in fun activities, exercise classes,
and quarterly virtual fitness challenges.
Running for Rosies
One of the projects our US-based interns
worked on in 2020 was the creation of adigital marketing campaign for child cancer
organization Coming Up Rosies. To continue
the work and achievements of our interns,
Illumina supported a global charity fitness
challenge: a virtual 5K run. Each entry into therun was linked to a donation from the Illumina
Corporation Foundation. In this way, we
encouraged employees to keep moving while
contributing to this special cause curated by
our interns.

Walk the World for Rare Disease
During the COVID-19 pandemic, we engaged
our employees to support their wellness andgive back by connecting charity to a fitness
challenge. “Walk the World for Rare Disease”
helped raise awareness about rare disease,and encouraged active, healthy lifestyles bypromoting walking.
The challenge was a great success, with
our employee participation rate more thandouble that of any previous fitness challenge.
Collectively we walked over 100 million
steps—the equivalent of walking around theworld. The $25,000 raised was donated to
five charities across the globe with a unique
or innovative approach to supporting raredisease in their communities.

Wellness While Remote
Our EMEA team members brought extra focus to wellness during the pandemic, training
a further 20 mental health advocates and eight mental health first aiders. The team also
launched Wellness Wednesdays activities, a virtual wellness fair, and guided meditations,yoga, and mindfulness classes.

59Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

60

COVID Care for Our Employees
Our culture of care has never been more relevant or important. In our
response to the global pandemic, employee safety and wellness was
our first and foremost priority.
Employee Safety

Remote Work Safety

 nvironmental, Health & Safety teamsE
led a risk-based framework to ourglobal response esources were provided to helpRestablish safe, ergonomic homeworking environments

 arly to implement shift to remote workEfor office-based associates

 250 provided to purchase keyboard,$
monitor, headset, or other home officeergonomic supplies

 arly to implement restrictions on visitors,
E
travel and large gatherings
Existing emergency preparedness
plans and business continuity plans
were activated

On-Site SafetyEnhanced cleaning procedures,
restricted visitor access, and thermal
temperature scansIntroduced safety features such as
plexiglass barriers, PPE, and anti-bacterial
stations, together with social distancing
rules, and expanded outdoor seating andwork areas
Created workforce separation practices
to minimize physical interaction while
maintaining social distancing

Facilitated transporting officechairs and ergonomic equipment toemployees’ homes ield-based customer-facing teams wereF
provided with access to daily COVID-19
risk screening and at-home testing

Wellness xpanded range of virtual healthE
and wellness classes
 onducted awareness campaigns toCremind employees of resources available
through the Employee Assistanceprogram (EAP) for daily life assistanceand emotional well-being support

CommunicationIncreased frequency of
all-company meetings
 reated a dedicated internal COVID-19
C
communication channel
Twice-weekly seminars with Chief
Medical Officer to provide expertise on thescience of the virus

Pay$1,000 COVID-19 Care cash allowance
distributed to all employees to help
address unanticipated financial needs(excluding VP and above) ay continuity for employees who wereP
self-isolating, and no COVID-19-related
furloughs or workforce reduction
 arly distribution of $500
E
Health & Lifestyle Allowance remium pay provided in early weeks ofP
the pandemic to select employees whose
work required them to be on-siteExpanded paid volunteer time offfrom 2 to 10 days for 2020

Benefits
 p to 30 days’ paid leave underU
our compassion and care time off(CCTO) programIncreased number of days from 10 to 30 for
emergency backup childcare programs
through Bright Horizons Crisis Care
(US employees)
 OVID-19 screening and testing-relatedC
office visits or in-patient services 100%covered by US medical plans xpanded access to telemedicine
E(US medical plans)Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

61

Supporting Early in Career and Beyond
To ensure we have exceptional
people at every level of thebusiness, we work tirelessly to
attract diverse talent, providing
the opportunities and support
people need to progress in theirchosen careers.
We believe in the importance of creatinga workplace in which all employees:• Are empowered to grow, contribute,and make an impact• Work in a culture that prioritizes
learning and continuous improvement• Collaborate and build relationships
with colleagues, whatever theirposition or seniority• Embrace our culture of innovation
and respect

DIVERSITY OF INTERN COHORT 2020

56+44+G 57+43+G
48+52+G

AMR:

56%
Women

57%
Minority

EMEA:

22%

1

48%
Women

Global Intern
Conversion Rate

Carolina Perez, MechanicalEngineering student, Manufacturing
Design Quality Summer Intern, US“This summer I had the pleasure ofworking as a Quality Engineering Internwithin Illumina’s Manufacturing Design
Quality team on a project improving risk
management. I learned so much during
my 10-week experience and am so
excited to finish up my undergraduate
career with reinvigorated passions for
improving personalized medicine!
Thank you for creating a memorable
and meaningful remote internshipexperience, for investing in future talent
and allowing us the chance to contributeto Illumina’s mission, even in the midst of
unprecedented circumstances.”

Connecting with Future TalentiAspire InternshipWe run several paid internship programsaround the world, enabling students
to make an impact by working on businesscritical projects. Giving the opportunity
to work alongside our engineers, scientists,and corporate employees, our internships
span multiple business functions andvarying academic levels (Bachelor’s,
Master’s, and PhD).

• Are rewarded and recognized• Participate in giving back to thecommunities and causes that mattermost to them
• Understand that diversity is strength

15%

Roles filled with internal candidates

23%

New hires referred by
Illumina employees
1 Average conversion rate between 2015 and 2020

Illumina is a company
that truly believes
its greatest asset isits people. There is atangible energy and collaborative
openness that stimulates growthin others. It enables us to be ourtrue selves and welcomes unique
ideas to the table. I am proud tobe part of Illumina.”
Nikki Alayari
Associate Director of Inside Sales

I have learned atremendous amountthroughout theinternship, not only
about environment, health, andsafety and the working world but
about myself too!”
Emily Naismith: EHS intern, Cambridge, UK,
12-month Intern Placement programIllumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

62

Investing in Developing Our People
Our aim is for our employees to enjoy a longand fulfilling career at Illumina. Our training
and development programs embody ourbelief that opportunities always exist to growand to learn regardless of where you are on
your career path. This growth mindset begins
with valuing learning over knowing, together
with seeking new ideas and embracing
challenges while developing.
From soft skills to technical knowledge, online
learning to coaching clinics, we empower
people to shape their own careers, taking
advantage of the frequent opportunities toprogress at Illumina.

Learning at Illumina
Career Development
All employees require the right tools tonavigate their career development.
To supplement our career development
workshops, employees can create anindividual development plan (IDP) to advancetheir knowledge and skills. Development
resources are carefully curated so that
employees can explore, share, plan, and act.
Other tools we offer include:• Tuition assistance/financial assistance forjob-related education

Coaching & Leadership
Development
We believe it is important that all our leaders
are impactful and have the ability to inspire,grow, and collaborate. Our leaders live ourvalues, lead change, and focus on results.
Moreover, they continuously inspire others
to live their passion and achieve theircareer goals.

Development does not stop at management,
and we promote a series of leadershipprograms for both new and experienced
leaders. Applicable trainings are available
in the classroom, virtually, and with digitallearning opportunities.

LEADING AT ILLUMINA

Illumina’s Mission
To improve human healthby unlocking the power ofthe genome.

What leaders do• Leading external speaker series• Open career panel discussions

CreateCompelling
Vision• TEK Talks (technical education knowledge)

The world is constantly
changing, creating anenvironment where
we can always learnsomething new or hone ourskills. We’re passionate about
continuous learning at every stageof our careers, enabling bothformal and informal opportunities
that support personal andprofessional growth.”
Karen Wetherholt, VP Human Resources• 360-degree assessments• Learning management system for required
and on-demand training
LinkedIn LearningThis online educational platform offers
on-demand content to support employees’
professional development. Last year, 85%of our employees took advantage of thisservice. Courses ranged from leading teams
to influencing others and time management.

Build
Great
Teams

85%

Deliver
Exceptional
Results

Champion
Illumina
CultureLive Our Values

Employees used LinkedIn Learning
Innovation
is in ourDNA

We are relentlessin the creation ofgreat products

We
collaborate
deeplyWe movefast andembrace change

We
are
open

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

63

Investing in Developing Our People continued
Sample leadership development opportunities1:
Emerging LeadersParticipants are nominated by their manager,
having demonstrated potential leadershipskills and an interest in people management.
Managing at Illumina and Leadership Edge
Provides those new to leadership with theinsights, tools, resources, and skills required
to effectively lead others.
Leadership Advantage
Comprehensive three-day event for thosewith several years’ leadership experience.
iLeap
Development program that matches potential
leaders with an Illumina executive who acts
as a mentor.
Power Hours
Sessions for frontline leaders, run by subject
matter experts, to develop the skills andknowledge required to lead teams effectively.
Discussion and Lean In Circles
Our business leaders front discussion on
important topics such as “Moving into
Management” and “Managing your Career.”
For example, we support “Lean In Circles,”identified by our Women at Illumina Network(WIN) employee resource group as aneffective initiative for female employees.
Mentoring Programs
The Horizons ERG hosts the Jedi-Padawan
buddy program, connecting early career
professionals with seasoned employees,
while the WIN employee resource groupoffers a mentor program called iMentor.

Culture of Coaching
We believe that every conversation is an
opportunity to coach. Our Coaching Learning
Path highlights a variety of options to help
leaders learn, practice, and build theircoaching skills.
Crucial Conversations
We facilitate workshops that teachcommunication skills for a variety ofsituations in which opinions may differ
significantly, and emotions run high. To
date, over 1,300 employees have taken part.

Recognizing Success
We have designed several award
programs to recognize employees’
outstanding achievements.
Rewarding Innovation
Innovation is a core element of ourculture and success. Every year, wecelebrate our pioneering scientists withan Innovation Award and this year welaunched a new Inventor Recognition program.
Our new Inventor Recognition program
recognizes employee inventors who annuallycontribute to our patent applications.
Values Award
Values Awards are presented to individual
employees and teams nominated by theirpeers for exemplifying our values.

1	Several of our “in-person” training programs suchas Emerging Leaders, Leadership Edge, Leadership
Advantage, and iLeap were paused during 2020 due to
COVID restrictions. Programming converted to ad hoc
training to support leaders in the virtual environment.
Plans are underway for a new learning program strategy
and program architecture for 2021 and beyond.

The mentorshipprogram has openeda space for me to getcandid feedback andthoughtful advice on how tonavigate the corporate landscape,improve my professional
interactions, and grow visibility
inside the company. Karen G. hastremendous experience, quick
wit, high emotional intelligence,and great communication skills,
which makes her an exceptional
leader. She generously carves out
time in her busy schedule to help
me grow my career and I am very
grateful for her support.”
Mentee Maude Champagne
Assoc. Director, Market Access

I had the pleasureof mentoring threeamazing women! I was
so impressed by theenthusiasm and engagementfrom all three mentees. They are
motivated to learn, grow, andcontribute to Illumina’s success.
I learned a lot myself and feel likethis experience helps me continue
to grow as a leader as well.”Mentor Karen Gutekunst
VP, Regulatory AffairsIllumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Committed to Health & Safety in the Workplace
Providing a Safe Workplace
Environment
We are committed to a safe and healthy work
environment for all our employees, contractors,
and the communities in which we operate.
EHS Management System
We continue to work under a management
system framework to measure performanceand continually seek improvement. Our
Singapore site achieved recertification to
ISO 14001 and ISO 45001 and our othermanufacturing locations continue to work
toward conformance by the end of 2021.
Precautionary Approach1
The precautionary approach is embedded
in our risk assessments, our environmental
aspects/impacts, our EHS Policy, ProductStewardship, and the engagement of ourpeople. This enables us to identify risk andtake preventative measures when necessary.
By continuously monitoring opportunities toimprove our products, we can make themmore sustainable, identify safer alternatives,and continue to innovate.

Engagement
Our programs are designed to inspire
employees to consider safety implications
in all that they do. We have established aseries of grassroots safety culture teams thatdrive continuous improvement projects. We
apply software tools to manage incidents andassess risks, enabling employees to easily
report and measure safety performance
focusing on prevention.
EHS Policy
14001 Certificate
45001 Certificate
Injury & Illness Prevention Program (IIPP)ENVIRONMENT, HEALTH AND SAFETY (EHS) POLICY
We embrace our mission through the establishment, implementation, and maintenance of an integrated EHS management system.
This commits us to:Prevent injury, illness, or ill health byproactively managing risk throughminimizing health and safety risks inthe workplace
Respect and protect the environment
by preventing pollution, minimizing
waste, and conserving resources

1 The UN Global Compact Principle 7 and The UN Global
Compact Principle 15 state in order to protect theenvironment, the precautionary approach shall be applied.

Review and improve our EHS
processes while meeting or exceeding
compliance and other obligations

Provide an environment for open
communication and collaboration for
employees at all levels
Evaluate and manage the EHS aspects
and risks of our processes, equipment,
and services based on hierarchyof control

Measure and enhance EHS
performance and provide aframework for setting objectives toachieve continual improvement
Require all employees to beaccountable for their commitment
to our EHS policy

64Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Committed to Health & Safety in the Workplace continued
Ergonomics
To help ensure employees do not sustain
injuries, we provide a number of preventionbased ergonomic resources:

Prevention and Preparedness
EHS's Global IIPP describes basic processes
our employees can take to maintain a safe,
healthy, and compliant workplace.

• Ergonomic and material handling training

Our Emergency Action teams—which
include our Evacuation Sweep team, firstaid volunteers, and Chemical Incidental Spill
Response team—work together to createawareness and lead regular preparedness
drills and activities.

• In-person ergonomic evaluations• Proactive processes and ergonomic
assessments of equipment• Office ergonomic software to provide
customized training and recommendations>3,000prevention reports

465

1,200

0.34

EHS Risk Assessmentscompleted globallyin 2020

Employees submit potential hazards, helping
focus on a culture of prevention before anear miss or incident occurs>30,000

ergonomic evaluations
completed in 2020

hours of EHSrelated training

Injury & Illness Rate in2020, down from 0.76
in 2018

ENVIRONMENT, HEALTH & SAFETY

2018
2019

Recordable
Injury &Illness
Rate

2020

Lost Time
Incident
Rate• Recordable Injury & Illness Rate calculated using total hours worked from employees + contingent workers. Lost Time
Incident rate calculated using total hours worked from employees + contingent workers. Rates have been calculated
based on 200,000 hours worked.

0

0.2

0.4

0.6

0.8

1

1.2

1.4

1.6

65

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

66

Committed to Health & Safety in the Workplace continued
OUR STORIES OF IMPACT

COVID-19 & EHS
Employee safety has been paramount throughout the pandemic response.
See more information on our COVID Care page.
• Site safety enhancements• Workforce separation practices• COVID-19 case management
and response framework• Self-collect employee COVID-19
testing program (AMR)• COVID-19 self-report tool

• On-site COVID-19 health check-in• Thermal scanning kiosks

Acrylic shield guards

Safe distancing setup

Hands-free automated taps

Hand sanitizer

Cleaning stations

UV fresh air



ILLUMINA AWARDED AS A WORKPLACE SAFETY AND HEALTH (WSH) EMPLOYER IN SINGAPORE
The award recognizes companies who have upheld high safety and health standards at their workplace.
This year, Illumina was specifically recognized for the category of WSH Innovation Award, showcasing
the shift from a semi-manual filling to a fully automated suite of reagent fill lines. The new system wasdesigned to reduce hazards and improve ergonomics. Illumina is focused on providing robust health andsafety systems, processes, equipment, and training, thus empowering our employees to perform in a safeand responsible manner.

Powershield misting
Automated doors
surface shield sanitization Contactless door buttons

Occupancy limitsIllumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

doing
business
responsibly
Focus on Integrity
In this section:
68
Q&A With Our General Counsel
69	Focus on Integrity: Overview
70
Governance With Integrity
71
Enabling a Culture of Compliance and Ethics
72
Ensuring Our Work Reflects the Best of Illumina
73
Respecting Human Rights
74
Risk Management and Resilience
75
Protecting Privacy
77
Magnifying Our CSR Impact Through Our Supply Chain
80
Partnering With Policymakers to Improve Human HealthIn our CSR program and across our business, we arecommitted to conducting ourselves with honesty,
integrity, and respect for all. We believe that we are best
able to magnify our mission to improve human health
if we act as a sustainable and responsible citizen at all
times, in all that we do.

67

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Q&A With Charles Dadswell
Chief Compliance Officer and General Counsel
Q: How has compliance been embeddedin the business?
A: We put a strong governance foundationin action through our Code of Conductand compliance programs. We anchor tothat Code in how we run the company, andrequire annual certification. That culture ofcompliance and ethics starts at the Board
level and is incorporated into every level ofour business.
Q: How has the Board of Directors been
engaged on the challenges of COVID-19,
racial equality, and climate change?
A: The Illumina Board of Directors has been
active on all three issues. For COVID-19,
the Board examined and discussed ourcommercial efforts, including our assay
development and FDA Emergency Use
Authorization, as well as our employee
support initiatives. In response to racial
equity, the Board discussed our philanthropic
engagements and ongoing diversity andinclusion programs. The Board provides
oversight on our CSR program, including the
key tenets of sustainability and our response
to climate change.
Q: How did the Ethics Advisory Board
evolve in 2020?
A: The Ethics Advisory Board (EAB) was
formed in 2008, and has a wealth ofexperience. In 2020, we welcomed a new anddiverse class of EAB members with an arrayof experience, including the subject areas of
informed consent, clinical research, patientadvocacy, international bioethics, and theimpact of race in genomics, research, andhealthcare. The EAB assists us on privacy,
ethics, and emerging issues in the genomic
space, as we continue to lead in all mattersthat our technology might touch.
Q: What do you see as a highlight for the
ethics programming in 2021 and beyond?
A: As genomics continues to evolve, we will
strengthen our programs and leadership on
the topics of data security, data privacy, andthe ethical concerns that could be related
to our technology. We are committed toensuring the power of genetics and the
genome is responsibly applied, even as thisfield is constantly developing.
Q: As the President of the Illumina
Corporate Foundation, how do you see thegiving evolve with your CSR program?
A: The Illumina Corporate Foundation is
one element of our holistic giving approachthat impacts our CSR focus areas. In 2020,
we were able to invest in initiatives that
supported increasing access to genomics
and STEM education for underrepresented
groups, and respond to the global pandemic.
I expect our programs to continue to growand help us make an impact globally.

We are committed to ensuring
the power of genetics andthe genome is responsibly
applied, even as this field isconstantly developing.”

Illumina Corporate Social Responsibility Report 2021

68

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

69

Focus on Integrity: Overview
Our Commitment

Our Objectives

We are committed todemonstrating leadership as
responsible corporate citizens
and doing business in a way thatreflects the very best of Illumina.

The tenets of strong governance arefoundational to doing business responsibly.
We put this in action through our Code of
Conduct and compliance programs. We
embrace ethics and transparency, humanrights and equity, product quality, and supply
chain engagement.

In our CSR program and acrossour business, we are committed
to conducting ourselves withhonesty, integrity, and respect
for all.
Achievements in 2020
Updated Illumina Codeof Conduct to reflect
expanded CSR program aintain a corporate governance frameworkM
to promote ethics and integrity in all we do
Achieved and continuing

Achieve a mix of Board members that
represents a diversity of backgroundand experience, including with respect
to age, gender, background, race, andspecialized experience

Our Why
Ensure all Illumina political activities promote
ethical and transparent engagement,
advance the Company purpose, andcomply with applicable laws andreporting requirements
Achieved and continuing

We believe our positive impact on humanity canbe magnified by doing business responsibly.
For us, doing the right thing is more than justcompliance, it is about having a deep sense of
integrity and honoring the trust given to us byemployees, patients, customers, shareholders,and our communities.

Continue working to ensure human rights
are respected in our workplace, our supply
chain, and the marketplace

We recognize that the longevity of our
success is linked to creating sustainablevalue for our shareholders and society.

Achieved and continuing

As leaders and pioneers in genomics, we
strive to drive positive progress and makeit useful for all. With that in mind, we aim
to ensure that the power of the genome isalways responsibly applied.

Demonstrate responsible data
stewardship with strong privacy andcybersecurity practices
Achieved and continuing

Achieved and continuing

Welcomed new members
to Ethics Advisory Board
Updated Supplier Codeof Conduct to expand
expectations alignedwith CSR commitments
Released new
position statements
Conducted Supplier Diversity
COVID Outreach Initiative

Early stages
In progress
Achieved and continuingIllumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Governance With Integrity
Good corporate governanceinvolves balancing the interestsof all our stakeholders, including
our employees, customers,
patients, suppliers, community,
government, and shareholders.
By exercising strong corporate governanceand ethical leadership, we aim to inspire
confidence in our company’s future,and create a safe and supportive work
environment for our employees.

Board of Directors
Our culture of compliance and ethics starts
at Board level, the highest level of ourleadership, and is integrated into every levelof our business. Our Board of Directors is
a diverse group of leaders who champion
scientific innovation. Its aim is to ensure thecompany is equipped with the tools it needs
to accelerate the power of genomics.
The Board has adopted Corporate Governance
Guidelines founded on a commitment tobuilding shareholder value, with an emphasis
on responsible governance. These guidelines,
together with the Code of Conduct and Board
Committee Charters, provide the framework
for corporate governance at Illumina.

Board Diversity
As specified in the Corporate Governance
Guidelines, our company seeks to achieve a Board
mix that represents a diversity of backgrounds
and experience. This applies to age, gender,
background, race, and specialized experience.
Furthermore, our governance guidelines requirethat independent directors constitute at least amajority of the Board. We have adopted standards
for director independence in compliance with the
NYSE corporate governance listing standards.

Board Members

Jay FlatleyFrancisdeSouza

Frances
Arnold, PhD

Caroline
Dorsa

Our Board has four Board Committees:• Nominating/Corporate Governance Committee

Ethics Advisory Board
Established in 2008, the Ethics Advisory Board(EAB) advises and provides recommendations on
ethical issues, policies, and regulations relevantto the genomics industry, including those related
to Illumina’s existing, emerging, and prospective
products, services, and processes from a researchand clinical perspective.
Illumina seeks guidance from our Ethics Advisory
Board on a quarterly basis. Work includes providing
strategic advice to Illumina about:• Ethical issues arising from specific technology
or products

Scott
Gottlieb,MD

Independent
Directors• Compensation Committee• Science and Technology Committee

Robert S.
Epstein,MD

8• Audit Committee• Emerging policies and regulations relevant to the
genomics industry and the company’s interests

10

BOARD OF DIRECTORS

Gary S.
Guthart,
PhD

PhilipSchillerSue
SiegelJohn W.
ThompsonCharmaineRoyal, MS,
PhD

Nita
Farahany, JD,
PhD

30%

Female Board
members

ETHICS ADVISORY BOARD

Clement
LeslieAdebamowo, Biesecker, MD
BM, ChB, ScD,FWACS, FACS

1:1

Ratio of women to men on Ethics Advisory Board

Freda
Lewis‑Hall,
MD, DFAPA,
MFPM

Glenn
Cohen, JD

70

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

71

Enabling a Culture of Compliance and Ethics
Our work deeply impacts the
lives of many people.

Compliance Committee
The Compliance Committee directs andoversees our compliance activities, including
the administration of our Code of Conduct.
It is composed of senior executives, andchaired by our General Counsel, who is also
the Chief Compliance Officer.

Patients entrust their medical and healthdecisions to us; our customers trust us toenrich their research and enhance theirreputations; and our employees and partners
count on us for financial and other reasons.
We operate responsibly to honor the trustthat our employees, patients, customers,
community, and shareholders place in us.

It is the responsibility of the Compliance
Committee to:Together, we are committed to reflecting thevery best of our people, practices, and purpose.

• Advocate and promote global awareness ofthe company’s compliance program efforts• Provide training and education
to employees• Maintain effective lines of communication
between employees and management• Conduct internal monitoring and auditing toensure compliance• Enforce policies and standards of conduct
through disciplinary guidelines• Respond to detected offenses and takecorrective actionCEO

Compliance Committee

Internal Audit

Committee Members

Chief
Medical
Officer• Designate a compliance officer andcompliance committee• Create written policies and standardsof conduct

Board of Directors

Chief
Operations
Officer

These elements include:• Foster a culture of ethics and compliance

COMPLIANCE MODEL

Chief
Compliance
Officer(GeneralCounsel)The Compliance Committee has adopted a
program framework based upon the sevenfundamental elements of an effective
compliance program established by the Officeof Inspector General.

Chief
Commercial
OfficerCompliance Director, Secretary to Committee

Chief
Financial
Officer

ChiefMarketing
Officer

Chief
PeopleOfficer

Ethics and Compliance
Reporting Hotline
We are committed to fostering a culture inwhich employees feel comfortable raisingcompliance concerns without fear of
retaliation. To this end, we promote an open
door policy that encourages our people toraise any concerns or questions with their
manager, human resources, and/or thecompliance reporting resources.
To help facilitate the reporting of good faithconcerns, we have established a third-party
compliance hotline and website that Illumina
employees and others may use for reporting
concerns. Our non-retaliation policies,
confidentiality policies, and mechanisms
ensure anonymity, and protect employees.
The Compliance and Fraud Prevention
reporting resources are available to both
employees and third-party partners, 24/7
at (800-461-9330), or electronically atCompliance and Fraud Prevention Reporting.
Callers may choose to self identify or remain
anonymous (where permitted by law)when reporting.

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

72

Ensuring Our Work Reflects the Best of Illumina
We take pride in conducting
our business with honesty andtransparency, and in accordancewith legal standards andethical principles.
Culture of Compliance
Our policies guide employees on how to apply
a culture of compliance to their daily work.
Our Code of Conduct promotes honest andethical conduct, compliance with applicablelaws and regulations, and protection of ourbusiness interests. It applies to all of ouremployees, consultants, temporary workers,
officers, and members of the Board of
Directors, regardless of location, seniority
level, business unit, function, or region, andis supported by written programs, training,
investigations, root cause analysis, risk
assessment, and monitoring. Our Code laysout guidance on making ethical decisions
while conducting business on behalf ofIllumina. Key topics include fraud prevention,bribery and corruption, anti-discrimination,
anti-harassment, human rights, diversity andinclusion, employee safety, corporate social
responsibility, marketing and sales claims,
and government interaction.

8

Code of Conduct languages

100%

Employees certified to the CodeCompliance Accountability
and Training
Our Compliance Committee directs andoversees compliance activities, including
administration of our Code of Conduct.
When an actual or potential instance of
non-compliance is identified, it isinvestigated by our Compliance Department.
Any non-compliance is addressed, andrisk mitigation and monitoring plans aredeveloped with relevant stakeholders, as
appropriate. In all cases, we take the steps
necessary to protect reporting or cooperating
parties from any form of retaliation.
We actively engage our employees in our
ethical governance program to ensure
they have a thorough understanding ofwhat is expected of them. Employees andmanagers are expected to behave ethically,
ask questions when in doubt, and report
any wrongdoing. We offer Code of Conduct
training through our enterprise learning
management system (LMS). All employees
receive training when onboarded andannually. Employees must acknowledge inwriting that they have read, understood, andwill abide by our Code of Conduct.

Anti-Corruption and Anti-Bribery
We forbid bribery and corruption in the
conduct of our business, and comply with
anti-corruption laws wherever we operate.
We support businesses working against
corruption in all its forms, including extortionand bribery, and expect all our partners tomaintain the same standards.

Anti-Competitive Behavior
We aim to compete and succeed in a fair andhonest marketplace, and do not engage inunethical, unfair, or illegal communications
with competitors. We always deal fairly
with customers, suppliers, competitors, andemployees, and do not take unfair advantage
of anyone. We do not enter into formal orinformal agreements with competitors toengage in any anti-competitive behavior, andstrictly comply with all related laws. We forbid
anti-competitive behavior, antitrust, andmonopoly practices.

Pricing
We maintain a responsible approach topricing our products. We negotiate andpartner with healthcare systems, payers, andresearch institutions to provide availabilityof our products at a fair net price. As inpast years, we limited our annual aggregate
list price increase while continuing to offer
new technologies that lower our customers’
costs per genome and provide increasing
access. Illumina is committed to offering
prices that enable broad access to genomic
technology. Prices are available to customers
through their account managers or online
on myIllumina.com. Customers can and areencouraged to place orders electronically.
Prices are also visible to customers on their
invoices and billing statements. Most of
Illumina’s customers are not on a supply/
purchasing agreement. When such an

agreement is in place, Illumina uses generalconfidentiality clauses in most cases.
Examples of factors that may affect priceinclude region and volume. Illumina sets
and adjusts list prices based on several
factors, including but not limited to costs,
inflation, and market dynamics. Illumina’s
pricing reflects its value proposition andenables Illumina to continue to innovate forour customers and accelerate access togenomics for all.

Interactions With Healthcare
Professionals and Organizations
As a company that manufactures and sells
products and services for medical use, weare subject to rigorous standards of conduct
regarding our interactions with healthcare
professionals and organizations. The Illumina
Policy for Interactions with Healthcare
Professionals and Organizations guides how
we conduct business with these groups,
together with ensuring compliance withapplicable laws, regulations, and standardsof conduct.

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

73

Respecting Human Rights
We are committed to respecting
human rights and treating
every stakeholder with dignity
and respect.

and regulations administered by the UnitedStates Department of the Treasury, Officeof Foreign Assets Control (OFAC), and allapplicable trade sanction regulations in the
countries where we do business. It provides
a risk-based approach to commercial andphilanthropic opportunities in sanctioned andembargoed countries.

Our Commitment
Integrity and fairness are central to ourvalues, how we operate in the workplace
and the marketplace.
We acknowledge and respect thefundamental principles contained in boththe Universal Declaration of Human Rights
and the United Nations Global Compact.
It is our commitment to integrate theseprinciples into our strategy, our culture,and our operations.
KEY PLEDGES OF OUR HUMAN
RIGHTS POLICY• Ethical business conduct• Supplier Code of Conduct• Right to exercise freedomof association• Fair wages and working hours• Protection of privacy• Safe workplace• Elimination of child and forced labor• Equal opportunity

We have highlighted a few of our
key Human Rights Policy pledges:
Elimination of Child Labor, Forced Labor,and Human Trafficking
We condemn all forms of exploitation ofchildren, will not recruit child labor, andsupport the elimination of exploitive childlabor. We support the elimination of all formsof forced, bonded, indentured, and involuntary
prison labor, and human trafficking. We will
never knowingly use a supplier, contractor,
channel partner, or business partner, engaged
in child, forced, or slave labor, nor will we
condone such practices.
Safe Workplace
Our Injury and Illness Prevention Programand Environment, Health and Safety (EHS)Management System Policy enable us
to proactively manage risk and engage
employees. We are committed to creatinga work environment free from violence andharassment of any kind that threatens,
intimidates, or coerces another person.

Equal Opportunity and Non-Discrimination
We support the elimination of discriminatory
practices with respect to employment. We arecommitted to fair and respectful treatment of
all employees, promoting equal opportunityand diversity in the workplace and in all
aspects of our business. Our policies prohibit
discrimination based on race, color, age,gender, sexual orientation, marital status,
gender identity and expression, ethnicity,religion, physical or mental disability, medical
condition, genetic information, veteran status,
national origin, or any protected class.
In addition, the Illumina State Sponsors ofTerrorism (SST) Policy prohibits businessin or with SST countries, as defined by the
US Department of State, and the Illumina
Sanctioned and Embargoed Countries
Policy prohibits business in or with parties(country, entity, individual) that violate
any applicable trade sanction regulationsin the countries where we do business.
This policy is based on the foundation ofcompliance with economic sanctions, laws,

Ethical Use of Genomic Technologies
Illumina is steadfast in our commitmentthat genomic technologies should be used
to benefit humanity, and we will only workwith partners who further this mission.
We take concerns about the ethical use of
Illumina technology and its impact on humanrights very seriously and have implemented
contractual and procedural safeguards toprevent misuse. Our customer agreements
outline our expectations regarding the ethicaluse of our technology and the steps we cantake in the event of a possible violation. In
addition, we have expanded and enhanced
the sales-review process for entities andgeographies of heightened concern in orderto monitor and enforce this commitment andprevent sales that could result in misuse or
human rights concerns before they happen.
Illumina will not hesitate to cease sales andservicing in the event of a confirmed ethics orhuman rights-related concern.

Human Rights Impact Assessment
In 2021, we will initiate a humanrights impact assessment to review
additional opportunities.

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Risk Management and Resilience
Links to
Corporate Governance Guidelines
Illumina Code of Conduct
Supplier Code of Conduct
Supplier Diversity Program
Channel Partner Code of Conduct
Anti-Bribery and Anti-Corruption Policy
Interactions with Healthcare
Professionals and Organizations
Policy Statement
Compliance and Ethics information
Privacy Policy
Commitment to Cybersecurity
Illumina Security
Resources & Best Practices
Ethics Advisory Board Charter
Human Rights Policy

Assessing and Managing Risk

Climate Resilience

We work to anticipate, assess, monitor,and manage emerging issues to identify
potential risk and opportunities.

At Illumina, we believe addressing climatechange is one of the key topics to achievinga sustainable, just, and resilient future for all.
We are committed to climate action and theintegration of climate resilience planning into
our risk and opportunity program, and we
support the calls for greater data transparency.

The Internal Audit Department provides
independent and objective feedback to theBoard Audit Committee. We continue toassess risks in our business, and endeavor
to ensure that all employees adhere to
our ethics and compliance protocols.
Our Business Continuity team is working
toward standardized processes across our
manufacturing network. Our programs andpractices protect our ability to do businesseven in adverse circumstances and enable
us to respond to unexpected events.
Our risk assessments consider various
quantitative and qualitative inputs, including:• Business and Finance• Operational• Legal and Regulatory

Conflict-Free Minerals Policy• Brand and Reputation

California Transparency inSupply Chain and Modern Slavery• Product Quality

Responsible Stem Cell Use
Position Statement• Environmental, Health & Safety

Animal Testing Position Statement
Corporate Social Responsibility Policy
Climate Change Position Statement
Environment Health & Safety (EHS)
Policy Statement
Injury and Illness Prevention Program
Quality Policy• Employee• Climate

We recognize that the risk and opportunities
span both physical risk (extreme
weather) and transition risks (regulations,
technology, policies).
In 2020, we conducted our first climate
scenario analysis using 2°C, 3°C, and
4°C models.

See the Appendix for additional details on
In this report, we are adding supplemental
our Task Force on Climate-related Financial
voluntary disclosures to our reporting framework. Disclosures (TCFD) index and climate
scenario insights.

74

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Protecting Privacy
Progress in genomics holds
immense promise to revolutionize
clinical care. To realize thepotential of genomic data to
inform discoveries that provide
public good, individuals musthave confidence that the privacyof their genomic information isrespected and secured.
With the large-scale analysis of genomic
data, scientists can better identify rare andundiagnosed diseases, discover variants
associated with cancer, and enable insights
into infectious disease research. We arecommitted to developing, upholding, andpromoting the highest standards for genomic
data privacy.
OUR PRIVACY GUIDING PRINCIPLES

Our Privacy Guiding Principles
Illumina believes that responsible data
stewardship, built on a foundation ofstrong privacy and data security protections,is essential to promote trust and support
innovation. Our Privacy Policy defines how
we may use, maintain, protect, disclose,or transfer certain types of personal
information in the provision of our
products and services. How we handle
personal information is aligned to our four
fundamental privacy guiding principles.

Transparency
We communicate our privacy practices and how
we use personal information in a clear way
Ethical Use
We only collect and use personal information for
purposes that further our mission, and always
do so in a lawful and transparent way

We believe that as the cost of sequencing continues todecrease and genomic data becomes more prevalent,
privacy practices that ensure the safety and integrityof that data—and the individuals it comes from—are essential.”
Chad McManamy, Data Protection Officer

Responsible StewardshipWe protect personal information to ensure that
it is confidential and secure
Accountability
We are committed to complying with all legal
requirements, and promoting internal practices
to achieve the highest privacy standards

75Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

76

Protecting Privacy continued
Cybersecurity
Genomics data is powering positive progressaround the world. Our technologies andservices inherently involve handling large
amounts of genomic and health data thatmust be protected, making cybersecurity
integral to achieving our company mission.
• All Illumina instruments are equippedwith an instrument control computer,and users are offered protection guidance>2,000employees virtuallyparticipated in our annual
October Cybersecurity
Awareness Month activities

KEY REFERENCES• NIST Cybersecurity Framework• ISO 27001• ISO 13485• General Data Protection
Regulation (GDPR)• California Consumer Privacy
Act (CCPA)• Health Insurance Portability andAccountability Act (HIPAA)• Clinical Laboratory Improvement
Amendments (CLIA)

Our Commitment to Cybersecurity consists of five pillars:

ProgramGovernancePartnerships

Secure Product Design
and Placement

Risk Analysis andSecurity Testing• Led by Chief Information
Security Officer (CISO)• Healthcare Information
Sharing and Analysis
Center (H-ISAC)• Products and systems
secured and maintained
throughout life cycle• Continuously assesscybersecurity risk

• Domestic Security
Alliance Council (DSAC)• Risk mitigation at earliest
stages of product design
and placement• CISO reports at least
quarterly to the Boardof Directors’ Audit
Committee• Annual assessment
against National
Institute of Standards
and Technology(NIST) Cybersecurity
Framework• Employees andcontractors trained
annually• Third-party workrequires cybersecurity
risk assessment prior to
engagement• Information 2 Systems
Security Association
International (ISSA)• Security design
requirements• Society for Information
Management San
Diego (SIM)• Cloud-based productsaligned with ISO 27001• Chief Information
Security Officer
Roundtable• Strong encryption
standards• InfraGard• Privacy by design• Strict data access
controls• Perform internal andexternal security testing
for all cloud software
products• Regularly put cloud
software products
through static analysis• Incident response planand team in place tohandle cyber-related
disruption, withbusiness continuity andcontingency plans• Internal vulnerability
analysis conducted• Internal tests deployed
to represent simulated
hacker attacks

Data
Protection• Data protected incompliance withapplicable laws andcybersecurity bestpractices• Data privacy and dataprotection align withstandards set by GDPR,
CCPA, HIPAA, otherregulations, and ourPrivacy Policy• CLIA laboratories
ensure data quality andsecurity with CLIA andregular HIPAA frameworkassessments• Backup capabilities
encrypt and store data
in immutable formats fordata confidentiality andintegrity• Amazon Web Services(AWS) hosts the Illumina
BaseSpace Suite, withadditional security
featuresIllumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Magnifying Our CSR Impact Through Our Supply Chain
Supply Chain Overview
Our suppliers are critical to our mission.
Together, we can magnify the positive impact
to our customers and communities where
we operate.
Our global supply chain consists ofsuppliers, sub-contractors, channel partners,
manufacturing sites, distribution centers, andcustomers. Our main manufacturing facilities
are in the US and Singapore.
We consider it business-critical to workwith suppliers who share our commitment
to integrity, and who support an ethical andcompliant culture. Our suppliers are held
to the same high standards of businessconduct that we set for ourselves. We
require them to comply with the standardsof behavior outlined in our Supplier Code of
Conduct and exhibit social responsibility andenvironmental stewardship.
The Illumina Supplier Code of Conduct isconsistent with commitments we made bothas a signatory of the United Nations Global
Compact and as a member of the Dow Jones
Sustainability World Index. All new suppliers
are required to acknowledge the Supplier
Code of Conduct in order to complete theonboarding process.
In 2020, we updated our Supplier Codeof Conduct to better reflect our growing
CSR program and expectations of our
supply partners.

Our updated Supplier Code of Conduct now
includes guidance for suppliers to provide
options that support environmentally
preferable products (EPP) that meet
performance requirements when submitting
proposals to Illumina for commodities andservices, wherever possible. Our internal buying
teams will prioritize purchasing EPPs whencompeting products have comparable function
and value.
We expect our suppliers to:• Comply with local regulations andapplicable US and international regulations• Uphold their employees’ human rights
and the Illumina Human Rights Policy

Strategic Supplier Sustainability

75%

Through our supplier scorecard program, we
have assessed our strategic suppliers forcommitments to reduce their environmental
footprint. By 2030, we aim to reach 100%.

OUR SUPPLY CHAIN
We have different types of suppliers that
range from off-the-shelf packaging material
to highly sophisticated reagents. We split
our suppliers into the following categories:
direct, indirect, strategic, differentiating,core, transactional, finished medicalof our strategic suppliers arecommitting to reduce theirenvironmental footprint

device, custom spec, off the shelf, internal,
external, and services.
We source components, software,equipment and services from 28 countries
across the Americas, Asia, Europe
and Africa.

• Ensure a safe and healthy workplace• Demonstrate social andenvironmental responsibility

3,700• Conduct business in an ethical manner

suppliers across
supply chain

Supplier Diversity Program
Illumina is committed to establishingcollaborative partnerships with qualified
small and diverse suppliers and recognizes
the importance of ensuring our supply basereflects the diversity of the communities
in which we live, work, and serve. Globally,
we encourage the use of local businesses
wherever possible to support economies
where our employees work and live.
Our goal is to achieve 20% spend withdiverse suppliers by 2030. In 2020, we
achieved 16%.

Supplier Diversity Program$396M
direct supplier
spend

$935M

$152M
spend with
334 diverse
suppliers

estimated payments
made to suppliers

77Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Magnifying Our CSR Impact Through Our Supply Chain continued
Channel Partners

Modern Slavery

Our products are available around the globe
through a robust channel partner network.
Our partners not only offer critical accessto our products throughout the world
but also provide the same level of sales,
marketing, service, and support that weoffer to customers directly. The Illumina
Channel Partner Code of Conduct requiresthat channel partners match Illumina’s
commitment to business integrity, ethicalconduct in the marketplace, adherence toall applicable laws, and the fundamental
elements of human rights. Illumina is amember of the Advanced Medical Technology
Association (AdvaMed) and MedTech Europe.
Channel Partners are required to adhere to
the applicable provisions of the AdvaMed
Code of Ethics and MedTech Europe Code of
Ethical Business Practice.

Illumina is committed to conducting its
business lawfully and with integrity.
We work to continually strengthen ourpractices to ensure no human trafficking,slavery, or forced or compulsory labor
occur in any part of our supply chainsand global operations. We also seek toensure that our global business partners
do not use modern slavery in any of its
forms in providing goods or services.

133

Channel Partners1

1	as of end of December 2020.

 alifornia Transparency in Supply ChainC
Act & UK Modern Slavery Act

Conflict-Free Minerals

Working With Business Partners

Verification and Due Diligence

We only build relationships with business
partners that share our commitment tofulfilling all legal and ethical obligations.
We never knowingly conduct business withbusiness partners that employ underage
individuals, employ forced labor, or use
corporal punishment to discipline employees,
regardless of whether such practices are
permitted by law.

We perform due diligence on new business
partners to verify that they meet ourstandards. This process involves conducting
initial risk assessments when onboarding
new suppliers, and conducting periodic
assessments of performance. In addition,
for supply chain areas of higher risk, wetake steps to enhance our risk mitigation
strategies. All employees and business
partners are encouraged to report potential
violations or concerns through a variety offormal channels, including our Legal team
and/or our compliance hotline.

Illumina supports international efforts
to ensure no conflict minerals directly
or indirectly benefit armed groups in
the Democratic Republic of Congo or
adjoining countries. To this end, Illumina
expects all suppliers to commit to the
Responsible Business Alliance (RBA)
Code of Conduct. Furthermore, throughour Conflict-Free Minerals Policy we
expect all our suppliers to establish
their own due diligence program toensure supply chains are free of conflictminerals and to make their due diligencemeasures available to Illumina uponrequest. Illumina routinely evaluates
its suppliers to ensure that they areadhering to Illumina’s expectationsand values.

78Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Magnifying Our CSR Impact Through Our Supply Chain continued
Supplier Quality Vision and Values

Product Quality

The aim of the Illumina Supplier Quality Vision
is to construct and foster a leading supplierbase that ensures safe and quality products
every time. The supplier quality management
life cycle incorporates the following phases:

Quality Policy
Illumina is dedicated to being the leading
provider of integrated solutions that
advance the understanding of genetics
and health. We will achieve this throughour focus on the customer experience, ourcommitment to continual improvement,
maintaining the effectiveness of our quality
management system, and complying withregulatory requirements.

• Audits• Monitoring
Working with our suppliers, we can focus
on the customer experience, continual
improvement, effectiveness of our quality
management system, and compliance.

Quality Management Systems
The following locations are certified
to the ISO 13485 Standard:

100% of Illumina owned or operated facilities
participate in third-party audit programs.
97% of Tier 1 suppliers participate in someform of third-party audit program, basedon our supplier qualification requirements.
All products shipped by Illumina carry abarcode for traceability and are tracked
via our inventory management system, SAP.

• Hayward• San Diego

Concept

Feasibility
and Planning

Development

Transfer

Sustaining

QMS and Compliance

QMS and compliance serves as a critical aspect at any stage of the
product life cycle, ensuring that policies and objectives are in place and product quality
standards are met to the highest caliber.
SUPPLIER QUALITY MANAGEMENT LIFE CYCLE• Madison• Netherlands• Singapore• Foster City

• Supplier selection• Supplier evaluation

Supplier Qualificationtion
lec ione
S ua tl• Non-conformance
management• Supplier Corrective
Action Request (SCAR)• Performance management• Business reviews• Scorecardp
S u niMo

The essence of the Illumina quality philosophy is that all
employees, both at Illumina and at our suppliers, have theresponsibility and discipline to ensure the quality of their own
work before passing it on to the next step in the process. We
strive to build quality into our products and processes starting early inthe development cycle to ensure that we meet customer expectations.
We expect the same from our suppliers.”

Qu Supali
fi

Supplier
Quality
Management
Life Cyclep
to li e r
ri n
g

r n
ie
pl atioc• Cambridge, UK

Supplier Selection
and Evaluation

Supplier Monitoring

Gary Workman, Vice President, Global Quality

Pilot

o
ic n e n
at
io n t• Qualification

Identifying the Quality teams that play a key role during the product life cycleSuppand lierEva• Initial risk assessments

QMS AND COMPLIANCE ROLES IN PRODUCT LIFE CYCLEpm
C o a l if
Qu

• Change notificationagreement• Quality agreement• Qualification audit

Component Qualification• First article inspection• Measurement systemanalysis• Process capability• Process Failure Modeand Effects Analysis(PFMEA)• Control plan
• Sub-tier supplier control

79

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

80

Partnering With Policymakers to Improve Human Health
We believe proactive, responsible
engagement with public policy
stakeholders translates to sharing
accurate and reliable information
about genomics and advocating
for policies that ensure andpromote broad access.

In compliance with the Lobbying Disclosure
Act, Illumina regularly files quarterly reports
as required by law, outlining:

Illumina participates in the political andpublic policy process with governments
and organizations around the world toengage and educate policymakers andkey stakeholders on issues that impact our
mission and business.

• Respective legislative body contacted

Pursuant to our Code of Conduct, we commit
to deal with governments, government
agencies, and public officials according
to the highest ethical standards and incompliance with all applicable laws. In 2020,
we released an updated public statement on
Political Contributions.
Our Global Government Affairs team is
responsible for advocacy activities. Illumina
does not have a Political Action Committee
but does retain outside strategic advisors
who support our global engagement with
policymakers and key stakeholders. They may
also provide expertise on policy and specificregional issues.

• Total federal lobbying expenditure• The name(s) of the respective
legislative topic(s)• A list of employees that lobbied
on our behalf
We file a similar publicly available lobbying
report at the state level as required bystate law.

Disclosures & Transparency

Oversight

Illumina complies with all applicable laws
and requirements in connection with its
global political and public policy activities.
These laws generally require reporting onlobbying activities and compliance withapplicable gift laws. Reports filed on behalf ofIllumina are publicly available in the following
government-hosted databases:

How we interact with policymakers
must align with our core values, ethicalresponsibilities and legal obligations. Thisapproach includes our political policy
interactions. The Nominating/Corporate
Governance Committee of Illumina’s Board of
Directors oversees this policy and Illumina’s
contribution practices. The Committee
maintains responsibility for ensuring all
Illumina political activities promote ethicaland transparent engagement, advance
the Company’s mission, and comply withapplicable laws and reporting requirements.
On an annual basis, Illumina will provide
an update on the Company’s public policy
priorities, political contributions, lobbying
expenditures, and information aboutsignificant memberships.

• Office of the Clerk, US
House of Representatives• Secretary of the Senate, US Senate• Lobbying Disclosure,
California Secretary of State• Transparency Register,
European Commission

We are committed
to constructive
and responsible
advancement of
the power and possibilities
of genomics for patients andcommunities worldwide.”
Kathy Lynch, Vice President, Global
Government Affairs & Public Policy

Trade Associations & Memberships
Illumina participates in various tradeassociations for collaboration and exchangeof ideas. Illumina pays annual dues to anumber of trade and industry associations,some of which utilize a portion of membershipfor non-deductible state and federal lobbying
and political expenditures. As part of thispolicy, we disclose memberships in tradeassociations for which we contributed over
$5,000 in the immediately preceding year,
as well as the total amount of such dues.
For trade association payments in excess
of $50,000, we also disclose the portionof payments that are non-deductible under
Section 162(e)(1)(B) of the Internal Revenue
Code, such as payments to organizations
designated as 501(c)(4) and 501(c)(6).

LEGISLATIVE PRIORITIES• Advancement of precision medicine• Adoption and reimbursement for
genetic testing• Adoption and reimbursement for NIPT
• Adoption and funding for genomic
infectious disease surveillance• Promoting STEM opportunities

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

ESG
Appendix81

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

82

Reporting Overview
We aim to help shape a moresustainable and equitable future
for all.
About This Report
This report was prepared in accordancewith the GRI Standards: Comprehensive
option. It has been designed to address
disclosures and material issues to provide
a comprehensive and integrated view ofour commitments, progress, and activities
related to sustainability and corporatesocial responsibility.
In addition to GRI, we have utilized thefollowing references:• Sustainability Accounting Standards
Board (SASB)• Task Force on Climate-related Financial
Disclosures (TCFD)• CDP• Dow Jones Sustainability Index• UN Sustainable Development Goals• UN Global Compact Communication
on Progress• UN Universal Declaration of Human Rights• CSR Industry Peer Groups: Business forSocial Responsibility (BSR), American
College of Clinical Pharmacy (ACCP), andCSR Board

Reporting Period• January 1, 2020 to December 31, 2020
• Publication annually in April• Second annual CSR Report
Reporting Scope• The CSR Report covers all Illumina global
locations, including main sites, distribution
centers, and commercial locations in theAmericas region, EMEA region, and Asia
Pacific region.
• In this CSR Report, we have included
the acquisitions of BlueBee and Enancioin the scope.
Materiality
Based on materiality assessment
completed in 2018–2019
Assurance
Limited assurance has been provided inaccordance with ISAE 3000 and ISAE 3410 on
the energy usage and greenhouse gas (“GHG”)
emissions data.
Currency references
US Dollars

Re-statements• Following our first CSR Report publication,
regular review of the data was carried out toensure accuracy and consistency. This has
led to a few changes in the data from our firstreport. The data quoted in this CSR Reportreflect the revised data. All data points thathave been adjusted are called out with ‘†’.
• We have updated our GHG emission
boundary definition. Our new boundary
definition for Scope 1 and 2 GHG emission
includes sites that are greater than 30,000
square feet or contain manufacturing,
distribution, or significant R&D activities.
These sites represent our jurisdictional
control plus material locations. This
scope accounts for 96% of our total
estimated footprint.
• We have updated our baseline year for
GHG inventory from 2018 to 2019 after
identifying that 2019 is the earliest
accurate, reliable and representative data
set for our portfolio. Our science-basedtargets of 30% reduction by 2030 willremain in effect and will now be tracked
against 2019 data.

Contents
82

Reporting Overview

83

Key Performance Indicator Summary

83

Focus on Illumina

84

Focus on Patients

84

Focus on Community

85

Focus on Environment

88

Focus on People

96

Focus on Integrity

98

Indices98

GRI Index

104 SASB Index
106 TCFD
110

UNGC Communication on Progress

111

Index of CSR Objectives and SDG Link

112 Data Verification Assurance Statements
114 Disclosures

Contact
Feedback welcomed at csr@illumina.com
More information available
www.illumina.com/csr

2020

America’s
Most Responsible
CompaniesIllumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Key Performance Indicator Summary
We are committed to transparency and continuous improvement. This section contains key performance indicatorsfor select economic, social, environmental, and governance metrics.
Focus on Illumina
General2020

Name of organization

Illumina, Inc.

Location of headquarters

San Diego, California, US

Number of global locations

25

Nature of ownership and legal form

Public corporation

Public corporation$3.2 billion

Revenue

Instruments: 13%
Service & Other: 16%
Consumables: 71%

Total capitalization (stockholder’s equity) market value as of 12/31/2020$54 billion

5Y CAGR

8%

10Y CAGR

14%

R&D % revenue investment

21%

R&D spend$681 million

Facility Changes

2019

2020

Building footprint1

2,601,433 sq feet

2,519,667 sq feet

Facility additions23

5Facility closures3

4†

4

Notes:
1 Average square feet during reporting year.
2	New commercial office in Russia, new warehouse in San Diego, Enancio acquisition, and BlueBee acquisition sites.
3 Closure associated with facilities and consolidation of two BlueBee locations to one.
† All data points that have been adjusted.

Illumina Corporate Social Responsibility Report 2021

83

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Key Performance Indicator Summary continued
Focus on Patients

Focus on Community

Access to Genomics

2020

Total Giving

2019

2020

Cost per genome$600

Illumina, Inc. + Illumina Corporate Foundation + employee giving$1,185,088$13,829,496

iHope patients supported

250

Clinical iHope network sites

28

Illumina, Inc. Giving

2019

2020

Total patients supported since iHope Program inception>850

In-kind product donations$537,000$4,387,325

Professional healthcare education programs launched

23

Charitable donations cash grant$23,088$2,759,125

Illumina Accelerator companies funded through December 202045

Coverage increase for genetic disease and NIPT over last four years

100%

Illumina Corporate Foundation Giving

2019

2020

Employee giving$312,000$573,728% Employee participation (giving)

19%

22%

Foundation match & volunteer rewards (Dollars for Doers)$208,000$721,111

Charitable grants$105,000$5,388,207

Volunteer Hours

2019

2020

Employee hours

13,9804,236% Employee participation (volunteering)

29%

5%

Intern hours

140

1,237

Employee Participation

2019

2020

Total employee participation (giving + volunteering)

40%

24%

Summary of International Giving (Outside US)1

2019

2020

Illumina, Inc.

-

$2,894,129

Illumina Corporate Foundation-$635,126# of countries

24

29

Note:
1 International giving dollars are included in the total giving numbers.

84

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Key Performance Indicator Summary continued
Focus on Environment
Energy Consumption (Units: Gigajoules)

2019†

2020*

Emission Intensity Ratios

2019†

2020

Total fuel consumption from non-renewable sources

247,576

390,564

Numerator for GHG emission intensity: Scope 1 and 2 (metric tons CO2e)34,40436,573

Total fuel consumption from renewable sources

1,566

3,333

Denominator for emission intensity: per million dollars revenue

3,500 million

3,200 million

Generation from renewable sources consumed by the organization

1,566

3,333

Denominator for emission intensity: square feet (rentable space)

2.49 million

2.43 million

Total energy consumption from renewable sources

1,566

3,333

7,802

7,828

Total energy consumption from non-renewable sources

503,658

561,258

Denominator for emission intensity: number of employees(full-time employees)

Total energy consumption

505,224564,591

GHG emission intensity per million dollars revenue

9.8

11.4

GHG emission intensity kgCO2e/square feet

13.8

15.1

GHG emission intensity employee number

4.4

4.7

Greenhouse Gas Breakdown(Units: Metric Tons CO2e)

2019†

2020*

CO2 Scope 1

12,475

19,681CH4 Scope 1

7

10

N2O Scope 1

6

10

Emission (Units: Metric Tons CO2e)

2019†

2020*

GHG emissions (Scope 1 & 2)

34,40436,573Gross direct GHG emissions (Scope 1)

12,48919,701Gross location-based energy indirect (Scope 2) GHG emissions

21,915

16,872Gross market-based energy indirect (Scope 2) GHG emissions

21,915

16,872

Consumption by Activity (Units: Gigajoules)

2019†

2020*

Total electricity (purchased + generated)

257,648

174,028

Purchased electricity

256,082

170,694

Generated electricity

1,566

3,333

Total fuel247,576

390,564

Natural gas

247,576

390,564

Total steam

00Electricity, heating, cooling, steam sold

00Notes:• Updated boundary definition for energy and greenhouse gas emission inventory: sites >30,000 square feetor contain manufacturing, distribution, or significant R&D activities. These sites represent our jurisdictional control
plus material locations. This scope accounts for 96% of our total estimated footprint.
• Within the boundary, data reported for energy and emission comes from direct utility sources. Where direct data wasunavailable, (shared tenant spaces, etc.), industry standards (CBECS) were applied as estimates to capture total impact.
• Updated energy and emission baseline year definition: updated from 2018 to 2019 after identifying that 2019is the earliest reliable and representative data set for our portfolio.
• Energy emission factor for fuel based on 2018 Climate Registry Default Emission Factors. Metric tons CO2e;
GWP Reference: IPCC Fifth Assessment Report (AR5 – 100 year).
• The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard is utilized as the methodology
to collect activity data and calculate Scope 1 and Scope 2 emissions.
• Refrigerant-specific data is not included.
• Some segments may not add up to total due to rounding.
† Data points that have been adjusted, including a re-statement of all 2019 data.
* Denotes data has been assured.

85

Illumina

Patient

Community

Environment

PeopleIntegrity

Key Performance Indicator Summary continued
Focus on Environment continued
Regional Data (Units: Metric Tons CO2e)

2019†

2020*

Scope 1 & 2 AMR region

22,90325,207

Scope 1 & 2 EMEA region

3,014

2,253

Scope 1 & 2 APAC/APJ region

8,488

9,113

Country-Specific Scope 1 (Units: Metric Tons CO2e)

2019†

2020*

China

0

0

Netherlands

73

73

Singapore00United Kingdom of Great Britain and Northern Ireland

1,132

801

United States of America

11,284

18,827

Country-Specific Scope 2 (Units: Metric Tons CO2e)

2019†

2020*

China

388

518

Netherlands

384

368

Singapore

8,099

8,595

United Kingdom of Great Britain and Northern Ireland

1,425

1,011

United States of America

11,619

6,380

Note:
• Some segments may not add up to total due to rounding.
† Data points that have been adjusted, including a re-statement of all 2019 data.
* Denotes data has been assured.

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

86

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

87

Key Performance Indicator Summary continued
Focus on Environment continued
Water (Units: Megaliters)

2019

2020

Interactions with water: total water (potable source + recycled source)

293

401

Water withdrawal (municipal)

214

315

Water withdrawal (recycled)

78

86

Water intensity (normalized by rentable square feet for main campuses
included in the water data)10.000127

0.000169

Effluent & Waste
Waste by type and disposal method (Units: Metric Tons)

2019

2020

Non-hazardous waste total

3,599†

3,703

Reuse

0

0

Recycling

911†

872

Composting

151†

203

Non-hazardous Waste

Total Waste (Units: Metric Tons)2

2019

2020

Recovery (including energy recovery)

760†

729

Total (hazardous + non-hazardous)

5,039†

4,979

Incineration00

Global average non-hazardous diversion from landfill

51%

49%

Deep well injection

0

0

Landfill

1,777†

1,899

On-site storage

0

0

Other

0

0

Hazardous waste total

1,440

1,276

Reuse

0

0

Recycling

413

489

Composting0

0

Recovery (including energy recovery)

850

707

Incineration

62

34

Deep well injection

0

0

Landfill

37

20

On-site storage

0

0

Other

77

26

†

Regional Waste Data AMR (Units: Metric Tons)

2019

2020

Non-hazardous waste total

2,723†

2,869

Hazardous waste total

902

699

Madison Site % diversion3

39%

43%

Foster City % diversion3

54%

48%

Hayward % diversion3

32%

22%

San Diego % diversion3

33%

56%

Regional Waste Data EMEA (Units: Metric Tons)

2019

2020

Non-hazardous waste total

451

397

Hazardous waste total

67

35

Illumina Centre Cambridge, UK % diversion3

100%

100%

Eindhoven % diversion3

100%

100%

Regional Waste Data APAC/APJ (Units: Metric Tons)

2019

2020

Non-hazardous waste total

424

437

Hazardous waste total

471

542

Singapore % diversion3

100%

100%

Hazardous Waste

Notes:
1	Water intensity based on total water consumption at main sites normalized by square feet of rentable space at main site locations. Water data includes main site locations (San Diego HQ, i3 and Warehouse, Hayward, Foster City, Madison, Eindhoven,
UK Cambridge Illumina Centre, and Singapore Woodlands).
2 Waste baseline data year is 2019 for application of 2030 targets.
3 % Diversion calculated using non-hazardous waste and % diverted from landfill.
† Updated data to reflect most current information.
• Some segments may not add up to total due to rounding.

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Key Performance Indicator Summary continued
Focus on People
General Employee Data

2018

2019

2020

Regional Employment Data: APAC/APJ

2018

2019

2020

Total employees

7,395

7,802

7,828

Total women

792

847

826

Employees by region AMR

4,788

4,973

4,937

Women in leadership

71

95

104

Employees by region EMEA

879

946

1,020

Full-time employees

1,728

1,882

1,871

Employees by region APAC/APJ

1,728

1,883

1,871

Part-time employees

0

1

0

Full-time employees

7,333

7,749

7,782

Temporary employees

103

164

146

Part-time employees

62

53

46

New employee hires

529

376

249

Temporary employees

1,476

1,247

1,459

31%

20%

13%

164

223

261

11%

12%

14%

132

188

207

9%

10%

11%

Employee turnover

Employee Data by Age Group

2018

2019

2020

Employees under 30

1,585†

1,527†

1,363

21%†

20%†

17%

4,706†

5,090†

5,235

64%†

65%†

67%

Regional Employment Data: EMEA

2018

2019

2020

1,104

1,185

1,230

Total women

374

416

449

15%†

16%

Women in leadership

61

72

85

Full-time employees

850

913

993

Employees 30–50
Employees over 50

†

15%†

†

Voluntary turnover

Regional Employment Data: AMR

2018

2019

2020

Part-time employees

29

33

27

Total women

1,953

2,071

2,067

Temporary employees

87

112

131

Women in leadership

364

404

421

New employee hires

207

180

176

Full-time employees

4,755

4,954

4,918

24%

19%

17%

Part-time employees

33

19

19

99

103

101

Temporary employees

1,286

971

1,182

12%

11%

10%

New employee hires

1,118

707

629

60

72

65

23%

14%

13%

7%

8%

7%

466

530

666

11%

11%

13%

293

384

442

7%

8%

9%

Employee turnover
Voluntary turnover

Employee turnover
Voluntary turnoverNotes:• For all people metrics unless specified, the values include only regular Illumina employees, not contingent workers.
• We do not track personal information for contingent workers.
• Total turnover = (involuntary + voluntary).
• For all gender statistics, percentage of women is based on number of employees that identify as male or female, not total number of Illumina employees.
• Some segments may not add up to total due to rounding.
† Age of employee data corrected from 2018 and 2019. In our previous report, data was pulled using age of employee as of the date the report was run as opposed to snapshot of employee age at end of each fiscal year. As such, the numbers forheadcount and turnover by age bracket are adjusted compared to last year’s submission.

88

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Key Performance Indicator Summary continued
Focus on People continued
Gender Data

2018

2019

2020

EEOC Minority Summary (US)

2018

2019

2020

Total women

3,119

3,334

3,342

2,429

2,422

43%

43%

Total employees identifying in minority race andethnicity statistics

2,304

42%
496

571

610

% Minority of total employees

48%

49%

49%

37%

39%

40%

% Non-Minority

47%

46%

46%

3,070

3,293

3,305

% Decline to State

5%

5%

5%

42%

43%

43%

94

112

136

EEOC Minority by Category (US)

2018

2019

2020

31%

33%

36%

# White/Caucasian

2,226

2,284

2,253

49

41

37

% White

47%

46%

46%

79%

79%

80%

# Native Hawaiian or Other Pacific Islander

64

62

56

N/A

N/A

N/A

% Native Hawaiian or Other Pacific Islander

1%

1%

1%

N/A

N/A

N/A

# American Indian or Native Alaskan

8

10

11

3

3

3

% American Indian or Native Alaskan

<1%

<1%

<1%

33%

33%

30%

# Asian

1,529

1,601

1,601

843

566

490

% Asian

32%

32%

33%

27%

17%

15%

# Hispanic or Latino

423

447

435

1,003

684

560

% Hispanic or Latino

9%

9%

9%

24%

15%

12%

# Black or African American

123

121

121

334

351

483

% Black or African American

3%

2%

2%

12%

11%

14%

# 2 or More

157

188

198

391

501

544

% 2 or More

3%

4%

4%

10%

12%

12%

# Choose not to self disclose

233

240

238

234

285

342

% Choose not to self disclose

5%

5%

5%

8%

9%

10%

# Veteran

136

143

141

250†

358

372

% Veteran

3%

3%

3%

6%

8%

8%

# Disabled

212

248

235

% Disabled

4%

5%

5%

Women in leadership
Full-time women
Women in executive leadership
Part-time women
Temporary women
Women on Board of Directors
New female employee hires
New male employee hires
Female employee total turnover
Male employee total turnoverFemale voluntary turnover
Male voluntary turnover††Notes:• For all people metrics unless specified, the values include only regular Illumina employees, not contingent workers.
• Minority defined as any EEOC category that is non-white/non-Caucasian. Does not include those that choose not to specify a race/ethnicity.
• Total turnover = (involuntary + voluntary).
• For all gender statistics, percentage of women is based on number of employees that identify as male or female, not total number of Illumina employees• Some segments may not add up to total due to rounding.
† Data correction from previous year due to calculation approach error for minority population, The field being used to count “Minority” groups was correctly excluding those that chose “Decline to State”, but not excluding those with a value of “Blank”,
which got mistakenly bundled into a group called “Other” that was being counted in the Minority population. 2018 and 2019 data has been updated with corrected metrics.

89

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Key Performance Indicator Summary continued
Focus on People continued
EEOC Data by Level (US)

2018

2019

2020

2018

2019

2020

# White/Caucasian

292

261

226

% White

25%

24%

23%

# White/Caucasian

401

413

421

% White57%

54%# Native Hawaiian or Other Pacific Islander

33

29

56%

31

# Native Hawaiian or Other Pacific Islander

9

11

9

% Native Hawaiian or Other Pacific Islander

3%# American Indian or Native Alaskan

2

3%

3%

% Native Hawaiian or Other Pacific Islander

1%

1%

1%

3

2

# American Indian or Native Alaskan

22% American Indian or Native Alaskan

2

<1%

<1%

<1%

% American Indian or Native Alaskan

<1%

<1%

<1%

# Asian

517

489

452

# Asian

155

182

174

% Asian

45%

45%

45%

% Asian

22%

24%

23%

# Hispanic or Latino

165

173

160

# Hispanic or Latino

65

65

61

% Hispanic or Latino

14%

16%

16%

% Hispanic or Latino

9%

9%

8%

# Black or African American

55

48

38

# Black or African American

16

17

21

% Black or African American

5%

4%

4%

% Black or African American

2%

2%

3%

# 2 or More

50

57

56

# 2 or More

18

22

21

% 2 or More

4%

5%

6%

% 2 or More

3%

3%

3%

# Choose not to self disclose

40

38

34

# Choose not to self disclose

39

46

48

% Choose not to self disclose

3%

3%

3%

% Choose not to self disclose

6%

6%

6%

# White/Caucasian

1,336

1,403

1,389

# White/Caucasian

197

207

217

% White

50%

50%

48%

% White

78%

75%

75%

# Native Hawaiian or Other Pacific Islander

22

22

16

# Native Hawaiian or Other Pacific Islander

0

0

0

% Native Hawaiian or Other Pacific Islander

1%

1%

1%

% Native Hawaiian or Other Pacific Islander

0%

0%

0%

# American Indian or Native Alaskan

3

4

6

# American Indian or Native Alaskan

1

1

1

% American Indian or Native Alaskan

<1%

<1%

<1%

% American Indian or Native Alaskan

<1%

<1%

<1%

# Asian

829

895

938

# Asian

28

35

37

% Asian

31%

32%

33%

% Asian

11%

13%

13%

# Hispanic or Latino

185

199

201

# Hispanic or Latino

8

10

13

% Hispanic or Latino

7%

7%

7%

% Hispanic or Latino

3%

4%

4%

# Black or African American

49

51

56

# Black or African American

3

5

6

% Black or African American

2%

2%

2%

% Black or African American

1%

2%

2%

# 2 or More

86

105

115

# 2 or More

3

4

6

% 2 or More

3%

4%

4%

% 2 or More

1%

1%

2%

# Choose not to self disclose

143

143

146

# Choose not to self disclose

11

13

10

% Choose not to self disclose

5%

5%

5%

% Choose not to self disclose

4%

5%

3%

Support to Entry Professional

EEOC Data by Level (US) continued
Manager to Associate Director

Intermediate to Senior Professional

Director and Above90

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Key Performance Indicator Summary continued
Focus on People continued% Female of Each EEOC Category

2018

2019

2020

Total New Hire Data

2018

2019

2020

% White

40%

41%

41%

Total number of new employee hires

1,854

1,263

1,054

% Native Hawaiian or Other Pacific Islander

38%

31%

27%

Rate of new employee hires

25%

16%

14%

% American Indian or Native Alaskan

50%

50%

45%

% Asian

45%

44%

44%

New Hire Data by Age1

2018

2019

2020

% Hispanic or Latino

36%

39%

40%

Employees under 30

770

422

†

380

% Black or African American

39%

37%

41%

49%†

30%†

28%

% 2 or More

41%

45%

46%

948†

715†

586

% Choose not to self disclose

38%

40%

40%

20%†

14%†

11%

136†

89†

88

12%

8%

7%

Employees 30–50
Employees over 50†% Male of Each EEOC Category

2018

2019

2020

% White

60%

59%

59%

% Native Hawaiian or Other Pacific Islander

63%

69%

73%

% New Hire per EEOC (US)

2018

2019

2020

% American Indian or Native Alaskan

50%

50%

55%

% White

44%

44%

47%

% Asian

55%

56%

56%

% Native Hawaiian or Other Pacific Islander

1%

1%

<1%

% Hispanic or Latino

64%

61%

60%

% American Indian or Native Alaskan

<1%

<1%

<1%

% Black or African American

61%

63%

60%

% Asian

34%

32%

33%

% 2 or More

59%

55%

54%

% Hispanic or Latino

10%

10%

7%

60%

% Black or African American

3%

2%

4%

% 2 or More

4%

7%

6%

% Choose not to self disclose

5%

5%

3%

% Choose not to self disclose

62%

60%

†

†

Notes:
1 % data for new hire by age represents the percentage of the total age group headcount for the reporting year.
• For all people metrics unless specified, the values include only regular Illumina employees, not contingent workers.
• For all gender statistics, percentage of women is based on number of employees that identify as male or female, not total number of Illumina employees.
• Some segments may not add up to total due to rounding.
† Age of employee data corrected from 2018 and 2019. In our previous report, data was pulled using age of employee as of the date the report was run as opposed to snapshot of employee age at end of each fiscal year. As such, the numbers forheadcount and turnover by age bracket are adjusted compared to last year’s submission.

91

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Key Performance Indicator Summary continued
Focus on People continued
Total Turnover Data

2018

2019

2020

Turnover by Level

2018

2019

2020

Total number of employee turnover

713

856

1,028

Voluntary turnover support to entry professional

8%

11%

11%

Rate of employee turnover

11%

11%

14%

Involuntary turnover support to entry professional

3%

3%

5%

Total number of voluntary terminations

476

644

714

Voluntary turnover intermediate to senior professional

7%

8%

8%

Rate of voluntary terminations

7%

9%

9%

Involuntary turnover intermediate to senior professional

3%

2%

4%

Voluntary turnover manager to associate director

5%

6%

8%

Employee Turnover Data by Age

2018

2019

2020

Involuntary turnover manager to associate director

6%

4%

4%

Employees under 30

173†

229†

224

Voluntary turnover director and above

5%

6%

13%

12%†

15%†

16%

Involuntary turnover director and above

8%

4%

4%

436†

489†

638

10%†

10%†

12%

Turnover by EEOC (US)

2018

2019

2020

104

†

138†

166

% Voluntary turnover for each of following

11%†

12%†

14%

% White

6%

8%

10%

143†

195†

182

% Native Hawaiian or Other Pacific Islander

9%

11%

10%

†

10%

13%

†

13%

% American Indian or Native Alaskan

13%

0%

0%

287†

366†

456

% Asian

6%

7%

8%

6%†

7%†

9%

% Hispanic or Latino

5%

8%

7%

46†

82†

76

% Black or African American

7%

11%

12%

5%

7%

6%

% 2 or More

13%

6%

11%

% Choose not to self disclose

8%

6%

8%

Employees 30–50
Employees over 50
Voluntary employee turnover under 30
Voluntary employee turnover 30–50
Voluntary employee turnover over 50††

Notes:• For all people metrics unless specified, the values include only regular Illumina employees, not contingent workers.
• Minority defined as any EEOC category that is non-white/non-Caucasian. Does not include those that choose not to specify a race/ethnicity.
• Total turnover = (involuntary + voluntary).
• We do not track personal information for contingent workers.
• Some segments may not add up to total due to rounding.
† Age of employee data corrected from 2018 and 2019. In our previous report, data was pulled using age of employee as of the date the report was run as opposed to snapshot of employee age at end of each fiscal year. As such, the numbers forheadcount and turnover by age bracket are adjusted compared to last year’s submission.

92

Illumina

Patient

Community

Environment

PeopleIntegrity

Key Performance Indicator Summary continued
Focus on People continued
Parental Leave

2019

2020

Total number of employees that were entitled to parental leave, by gender

4,714

4,900

Total number of employees that took parental leave, by gender

Female 116

Female 181

Male 65

Male 121
Blank 1

Total number of employees that returned to work in the reporting period
after parental leave ended, by gender

Female 116

Female 191

Male 65

Male 138

Total number of employees that returned to work after parental leave
ended that were still employed 12 months after their return to work,by gender

Female 100

Female 177

Male 54

Male 123

Return to work and retention rates of employees that took parental leave,by gender

Return to Work:
Female 100%Return to Work:
Female 100%

Male 98%

Male 98%

Retention:
Female 86%

Retention:
Female 86%

Male 83%

Male 83%

Blank 1

Blank 1

Benefit Plan and Other Retirement

2018–2020

Percentage of salary contributed by employee
or employer

US 401(k): Employee elected between 0–80%,
Illumina matching contribution of 50% up to the first
6% employee election (3% of eligible salary)

Level of participation in retirement plans, such as
participation in mandatory or voluntary schemes,
regional or country-based schemes, or those withfinancial impact

US 401(k): 97% employee voluntary participation

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

93

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Key Performance Indicator Summary continued
Focus on People continued
Ratio of Average Compensation Ratio—Women to Men

2019

2020

Training

2018

2019

2020

Across all employee categories

100%

100%

Average hours of training per employee per year

53

60

64

Support to entry professional

102%

102%

Total hours of training by gender: Male

53

60

66

Intermediate to senior professional

100%

100%

Total hours of training by gender: Female

52

61

61

Supervisor1 to associate director

98%

99%

55

64

68

Director and above

101%

98%

Hours of training by employee category:
Individual Contributor

61

71

76

Compensation Ratio

2019

2020

Hours of training by employee category:
Middle Management

Annual compensation ratio. Ratio of annual total compensation for theorganization's highest-paid individual in each region to the median annual
total compensation for all employees

15 to 1

Refer toProxy Filing

Hours of training by employee category:
Senior Management

36

38

38

Hours of training by employee category:
Executive Leadership

24

22

24

Performance & Career Development Reviews

2018

2019

2020

Hours of training by functional category:
Commercial Operations

43

50

46

Percentage of employees receiving regular performanceand career development reviews

100%

100%

100%

Hours of training by functional category:
General Operations

24

23

25

Employees receiving regular performance and careerdevelopment reviews by level (senior management,
middle management)

100%

100%

100%

Hours of training by functional category: Manufacturing

72

91

104

51

53

57

Employees receiving regular performance andcareer development reviews by function (technical,
administrative, production)

100%

Hours of training by functional category: Research &Development
Total number of hours devoted to training on
human rights

1,176

1,737

5,578

Applicable employees certified to Code of Conduct

100%

100%

100%

Employee Survey (iPulse)2

2018

2019

2020

Participation rate for employee iPulse survey

89%

89%

79%

100%

100%

Notes:
1	Previous report listed Manager instead of Supervisor as label of the grouping. No change to data set. Updated accurate description of category.
2 iPulse participation rates in 2018 and 2019 are calculated using an average of two surveys per year (Q2 and Q4 of each year). For 2020, the participation rate is based on
an average of three quarterly surveys (Q2–Q4). Quarterly cadence moving forward.
• For all people metrics unless specified, the values include only regular Illumina employees, not contingent workers.
• For all training hour metrics, the values include only regular Illumina employees, not contingent workers.

94

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Key Performance Indicator Summary continued
Focus on People continued
Health & Safety

2018

2019

2020

Safety Workers who are not employees but
whose work and/or workplace is controlled by
the organization

2018

2019

2020

Global recordable injury or illness incident rate (incident
per 100 employees)

0.76

0.52

0.34

Lost time incident rate

1.44

0.74

0.18

Number of work-related fatalities

0

0

0

Environment, Health & Safety notices of violations

0

0

0

Rate of work-related fatalities

0

0

0

The number of high-consequence work-related injuries
and illnesses (excluding fatalities)

10

Environmental fines

0

0

0

3

Prevention reporting statistics

2,318

3,611

3,018

The rate of high-consequence work-related injuries andillnesses (excluding fatalities)

0.08

0

0.07

Safety Employees

2018

2019

2020

Number of work-related fatalities

0

0

0

The number of recordable work-related injuries
and illnesses

1

0

3

Rate of work-related fatalities

0

0

0

The rate of recordable work-related injuries and illnesses

0.08

0

0.07

The number of high-consequence work-related injuries
and illnesses (excluding fatalities)

62

49

29

The main types of work-related injury and illness

Ergonomics (repetitive stress injury), strain,
contusion, and sprain		The rate of high-consequence work-related injuries andillnesses (excluding fatalities)

0.88

0.62

0.39

The number of hours worked

2,552,606

2,741,396

2,798,888

The number of recordable work-related injuries
and illnesses

62

49

29

Environmental, Health & Safety Training

2018

2019

2020

The rate of recordable work-related injuries and illnesses

0.88

Total hours of EHS training

16,552

26,75830,054The main types of work-related injury and illness

Ergonomics (repetitive stress injury), strain,
contusion, and sprain		

Average hours per employee

2.72

3.7

3.4

The number of hours worked

13,582,299

0.62

15,647,395

0.39

15,344,520

Notes:• Recordable injury & illness rate calculated using total hours worked from employees + contingent workers.
• Contingent workers: workers who are not employees but whose work and/or workplace is controlled by the organization.
• Lost time incident rate calculated using total hours worked from employees + contingent workers.
• High-consequence work-related injuries are defined as all recordable injuries.
• Rates have been calculated based on 200,000 hours worked.

95Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

96

Key Performance Indicator Summary continued
Focus on Integrity
Governance

2019

2020

Board of Directors

2019

2020

Non-compliance with environmental laws and regulations0

0

Board of Directors–level oversight for CSR/Sustainability

Yes

Yes

Clawback provision

Yes

Yes

Commitment to gender diversity on board

Yes

Yes

Board of Directors composition by gender

33%

30%2

Significant fines and non-monetary sanctions for non-compliance withenvironmental laws and/or regulations# of FDA recalls/total units recalled00

Number of substantiated complaints concerning breaches of customer
privacy and losses of customer data

00Anti-corruption

0

0

2

0

Nature and total number of critical concerns communicated to highest
governance body regarding CSR topics

0

Total employees covered by collective bargaining agreements0Anti-competitive1

Supply Chain

2019

2020

Quantity of product shipped3

3,118,142 units

3,297,561 units0

Spend on direct suppliers$440 million$396 million

Supplier Code of Conduct in place

Yes

Yes

0

Geographic location of suppliers4

Countries†: AE, AM, AR, AT, AU,
BE, BS, CA, CH, CL, CN, CO,
CZ, DE, DK, EE, ES, FI, FR, GB,
GR, HK, ID, IE, IL, IN, IS, IT, JP,
KR, LT, LU, MO, MX, MY, NL,
NO, NZ, PA, PE, PH, PL, PT, RO,
RU, SE, SG, SI, TH, TR, TW, UA,
US, UY, VN, ZA

Countries: AE, AM, AR, AU, AU,
BE, BR, BY, CA, CH, CL, CN,
CR, CZ, DE, DK, EE, ES, FI, FR,
GB, GH, HK, ID, IE, IL, IND, IS,
IT, JP, KR, LT, LU, MY, MX, NL,
NO, NZ, PE, PH, PL, PT, RU, SA,
SE, SG, TH, TR, TW, UA, US,
UY, ZAA description of the organization’s
supply chain

Illumina’s global supply chain consists of suppliers,sub-contractors, channel partners, manufacturing sites,
distribution centers, and customers

Types of suppliers

Direct, indirect, strategic, differentiating, core, transactional,
finished medical device, custom spec, off the shelf, internal,
external, and services

Number of suppliers engaged
by organization

3,891†

3,704

Estimated monetary value of payments
made to suppliers>$1 billion$935 million

Number of active diverse suppliers (US)

>400

334

Incidents of discrimination and corrective actions taken
During the past 11 years, neither the EEOC nor any court or administrative agency has issued a finding against
Illumina in a claim involving discrimination.
In 2020, there were four requests for arbitration filed, each of which Illumina has challenged. Illumina isdefending the cases and denies that any discrimination has occurred.
We do not tolerate acts of discrimination, and promote an open culture to report concerns (including
anonymously). Illumina takes all reports of misconduct seriously and has a strict nonretaliation policy. If a report
is substantiated, the company will respond as it deems appropriate or necessary, consistent with the law, andwill act swiftly to correct the problem and deter future occurrences. Depending on the circumstances, this may
include training and/or disciplinary action up to, and including, termination. Individuals may also be subject tocivil or criminal prosecution for violating the law.

ESG Governance Topics

Position

Level from CEO

Level from Board

Corporate Social Responsibility

SVP, Chief Financial Officer

12

Environment, Health & Safety

SVP, Global Quality &Operations

1

2

People, Diversity, Inclusion,
Employment Equity

SVP, Chief People Officer

1

2

Diverse supplier spend$190 million$152 million

Supply Chain

SVP, Global Quality &Operations

1

2% of total PO spend with diverse suppliers

19%

16%

SVP, General Counsel

1

2Percentage of suppliers screened usingsocial criteria

Social screening is included in our Request for Information (RFI)
tools for evaluating potential suppliers

Percentage of new suppliers that werescreened using environmental criteria

Environmental screening is included in our RFI tools forevaluating potential suppliers

Compliance, Ethics, Legal

Notes:
1	No new claims. Main outcomes of completed legal actions, including any decisions or judgments: The International Equipment Trading, Ltd. (IET) civil action noted in our 2019 CSR report was resolved on July 13, 2020, by confidential settlement with
Illumina expressly denying any liability or wrongdoing.
2	No change to the number of women on the Board. There were 3 out of 9 in 2019 and 3 out of 10 in 2020. As of March 19, 2021, there were 3 out 9 again.
3 Shipped quantity represents units based on customer-facing physical order types.
4 All direct and indirect suppliers are included.
• All data points that have been adjusted are called out with †.

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Key Performance Indicator Summary continued
Focus on Integrity continued
Political Contributions1

2019

2020

Total monetary value of financial and in-kind political contributions made directly and indirectly by the organization by country and recipient/beneficiary$50,000$0

Trade Association & Memberships22020 Fees

Illumina participates in various trade associations and industry memberships for collaboration and exchange of ideas. Some of these organizations may utilize a portion of membership fees for non-deductible state and federal
lobbying and political expenditures. As part of our transparency practices, we disclose trade memberships for which we contribute at least $5,000 annually in fees.
Trade and industry group memberships above $5,000 threshold annually
National Association of Manufacturers (NAM) Manufacturing Leadership Council$49,000

Coalition for 21st Century Medicine$47,500

US Chamber of Commerce$25,000

AdvaMed$19,950

San Diego Regional Chamber of Commerce$15,300

US-China Business Council$15,000

US-UAE Business Council$10,775

MIPI Alliance$8,240Industrial Environmental Association (IEA)$6,000

Healthcare Businesswomen's Association (HBA)$5,000International memberships of potential equivalent scope to trade association and industry memberships above $5,000 annually
All.Can International (ASBL), Belgium$34,939

MedTech Europe$25,858

EUCOPE$10,482

Guangdong Precision Medicine Application Association$7,413

Pathology Technology Australia$6,711

German Diagnostics Industry Association VDGH

$5,928International Quality Network for Pathology, Luxembourg (IQN Path)$5,410Organization

Total annual membership fee% Membership fees used for state or federal lobbying

Dollars applied to state or federal lobbying frommembership fees

For the trade associations with membership fees that we contribute greater than $50,000, we are also disclosing the percentage of membership fees associated with state and federal lobbying efforts annually.
World Economic Forum$386,514

00World 50, Inc.

$160,000

00

Access to Comprehensive Genomic Profiling Coalition$95,000

00

Coalition for Access to Prenatal Screening (CAPS)$100,00020%$20,000

Biocom$55,000

8%$4,400American Clinical Laboratory Association$50,000

22%$11,000

Notes:
1	In December 2019, Illumina contributed $50,000 in support of the Yes! For a Better San Diego initiative on the March 2020 Primary Election Ballot in San Diego.
2	Trade memberships are defined as organizations with categorization of 501(c) (4) or 501 (c) 6 status or equivalent scope.

97

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

98

GRI Index
GRI Description

GRI Section

Illumina Report Section

Page Number

Name of organization

GRI 102-1

Focus on Illumina, ESG Appendix

9, 83

Activities, brands, products, and services

GRI 102-2

Focus on Illumina

9, 10, 11Location of headquarters

GRI 102-3

Focus on Illumina, ESG Appendix

10, 83

Location of all operations

GRI 102-4

Focus on Illumina

10

Ownership and legal form

GRI 102-5

ESG Appendix

83

Markets served

GRI 102-6

Focus on Illumina, ESG Appendix

9, 10, 11, 83

Scale of organization

GRI 102-7

Focus on Illumina, Focus on People, ESG Appendix

10, 11, 52, 83

Information on employees and other workers

GRI 102-8

Focus on Illumina, Focus on People, ESG Appendix

10, 52, 83, 88–94

Supply chain

GRI 102-9

Focus on Integrity, ESG Appendix

77–79, 96

Significant changes to organization and its supply chain

GRI 102-10

Focus on Integrity, ESG Appendix

77–79, 82, 96

Precautionary Principle or approach

GRI 102-11

Focus on Environment, Focus on People

44, 64External initiatives

GRI 102-12

Focus on Illumina, Focus on Integrity, ESG Appendix

14, 76, 80, 82, 97, 106,
110, 111

Membership of associations

GRI 102-13

Focus on Illumina, Focus on Integrity, ESG Appendix

14, 76, 80, 82, 97, 106,
110, 111

Statement from senior decision maker/CEO

GRI 102-14

Message From Our CEO

3–4

Key impacts, risks, and opportunities

GRI 102-15

Message From Our CEO, Focus on Illumina, Focus on Patients, Focus on
Community, Focus on Environment, Focus on People, Focus on Integrity,
ESG Appendix

3–4, 9, 13, 17–19, 22–25, 29,
31, 35, 40–46, 50, 54–56,
60, 69, 73–79, 106–109, 111

Values, principles, standards, and norms of behavior

GRI 102-16

Focus on Illumina, Focus on Patients, Focus on Community, Focus on
Environment, Focus on People, Focus on Integrity

9, 17, 20, 29, 31, 40, 50–66,
69–80

Mechanisms for advice and concern about ethics

GRI 102-17

Focus on Integrity

69–74, 77–78

Governance structure

GRI 102-18

Focus on Illumina, Focus on Integrity, ESG Appendix

12, 70, 71, 96

Delegating authority

GRI 102-19

Focus on Illumina, ESG Appendix

12, 96

Executive level responsibility for economic, environmental, and social topics

GRI 102-20

Focus on Illumina, Focus on Integrity, ESG Appendix

12, 70, 96

Consulting stakeholders on economic, environmental, and social topics

GRI 102-21

Focus on Illumina

14

Composition of the highest governance body and its committees

GRI 102-22

Focus on Illumina, Focus on Integrity, ESG Appendix

12, 70, 96

Chair of the highest governance body

GRI 102-23

Focus on Illumina, Focus on Integrity, ESG Appendix

12, 70, 96

Nominating and selecting the highest governance body

GRI 102-24

Focus on Illumina, Focus on Integrity, ESG Appendix

12, 70, 96

Conflicts of interest

GRI 102-25

Focus on Integrity, Board Corporate Governance Guidelines

70

Role of highest governance body in setting purpose, values, and strategy

GRI 102-26

Focus on Illumina, Focus on Integrity, ESG Appendix

12, 70, 96

Collective knowledge of highest governance body

GRI 102-27

Focus on Integrity

70

GENERAL: Disclosure 102
Organizational Profile

Strategy

Ethics & Integrity

GovernanceIllumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

GRI Index continued
GRI Description

GRI Section

Illumina Report Section

Page Number

Evaluating the highest governance body’s performance

GRI 102-28

Focus on Integrity, Board Corporate Governance Guidelines

70

Identifying and managing economic, environmental, and social impacts

GRI 102-29

Focus on Illumina, Focus on Integrity, ESG Appendix

12, 69, 96

Effectiveness of risk management processes

GRI 102-30

Focus on Illumina, Focus on Integrity, Board Audit Committee Charter,
ESG Appendix

12, 69, 70–72, 73, 95

Review of economic, environmental, and social topics

GRI 102-31

Focus on Illumina

12Highest governance body’s role in sustainability reporting

GRI 102-32

Focus on Illumina, Focus on Integrity, ESG Appendix

12, 70, 96

Communicating critical concerns

GRI 102-33

Focus on Illumina, Focus on Integrity, ESG Appendix

12, 70, 96

Nature and total number of critical concerns

GRI 102-34

Focus on Illumina, Focus on Integrity, ESG Appendix

12, 70, 96

Remuneration policies

GRI 102-35

Focus on People, ESG Appendix

54, 55, 94

Process for determining remuneration

GRI 102-36

Focus on People, ESG Appendix

54, 55, 94

Stakeholders’ involvement in remuneration

GRI 102-37

Focus on People, ESG Appendix

54, 55, 94

Annual total compensation ratio

GRI 102-38

Focus on People, ESG Appendix

54, 55, 94

Percentage increase in annual total compensation ratio

GRI 102-39

Focus on People, ESG Appendix

54, 55, 94

List of stakeholder groups

GRI 102-40

Focus on Illumina

14

Collective bargaining agreements

GRI 102-41

Focus on Integrity

73

Identifying and selecting stakeholders

GRI 102-42

Focus on Illumina

14

Approach to stakeholder engagement

GRI 102-43

Focus on Illumina

14

Key topics and concerns raised

GRI 102-44

Focus on Illumina

13–14

Entities included in the consolidated financial statements

GRI 102-45

ESG Appendix

82

Defining report content and topic Boundaries

GRI 102-46

ESG Appendix

82

List of material topics

GRI 102-47

Focus on Illumina

14

Restatements of information

GRI 102-48

ESG Appendix

82

Changes in reporting

GRI 102-49

ESG Appendix

82

Reporting period

GRI 102-50

ESG Appendix

82

Date of most recent report

GRI 102-51

ESG Appendix

82

Reporting cycle

GRI 102-52

ESG Appendix

82

Contact point for questions regarding the report

GRI 102-53

ESG Appendix

82, 114Claims of reporting in accordance with the GRI Standards

GRI 102-54

ESG Appendix

82

GRI content index

GRI 102-55

ESG Appendix

98–103External assurance

GRI 102-56

ESG Appendix

112–113

GENERAL: Disclosure 102

Stakeholder Engagement

Reporting Practice99

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

GRI Index continued
GRI Description

GRI Section

Illumina Report Section

Page Number

Management Approach: Economic Performance

GRI 103-1, 103-2, 103-3

Focus on Illumina, Focus on Patients, Focus on Community, Focus on
Environment, Focus on People, Focus on Integrity

8–14, 17, 29, 40, 51, 69

Direct economic value generated and distributed

GRI 201-1

Focus on Illumina, ESG Appendix

11, 83Financial implications and other risks and opportunities due to climate change

GRI 201-2

Focus on Environment, Focus on Integrity, ESG Appendix: TCFD Index

40–48, 74, 106–109

Defined benefit plan obligations and other retirement plans

GRI 201-3

Focus on People, ESG Appendix

58–59, 93

Management Approach: Indirect Economic Impact

GRI 103-1, 103-2, 103-3

Focus on Patients, Focus on Communities, Focus on Integrity, ESG Appendix

16–26, 29–37, 69–80, 84

Significant indirect economic impacts

GRI 203-2

Focus on Patients, Focus on Communities, Focus on Integrity, ESG Appendix

16–26, 29–37, 69–80, 84

Management Approach: Anti-Corruption

GRI 103-1, 103-2, 103-3

Focus on Integrity, ESG Appendix

71–74, 77–79, 96

Operations assessed for risks related to corruption

GRI 205-1

Focus on Integrity, ESG Appendix

71–74, 77–79, 96

Communication and training about anti-corruption policies and procedures

GRI 205-2

Focus on Integrity, ESG Appendix

71–74, 77–79, 94, 96

Confirmed incidents of corruption and actions taken

GRI 205-3

ESG Appendix

96

Management Approach: Anti-Competitive Behavior

GRI 103-1, 103-2, 103-3

Focus on Integrity, ESG Appendix

71–74, 77–79, 96

Legal actions for anti-competitive behavior, anti-trust, and monopoly practices

GRI 206-1

ESG Appendix

96

ECONOMIC: Disclosure 200
Economic Performance

Indirect Economic Impact

Anti-Corruption

Anti-Competitive Behavior

100Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

GRI Index continued
GRI Description

GRI Section

Illumina Report Section

Page Number

Management Approach: Energy

GRI 103-1, 103-2, 103-3

Focus on Environment, Focus on People

40, 64

Energy consumption within the organization

GRI 302-1

Focus on Environment, ESG Appendix

40–42, 45, 85–86

Energy intensity

GRI 302-3

ESG Appendix

85

Reduction of energy consumption

GRI 302-4

Focus on Environment, ESG Appendix

40–46, 85–86

Management Approach: Water

GRI 103-1, 103-2, 103-3

Focus on Environment, Focus on People

40, 64

Interactions with water as a shared resource

GRI 303-1

Focus on Environment, ESG Appendix

40, 43, 87

Water withdrawal

GRI 303-3

Focus on Environment, ESG Appendix

40, 43, 87

Management Approach: Biodiversity

GRI 103-1, 103-2, 103-3

Focus on Environment, Focus on People

40–41, 64

Operational sites owned, leased, managed in, or adjacent to, protected areas and areas ofhigh biodiversity value outside protected areas

GRI 304-1

Focus on Environment

40–41

Habitats protected or restored

GRI 304-3

Focus on Environment

40–41Management Approach: Emissions

GRI 103-1, 103-2, 103-3

Focus on Environment, Focus on People

40, 64

Direct (Scope 1) GHG emissions

GRI 305-1

Focus on Environment, ESG Appendix

40–42, 45, 85–86

Energy indirect (Scope 2) GHG emissions

GRI 305-2

Focus on Environment, ESG Appendix

40–42, 45, 85–86

GHG emissions intensity

GRI 305-4

ESG Appendix

85

Reduction of GHG emissions

GRI 305-5

Focus on Environment, ESG Appendix

40–46, 85–86

Management Approach: Effluent and Waste

GRI 103-1, 103-2, 103-3

Focus on Environment, Focus on People, ESG Appendix

40, 44–47, 64, 87

Waste by type and disposal method

GRI 306-2

Focus on Environment, Focus on People, ESG Appendix

40, 44–47, 64, 87

Management Approach: Environmental Laws & Regulations

GRI 103-1, 103-2, 103-3

Focus on Environment, Focus on People, ESG Appendix

40, 51, 64, 95

Non-compliance with environmental laws and regulations

GRI 307-1

Focus on Environment, Focus on People, ESG Appendix

40, 51, 64–65, 95–96

Management Approach: Supplier Environmental Assessment

GRI 103-1, 103-2, 103-3

Focus on Environment, Focus on People, Focus on Integrity

40, 64, 69, 73–74, 77–79

New suppliers that were screened using environmental criteria

GRI 308-1

Focus on Integrity

77–79

ENVIRONMENTAL: Disclosure 300
EnergyWater

Biodiversity

EmissionsEffluent and Waste

Environmental Compliance

Supplier Environmental Assessment

101

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

GRI Index continued
GRI Description

GRI Section

Illumina Report Section

Page Number

Management Approach: Employment

GRI 103-1, 103-2, 103-3

Focus on People, Focus on Integrity

51–66, 69–73

New employee hires and employee turnover

GRI 401-1

Focus on People, ESG Appendix

51, 61, 63, 88–89, 91–92

Benefits provided to full-time employees that are not provided to temporary
or part-time employees

GRI 401-2

Focus on People, ESG Appendix

51, 58–60, 88–94

Parental leave

GRI 401-3

Focus on People, ESG Appendix

58, 93

Management Approach: Occupational Health & Safety

GRI 103-1, 103-2, 103-3

Focus on People, ESG Appendix

64–66, 95

Occupational health and safety management system

GRI 403-1

Focus on People, ESG Appendix

64–66, 95

Hazard identification, risk assessment, and incident investigation

GRI 403-2

Focus on People, ESG Appendix

64–66, 95Worker participation, consultation, and communication on occupational health and safety

GRI 403-4

Focus on People, ESG Appendix

64–66, 95Worker training on occupational health and safety

GRI 403-5

Focus on People, ESG Appendix

64–66, 95

Promotion of worker health

GRI 403-6

Focus on People, ESG Appendix

64–66, 95Workers covered by an occupational health and safety management system

GRI 403-8

Focus on People, ESG Appendix

64–66, 95

Work-related injuries

GRI 403-9

Focus on People, ESG Appendix

64–66, 95

Work-related illness

GRI 403-10

Focus on People, ESG Appendix

64–66, 95

Management Approach: Training & Education

GRI 103-1, 103-2, 103-3

Focus on People, Focus on Integrity, ESG Appendix

51, 53, 58, 62–65, 69, 95

Average hours of training per year per employee

GRI 404-1

Focus on Illumina, Focus on People, Focus on Integrity, ESG Appendix

10, 61–63, 73–74, 94

Programs for upgrading employee skills and transition assistance programs

GRI 404-2

Focus on People

51, 61–63

Percentage of employees receiving regular performance and career development reviews

GRI 404-3

ESG Appendix

94

Management Approach: Diversity & Equal Opportunity

GRI 103-1, 103-2, 103-3

Focus on Community, Focus on People, Focus on Integrity

29, 35, 37, 50–57, 69, 73,
77–78

Diversity of governance bodies and employees

GRI 405-1

Focus on People, Focus on Integrity, ESG Appendix

51–57, 70, 88–92, 96

Ratio of basic salary and remuneration of women to men

GRI 405-2

Focus on People, ESG Appendix

51–55, 94

Management Approach: Child LaborGRI 103-1, 103-2, 103-3

Focus on Integrity

69, 73–74, 77–78

Operations and suppliers at significant risk for incidents of child labor

GRI 408-1

Focus on Integrity, ESG Appendix

69, 73–74, 77–78, 96

Management Approach: Forced or Compulsory LaborGRI 103-1, 103-2, 103-3

Focus on Integrity

69, 73–74, 77–78

Operations and suppliers at significant risk for incidents of forced or compulsory labor

GRI 409-1

Focus on Integrity, ESG Appendix

69, 73–74, 77–78, 96

SOCIAL: Disclosure 400
Employment

Occupational Health & Safety

Training & Education

Diversity & Equal Opportunity

Child Labor

Forced or Compulsory Labor

102

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

GRI Index continued
GRI Description

GRI Section

Illumina Report Section

Page Number

Management Approach: Human Rights

GRI 103-1, 103-2, 103-3

Focus on Integrity

69, 73–74, 77–78

Operations that have been subject to human rights reviews or impact assessments

GRI 412-1

Focus on Integrity, ESG Appendix

69, 73–74, 77–78, 96

Employee training on human rights policies or procedures

GRI 412-2

ESG Appendix

94

Significant investment agreements and contracts that include human rights clauses or that
underwent human rights screening

GRI 412-3

Focus on Integrity, ESG Appendix

69, 73–74, 77–78, 96

Management Approach: Local Communities

GRI 103-1, 103-2, 103-3

Focus on Patients, Focus on Community

17, 29Operations with local community engagement, impact assessments, anddevelopment programs

GRI 413-1

Focus on Patients, Focus on Community

17, 19, 20–23, 29–37

Management Approach: Supplier Social Criteria Screening

GRI 103-1, 103-2, 103-3

Focus on Integrity

69, 73–74, 77–78

New suppliers that were screened using social criteria

GRI 414-1

Focus on Integrity, ESG Appendix

69, 73–74, 77–78, 96

Management Approach: Public Policy

GRI 103-1, 103-2, 103-3

Focus on Integrity, ESG Appendix

69, 80, 97

Political contributions

GRI 415-1

Focus on Integrity, ESG Appendix

69, 80, 97

Management Approach: Customer Privacy

GRI 103-1, 103-2, 103-3

Focus on Integrity

69, 75–76

Substantiated complaints concerning breaches of customer privacy and losses ofcustomer data

GRI 418-1

Focus on Integrity, ESG Appendix

69, 75–76, 96

SOCIAL: Disclosure 400
Human Rights

Local Communities

Supplier Social Criteria Screening

Public Policy

Customer Privacy

103

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

104

SASB Index
The Sustainability Accounting Standards Board (SASB) is an independent standards-setting organization that promotes disclosure of material sustainability information to meet investor needs. Illumina
is reporting to the SASB Standards for the first time in 2021 based on our 2020 reporting data. Illumina is classified officially in the Health Care Sector and Medical Equipment & Supply Industry.
In addition to the recommended disclosure topics for our assigned industry, we have identified supplemental sections that we feel closely align with our business. Therefore, we have chosen to add
relevant sections from the industry category of Biotechnology & Pharmaceuticals Industry as well as the Software & IT Services Industry to capture employee engagement and diversity topics.
We are committed to supporting improvements on the effectiveness and comparability of corporate disclosure on environmental, social, and governance (ESG) factors.
Dimension

General Issue Category

Disclosure Topic

Code

Accounting MetricResponse

Affordability and Pricing

HC-MS-240a.1

Ratio of weighted average rate of net price increases (for all products) to the annual
increase in the U.S. Consumer Price Index

Illumina’s annual price change1
was below the CPI.

Affordability and Pricing

HC-MS-240a.2

Description of how price information for each product is disclosed to customers or totheir agents

Focus on Integrity, 72

Product Safety

HC-MS-250a.1

Number of FDA recalls issued, total units recalled0

Product Safety

HC-MS-250a.2

List of products listed in the FDA’s MedWatch safety alerts for human medical
products database0

Product Safety

HC-MS-250a.3

Number of fatalities related to products as reported in the FDA Manufacturer andUser Facility Device Experience

0

Product Safety

HC-MS-250a.4

Number of FDA enforcement actions taken in response to violations of Current Good
Manufacturing Practices (cGMP), by type0

Ethical Marketing

HC-MS-270a.1

Total amount of monetary losses as a result of legal proceedings associated withfalse marketing claims

0

Ethical Marketing

HC-MS-270a.2

Description of code of ethics governing promotion of off-label use of products

Focus on Integrity, 72

Product Design &Lifecycle Management

HC-MS-410a.1

Discussion of process to assess and manage environmental and human healthconsiderations associated with chemicals in products, and meet demand forsustainable products

Focus on Environment, 45–47

Product Design &Lifecycle Management

HC-MS-410a.2

Total amount of products accepted for takeback and reused, recycled, or donated,broken down by: (1) devices and equipment and (2) supplies

Focus on Environment, 45–47

Supply Chain Management

HC-MS-430a.1

Percentage of (1) entity’s facilities and (2) Tier I suppliers’ facilities participating inthird-party audit programs for manufacturing and product quality

Focus on Integrity, 79

Supply Chain Management

HC-MS-430a.2

Description of efforts to maintain traceability within the distribution chain

Focus on Integrity, 77–79

Supply Chain Management

HC-MS-430a.3

Description of the management of risks associated with the use of critical materials

Focus on Integrity, 77–79

Business Ethics

HC-MS-510a.1

Total amount of monetary losses as a result of legal proceedings associated withbribery or corruption

Focus on Integrity, 77–79

Business Ethics

HC-MS-510a.2

Description of code of ethics governing interactions with health care professionals

Focus on Integrity, 72

PRIMARY SICS SECTOR: HEALTH CARE
Primary SICS Industry: Medical Equipment & Supplies
Social Capital

Access & Affordability

Product Quality & Safety

Selling Practices &Product Labeling

Illumina Code of Conduct
Business Model &Innovation

Product Design &Lifecycle Management

Focus on People, 64–66

Focus on People, 64–66
ESG Appendix, 87

Supply Chain Management

Leadership &GovernanceBusiness Ethics

ESG Appendix, 96
HCP Policy

Notes:
1	December 2019 to December 2020.

continued on next page

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

105

SASB Index continued
In addition to the recommended disclosure topics for our assigned industry, we have identified supplemental sections that we feel closely align with our business. Therefore, we have chosen to add
relevant sections from the industry category of Biotechnology & Pharmaceuticals Industry as well as the Software & IT Services Industry to capture employee engagement and diversity topics.
Dimension

General Issue Category

Disclosure Topic

Code

Accounting MetricResponse

Activity Metrics

HC-MS-000.A

Number of units sold by product category

ESG Appendix, 96

Employee Recruitment,
Development & Retention

HC-BP-330a.1

Discussion of talent recruitment and retention efforts for scientists and research anddevelopment personnel

Focus on People, 51–54, 61–62

Employee Recruitment,
Development & Retention

HC-BP-330a.2

1) Voluntary and 2) involuntary turnover rate for a) executive/senior managersb) mid-level managers c) professionals d) all others

ESG Appendix, 88–94

TC -SI-330a.3

Percentage of gender and racial/ethnic group representation for 1) management
2) technical staff 3) all other employees

ESG Appendix, 88–94

PRIMARY SICS SECTOR: HEALTH CARE
Other

Activity Metrics

Supplemental SICS Industry: Biotech & Pharma
Human Capital

Employee Engagement,
Diversity & Inclusion

Supplemental SICS Industry: Software & IT Services
Human Capital

Employee Engagement,
Diversity & Inclusion

Recruiting & Managing
a Global, Diverse &Skilled WorkforceIllumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Task Force on Climate-related Financial Disclosures (TCFD) Index
Illumina is committed to providing transparency on our climate change risk management. TCFD has created voluntary climate-related disclosures for use by companies to provide information to
stakeholders. We have used the TCFD recommendations to guide our reporting.
TCFD Disclosure Element

Topic

Description

Illumina CSR Report Section

Governance: Describe organization’s governance around climate-related risks and opportunities			
Governance

Board oversight

Describe Board’s oversight of climate-related risks and opportunities.

Focus on Illumina, TCFD Details

Management role

Describe management role in assessing and managing risks and opportunities.

Focus on Illumina, TCFD Details

Strategy: Disclose the actual and potential impacts of climate-related risks and opportunities on the organization’s businesses, strategy, and financial planning where such information is material. 		
Strategy

Climate risk and opportunities timeline

Describe the climate-related risks and opportunities the organization has identified overthe short, medium, and long term.

Focus on Environment, Focus on Integrity,

Climate risk and opportunities impact

Describe the impact of climate-related risks and opportunities on the organization’s
businesses, strategy, and financial planning.

Focus on Environment, Focus on Integrity,

Targets to manage climate risk and opportunities

Describe the resilience of the organization’s strategy, taking into consideration different
climate-related scenarios, including a 2°C or lower scenario.

Focus on Environment, Focus on Integrity,

TCFD Details
TCFD Details
TCFD Details

Risk Management: Disclose how the organization identifies, assesses, and manages climate-related risks.
Risk Management

Process to identify climate risk

Describe the organization’s processes for identifying and assessing climate-related risks.

Focus on Environment, Focus on Integrity,
TCFD Details

Process to manage climate risk

Describe the organization’s processes for managing climate-related risks.

Focus on Environment, Focus on Integrity,
TCFD Details

Process to integrate climate risk in overallrisk management

Describe how processes for identifying, assessing, and managing climate-related risks areintegrated into the organization’s overall risk management.

Focus on Environment, Focus on Integrity,
TCFD Details

Metrics & Targets: Disclose the metrics and targets used to assess and manage relevant climate-related risks and opportunities where such information is material.
Metrics & Targets

Climate-related metrics

Disclose the metrics used by the organization to assess climate-related risks andopportunities in line with its strategy and risk management process.

Focus on Environment, Focus on Integrity,

GHG emission data

Disclose Scope 1, Scope 2, and, if appropriate, Scope 3 greenhouse gas (GHG) emissions,and the related risks.

Focus on Environment, Focus on Integrity,

Describe the targets used by the organization to manage climate-related risks andopportunities and performance against targets.

Focus on Environment, Focus on Integrity,

Targets to manage climate risk and performance
to targets

ESG Appendix, TCFD Details
ESG Appendix, TCFD Details
ESG Appendix, TCFD Details

106Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

107

TCFD Index continued
At Illumina, we believe addressing climate change is one of the key topics to achieving asustainable, just, and resilient future for all.
To understand the potential risks and opportunities of climate change, we conducted anassessment using the recommendations of the Task Force on Climate-related Financial
Disclosures (TCFD).
We are committed to transparency and as our program evolves, we will continue to share
progress in our annual CSR Report and CDP submissions.
Governance
The Board of Directors (Board) provides oversight to the CSR program covering environmental,social, and governance (ESG) topics, including climate-related issues. The Board receives
updates at least annually on current performance and future strategic plans, with additional
updates provided if material changes occur.
The Illumina CEO is responsible for directing all aspects of company strategy, planning,and operations. Climate-related issues and projects associated with the reduction of ourenvironmental footprint are escalated to the Board through the Illumina CEO and their direct
reports. On at least an annual basis, updates on CSR, including climate-related topics, areprovided to the Board of Directors.
The Chief Financial Officer (CFO) chairs the Executive CSR Steering Committee, which
comprises a team of senior leaders drawn from across the organization, including the
Chief People Officer, Chief Medical Officer, Chief Marketing Officer, General Counsel,
Chief Product Officer, and SVP Operations. The CSR Executive Committee has overall
responsibility for reviewing company activities related to CSR, including climate change.

Strategy
Environmental sustainability was identified as one of our CSR core focus areas following our
first materiality assessment and stakeholder engagement exercises. With the publication of our
first CSR Report in April 2020, we announced our approach, focus, and targets. We establishedtargets in support of the science-based methodology to align with the Paris Agreement anda scenario of well below 2°C. Our first sustainability targets are centered around our facilities,
our supply chain, and our products. We plan to expand to include Scope 3 assessments in 2021.
We recognize that climate-related risks and opportunities span both physical risk (extreme
weather) and transition risks (energy pricing, customer expectations, regulations, andtechnology). The following types of risk were identified in line with TCFD terminology:
technology; market; reputation; acute physical; and chronic physical. Impact could be the resultof business interruption due to climate-related risk or business operational impact. Impact isassessed for financial, operational, and reputational risk.
The following definitions apply to our assessment:
Time Horizon: Short (0–5 years), Medium (5–8 years), Long (8–10 years)
Likelihood: Not likely, As likely as not, More likely than not, Likely, Virtually certain
Impact: Low (ability to absorb financial, operational, reputational impact), Moderate (someimpact to finances, operations, reputation), High (substantive financial, operational, strategic,
reputational impact. Substantive financial impact would likely require material financial
reporting disclosure)Time
Horizon

Risk

Description

Likelihood

Impact

The CSR functional group reports directly to the Chief Financial Officer (CFO), withresponsibility for program recommendations, management, reporting, and oversight onefforts to incorporate sustainability into our business practices.

Acute
PhysicalIncreased severity and frequency of
extreme weather

MediumMore likely
than notModerate

Increased severity and frequency of wildfires

MediumMore likely
than notModerate

CSR is increasingly embedded into all areas of our business, including several supporting
working groups with targeted focus such as: Diversity & Inclusion Steering Committee;
Environment, Health & Safety Steering Committee; Quality Council; Public Policy Committee;
Illumina Cares Champions; Sustainability Green Teams, and employee resource groups.

Chronic
PhysicalChanges in patterns for precipitation and extreme
variability in weather

Long

More likely
than notLow

Rising temperatures and sea levelsLong

Not likely

Moderate

Reputation

Increased stakeholder concern or negative
stakeholder feedback

MediumNot likely

Low

As we grow our CSR programming and the external sustainability landscape evolves, we will
re-assess the frequency of regular updates to the Board and the potential assignment ofresponsibility to a Board sub‑committee.

MarketCarbon or energy tax

MediumNot likely

Low

Supply chain raw material availability and costMediumNot likely

ModerateIllumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

108

TCFD Index continued

Opportunities

Description

Time
HorizonEnergySourceLower emission source of energy

Products &Services

Likelihood

Impact

Short

More likely
than notModerate

Development of new products or services throughR&D and innovation

MediumMore likely
than not

Low

Resource
Efficiency

More efficient buildings, processes, modesof transport

Short

More likely
than notLow

Markets

Access to new markets

MediumMore likely
than not

Low

Resilience

Participation in renewable energy programs andadoption of energy-efficiency measures

Short

More likely
than notModerate

Reputation

Consumer preferences

Short

As likely
as notLow

The climate change elements that have most influenced our strategy are physical risk tooperations, supply chain impact, and reputation. These risks have been incorporated intobusiness continuity planning, future product development, redundancy in supply chain where
possible, and site selection for future growth. We are actively reviewing opportunities to further
integrate climate into our processes and path to further expand resilience.
Examples of incorporation include: targets to align with the UN Sustainable Development
Goals and utilize the Science Based Targets initiative (SBTi) methodology for a well below
2°C scenario (2DS); holistic goals of reducing the environmental footprint of our products
throughout the life cycle; incorporation of Design for Environment into our new product design;
and addition of a new logistics location to our network on the east coast resulting in costsavings, improved supply chain planning, and a reduction of air emissions. We have implemented
redundant planning and maintained safety stock to provide resilience during severe weather
events. For financial planning, we include risk and opportunities evaluated through our standard
budget planning. Investment in energy-reduction projects that require capital expenditures areevaluated through the Capital Committee planning process. Potential indirect cost associatedwith supply chain, future tax, or increased operating costs from extreme weather would connect
with these internal workstreams.

Climate Scenario Analysis
In 2020, we engaged with BSR (Business for Social Responsibility) to develop three 2030
climate scenarios linked to global warming by 2100. Our goal was to better understand theimplications of climate change for our business and identify opportunities to build resilience.
Climate scenario analysis was completed using three plausible narrative future representationsof our operating environment respectively aligned to a well below 2°C, a 3°C , and a 4°C level ofwarming. To map assumptions for each trajectory, we utilized standardized third-party climate
modeling data, such as the Shared Socioeconomic Pathways (SSPs) and the Intergovernmental
Panel on Climate Change (IPCC) Representative Concentration Pathways (RCP).
Climate Trajectory

SSP Scenarios

RCP

Variables Assessed

4°C

SSP 3 – baseline

RCP 8.5

3°C

SSP 4-45

RCP 6.0

Well below 2°C

SSP 1-26

RCP 2.6

GHG emissions, energy consumption,
carbon price; physical impacts including
temperature change, drought likelihood,heat wave probability, and maximum
rainfall. Physical climate impact models
used The World Bank Climate Change
Knowledge Portal.

Under the 4°C scenario, global warming reaches 4°C by 2100, relative to pre-industrial
temperatures. In 2030, we assume a geopolitically fragmented world with limited flows of goods
or knowledge, and a challenging economic situation, worsened by disinformation and general
mistrust. Limited action on climate policy will be taken and a doubling down on fossil-basedenergy sources will result. More frequent climate-related weather events impact most regions
by 2030. This scenario utilizes data from RCP 8.5 and SSP 3 (high challenges to mitigation
and adaptation).
Under the 3°C scenario, we assume a world in 2030 facing a slow global economy withfraught geopolitical alliances. Accelerating automation with uneven benefits leads to a focus oninequality. Society is slow to react to climate impacts, distracted by larger economic concerns.
Carbon emissions have started to decline slightly: energy efficiency and renewable gains areeasily offset by increased use of energy-intensive tech. This scenario causes some physicalclimate impacts by 2030. This model utilizes data from RCP 6.0 and SSP 4 (low challenges tomitigation, high challenges to adaptation).
Under the well below 2°C scenario, we assume a world in which global cooperation leads toeconomic recovery that fully embraces the low-carbon transition, with strong climate policy andregulatory action. Some severe climate impacts felt spur coordinated risk-containment efforts.

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

109

TCFD Index continued
While some physical impacts are already locked in, the pace of change slows and by 2050 theworld is on a well below 2°C trajectory. This model utilizes data from RCP 2.6 and SSP 1 (lowchallenges to mitigation/adaptation).
The scenarios were reviewed in a cross-functional workshop that included key stakeholders
across various business units. The implications for each scenario were discussed andparticipants identified risk and opportunity hot spots to help direct further integration ofresilience planning and embed climate into our developing enterprise risk management program.
We will be utilizing the climate scenario insights to expand influence on our climate planning
evolution and business continuity plans.
Sample hot spots identified for further consideration included:
Hot Spot

Description

Supply Chain

Raw material availability, cold chain, and supplier community climate resilience

Physical Risks

Risk of acute and chronic physical risks to Illumina’s operations and employees

EnergyEnergy pricing and availability, renewables, customer expectations, and productenergy efficiency

New Products/
Markets

Opportunities generated by climate change in agriculture, human health, andclimate science

Geopolitical andTrade Dynamics

Availability of materials and feasibility of current operating model

Employee
Demographics

Changing workforce demographics and culture, including implications of remote work

Social License
to Operate

Perceptions of genomics, data privacy and security, and ethics of product use

Risk Management
To identify and manage climate-related issues we are integrating climate impact into ourexisting risk management structure using the Environment, Health & Safety team management
system, the CSR materiality assessment, business continuity program management, supply
chain risk reviews, and internal audit risk program. As our enterprise risk management program
evolves, we plan to integrate climate as a key component.
Metrics and Targets
In 2020, we announced our 2030 sustainability targets with a focus around energy, water,
and waste at our facilities. We created targets on engaging our strategic suppliers in our supply
chain, and incorporating Design for Environment into our products and packaging. In 2021,
we will assess our Scope 3 footprint and initiate planning for addressing our more holistic
environmental footprint.

Metrics

Targets

Next Steps

Embed green
design in new
construction projects

Achieve LEED certification elements orregional equivalentContinue reviewing opportunities to green
our current and new facilities

Reduce emissions

30% reduction in portfolio level Scope 1
and 2 by 2030

Add Scope 3 emission reduction targets

Increase
renewable use

50% increase from 2019 baseline by 2030

Continue to investigate renewable
opportunities for our sites and start toreview carbon offsets and/or PPA tocomplement energy conservation projects

Reducewater footprint

10% decrease at our main site locations
by 2030

Identify water conservation projects thatcan be initiated at main sites

Reduce waste

Achieve >90% landfill diversion at our
main site locations by 2030

Continue to seek opportunities to reduce
sources of waste, repurpose waste, andincrease recycling

Integrate Designfor Environment
principles in new
product design

All new product development includes
Design for Environment assessments

Identify product quantitative targets suchas energy optimization in sequencers,
plastic reduction, green chemistry, andcircular model options

Packaging reduction

By 2030, achieve a 75% reduction inpackaging; 50% recyclable primary
packaging; 90% recyclable or reusable
secondary and tertiary packaging; and90% reduction in use of dry ice

Measure Scope 3 emissions and create
targets for reduction

Magnify impact
with suppliers

100% of our strategic suppliers
have a commitment to reduce theirenvironmental footprint

Scope 3 assessment, supplier physicalrisk assessment on key raw materials,
develop climate indicators to embed in
procurement process and vendor selection

Additional details on current energy, water, and waste levels can be found in the performancesummary of this CSR Report, with additional impact stories in the sections on Focus on
Environment and Focus on Integrity.
Results
The results of our scenario analysis and review of the TCFD recommendations indicate there aresome risks and opportunities in each scenario path. While we are confident that our businessmodel is resilient and will continue on our growth trajectory, it is clear that we will need tocontinue to work to enable the realization of a world with a temperature rise of well below 2°C.
We are currently evaluating how the results of this predictive analysis can best support inclusionof climate-related scenario analysis in business strategy development going forward. We arecommitted to investing to support a more sustainable future and will continue to evaluate risk
and opportunities as external conditions evolve.

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

110

UNGC Communication on Progress
Illumina has been a member of the United Nations Global Compact (UNGC) since December 2019. We
remain committed to aligning our business practices to the 10 UNGC principles in the areas of humanrights, labor, environment, and anti-corruption. This report serves as our annual UNGC Communication on
Progress. The table below shows the reference location of our disclosures against each UNGC Principle.
January 11, 2021
UN Global Compact Communication on Progress
United Nations Global Compact Support
Secretary-General
United Nations
New York, NY 10017
USA
Dear Mr. Secretary-General,
Illumina, Inc. is proud to be a member of the Global Compact. I am pleased tore-confirm our support of and continued commitment to the Ten Principles of
the United Nations Global Compact. In this, our first annual Communication
on Progress, we describe our actions to integrate the Global Compact and its
principles into our business strategy, culture, and daily operations. We are also
committed to share this information with our stakeholders using our annual
Corporate Social Responsibility report available on our website.
My signature below affirms our company’s ongoing commitment and our intent tosupport and advance the Compact’s ten universally accepted principles in the areasof human rights, labor, environment, and anti-corruption. We are committed tosupport of achieving the United Nations Sustainable Development Goals.

Principle

Response/Illumina
CSR Report section

Cross Reference Applicable
GRI Section
GRI 102, 205, 401, 403, 405,
408, 409, 412, 413, 414

Human Rights			
1

Businesses should support and respect
the protection of internationallyproclaimed human rights.

Focus on Integrity

2

Businesses should make sure thatthey are not complicit in humanrights abuses.

Focus on Integrity

3

Businesses should uphold thefreedom of association and theeffective recognition of the right tocollective bargaining.

Focus on Integrity

4

Businesses should uphold theelimination of all forms of forced andcompulsory labour.

Focus on Integrity

5

Businesses should uphold the effective
abolition of child labour.

Focus on Integrity

6

Businesses should uphold theelimination of discrimination in respectof employment and occupation.

Focus on Integrity

Businesses should support
a precautionary approach toenvironmental challenges.

Focus on Environment

8

Businesses should undertake
initiatives to promote greater
environmental responsibility.

Focus on Environment

9

Businesses should encourage
the development and diffusion ofenvironmentally friendly technologies.

Focus on Environment

Labour		

Sincerely yours,

GRI 401, 402, 405, 408, 409,
412, 414

Focus on People

Environment
7

Francis de Souza
Chief Executive Officer
Illumina, Inc.

GRI 302, 303, 305, 306, 308

Focus on People

Anti-Corruption			
Illumina • 5200 Illumina Way • San Diego, CA 92122 • Tel 858.202.4500 • Fax 858.202.4766 • www.illumina.com

10

Businesses should work against
corruption in all its forms, including
extortion and bribery.

Focus on Integrity

GRI 205, 206, 414, 415, 417

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

Index of CSR Goals and SDG Link
CSR Focus Area

Description

Accessto Genomics

Enable innovation and reduce the cost per genome, working toward$100 genome

SDG Link

CSR Focus Area

Description

Our People

Acquire and grow extraordinary talent and teams to create a deep anddiverse pipeline

Expand reach to >400 patients in 2021 for philanthropic cWGS
through iHope

Steward our employee safety and wellness
Maintain above 80% engagement index in iPulse employee surveys

Broaden genomic literacy with HCP and STEM education

Increase representation of women in senior leadership

Continue to support genomic startups with global expansionof Illumina for Startups and support for Illumina Ventures

Empower
Our Community

Increase representation of black, Latinx, and multi-racial workforce

Nurture the genomic ecosystem through collaborations, market accessefforts, and partnerships

Elevate racial and ethnic representation in senior leadership

Double participation in our STEM programs to reach 600,000
participants a year

Increase participation of veterans in our workforce

Drive meaningful employee engagement opportunities to support
a culture of community outreach with at least 50% employee
participation (giving + volunteer)

Maintain pay equity with zero net pay gap

Increase participation of disabled people in our workforce
Achieve a diverse intern cohort by gender, race, and ethnicity
Foster an environment where people feel Illumina is a great place towork for everyone

Support our CSR focus areas through philanthropic activities thatmagnify our impact, including partnering with nonprofits to address
unmet needs locally and globally

Embed diversity, inclusion, and fairness in all that we do
Offer employees the resources and support they need to bring theirpersonal best every day and reinforce our culture of careAchieve 90% positive survey rate on employees’ responses to Illumina
Cares programming and connection to our mission
Environmental
Sustainability

Increase prevention-based safety reporting and decrease injury andillness rates

Integration of green design principles in new construction projects
with LEED certification elements or regional equivalent

Maintain certification of ISO 14001 and 45001 at Singapore site andachieve conformance at all other manufacturing locations by endof 202130% reduction in Scope 1 and 2 carbon emissions
Increase renewable energy use by 50% from 2019 baseline
10% reduction in water footprint
Landfill diversion of 90% at each main site
Integration of green principles associated with Design for Environment
in new products
Optimize sequencer power consumption and processing efficiency
Reduce plastic associated with productReplace use of chemicals of concern wherever possible withgreener alternatives
75% reduction in packaging
50% recyclable primary packaging
90% recyclable or reusable secondary and tertiary packaging
90% reduction in use of dry ice
Notes:• Unless otherwise specified, targets are linked to 2030 timeline.

Our Integrity

Maintain a corporate governance framework to promote ethics andintegrity in all we doContinue working to ensure human rights are respected in our
workplace, our supply chain, and the marketplace
Demonstrate responsible data stewardship with strong privacy andcybersecurity practices

SDG Link

111

Illumina

Patient

Community

Environment

PeopleIntegrity

ESG Appendix

Illumina Corporate Social Responsibility Report 2021

112

Independent Limited Assurance Reportto Illumina, Inc.
We engaged a third-party organization,
ISOS Group, Inc., to provide limited assurance
engagement in accordance with ISAE 3000
and ISAE 3410 on our energy usage and GHG
emission data.
Background and introduction
ISOS Group, Inc. (“ISOS” or “we”) were
engaged by Illumina, Inc. (“Illumina” or“Company”) to undertake a limited assurance
engagement in accordance with ISAE 3000
and ISAE 3410 to report the energy usage andgreenhouse gas (“GHG”) emissions of Illumina
for the period beginning January 1, 2020 andending December 31, 2020 (“FY20”).
We have performed our limited assurance
engagement in accordance with theInternational Standard on Assurance
Engagements 3000 (ISAE 3000), Assurance
other than Audits or Reviews of Historical
Financial Information, as well as theInternational Standard on Assurance
Engagements 3410 (ISAE 3410) Assurance
Engagements on Greenhouse Gas Statements,
issued by the International Auditing andAssurance Standards Board. The engagement
covered all entities and all facilities under theoperational control of Illumina.
Our review was limited to the data reported
in the Key Performance Indicator Summary(pages 85–86) (“Summary”):• Energy Consumption (Units: Gigajoules)• Emission (Units: Metric Tons CO2e)• Consumption by Activity (Units: Gigajoules)• Regional Data (Units: Metric Tons CO2e)• Greenhouse Gas Breakdown (Units:
Metric Tons CO2e)• Country-Specific Scope 1 (Units:
Metric Tons CO2e)• Country-Specific Scope 2 (Units:
Metric Tons CO2e)
Several smaller Scope 1 GHG emission
sources (i.e., refrigerant releases, mobile
combustion sources, emergency generators)
and Scope 3 GHG emissions have been
excluded from this review. We have not
performed any procedures with respect toother information included in the Illumina
2021 Corporate Responsibility Report and,
therefore, no conclusion on the Report as awhole is expressed.
Illumina’s responsibilities
The Company’s management are
responsible for:• Preparing the Summary in accordance with
the World Resources Institute’s Greenhouse
Gas Protocol• The accuracy and completeness of theinformation contained in the Summary• The design, implementation andmaintenance of internal controls relevantto the preparation of the report to provide
reasonable assurance that the report is freefrom material misstatement, whether due tofraud or error• Ensuring the performance summary is fairly
stated in accordance with the applicable
criteria and for the content and statements
contained therein.

Inherent uncertainty
ISAE 3410 recognizes that greenhousegas quantification process can rarely be
100 percent accurate due to:• Scientific uncertainty, arising fromincomplete scientific knowledge about
the measurement of the gases• Measurement uncertainty, arising fromlimitations in measurement techniques andthe use of estimations.
Where significant assumptions or deductions
are utilized, they are disclosed.

To provide a consistent basis formeasurement and reporting the Company
utilizes a third-party data management
system. Where direct data was unavailable,
the company used industry standards asestimates. The assurance provided therefore
does not guarantee or provide certainty overthe completeness of reported data.
The emissions have been impacted bychanges in working practices as a resultof COVID-19 restrictions, but this has notchanged the basis of reporting or restricted
our ability to undertake testing.
continued on next page

Illumina

Patient

Community

Environment

PeopleIntegrity

Criteria
The greenhouse gas data was preparedin accordance with the Greenhouse Gas
Protocol, a Corporate Accounting andReporting Standard (revised edition,2004). The testing conducted at company
facilities across 12 countries in scope of thereporting varied based upon the proportionof energy consumption and corresponding
emissions relating to Scope 1 and 2. Testing
focused on two facilities which accounted
for a significant proportion of the Illuminaenergy consumption and emissions andwere individually material. The two material
facilities were in the United States andSingapore. Other facilities were tested
only when there was potential for errors
to accumulate to material amounts.

Work performed
The procedures we performed were based on
our professional judgment. We:

Our responsibility
Our responsibility is to express a limited
assurance conclusion in accordance with
ISAE 3000 and ISAE 3410 and to provide thisin a report to Illumina. In providing this limited
assurance report, it is important to notethat the procedures performed in a limited
assurance engagement vary in nature from,and are less in extent than for, a reasonableassurance engagement. As a result, the levelof assurance obtained in a limited assurance
engagement is substantially lower than theassurance that would have been obtained
had a reasonable assurance engagement
been performed.

• Tested a sample of records against
underlying records• Carried out interviews with key personnel
to understand the systems and controls inplace during the reporting period• Assessed the systems, processes, andcontrols to collate, aggregate, validate andreport the data
• Checked the relevant conversion factors
and GHG emission calculations• Reviewed any matters showing significant
variations from prior years• Reviewed the appropriateness of the GHG
emissions and other environmental data
provided by Illumina and their third-party
data management system service provider

The relative effectiveness and significanceof specific control procedures at Illumina
and their effect on assessment of control
risk at a facility level are dependent on theirinteraction with the controls and other factors
present at individual facilities. We havenot performed any procedures to evaluate
the effectiveness of controls at individual
facilities. We have not conducted any workoutside the agreed scope and therefore
restrict our conclusion to the abovementioned subject matter.

ESG Appendix

Inherent limitations
Given the characteristics of the subject
matter and the methods used for determining
such information, greenhouse gas emission
information is subject to inherent limitations.
The absence of a significant body ofestablished practice on which to draw allows
for the selection of different but acceptablemeasurement techniques which can resultin materially different measurements andcan impact accuracy and comparability.
Greenhouse gas quantification is unavoidably
subject to inherent uncertainty because of bothscientific and estimation uncertainty and forother non-financial performance information the
precision of different measurement techniques
may also vary. Furthermore, the nature andmethods used to determine such information,
as well as the measurement criteria and theprecision thereof, may change over time.
Restriction of use
This assurance report is made solely to
Illumina in accordance with the terms of
our engagement, which include agreed
arrangements for disclosure. Our work has
been undertaken so that we might state to
Illumina those matters we have been engaged
to state in this limited assurance report andfor no other purpose. Our limited assurance
report should not be regarded as suitable tobe used or relied on by any party wishing toacquire rights against us other than Illumina
for any purpose or in any context. Any party
other than Illumina who obtains accessto our limited assurance report or a copy

Illumina Corporate Social Responsibility Report 2021

113

thereof and chooses to rely on our limited
assurance report (or any part thereof) will
do so at its own risk. To the fullest extent
permitted by law, we accept or assume no
responsibility and deny any liability to any
party other than Illumina for our work, for thisindependent limited assurance report, or forthe conclusions we have reached.
Other matter
The data reviewed in the Illumina Summary
for FY20 was subject to the first year of
independent limited assurance. Comparative
figures are not in scope and are unaudited.
Conclusion
Based on the procedures we have performed
and the evidence we have obtained, nothing
has come to our attention that causes us
to believe that the “Energy Consumption,”“Emission,” “Consumption by Activity,”“Regional Data,” “Country-Specific Scope 1,”
and “Country-Specific Scope 2” data
noted in the Key Performance Indicator
Summary (pages 85–86) for FY20 ended on
December 31, 2020, has not been prepared,in all material respects, in accordance with
Illumina’s reporting methodologies.

Brian Noveck
CSAP Practitioner for, and on behalf of,
ISOS Group, Inc.
29 March 2021

Disclosures
This report contains forward-looking statements thatinvolve risks and uncertainties, including our expectations
and beliefs regarding future conduct and growth of thebusiness and the markets in which we operate. Amongthe important factors that could cause actual results
to differ materially from those in any forward-looking
statements are: (i) changes in the rate of growth in themarkets we serve; (ii) the volume, timing, and mix ofcustomer orders among our products and services; (iii)
our ability to adjust our operating expenses to align with
our revenue expectations; (iv) our ability to manufacturerobust instrumentation and consumables; (v) the successof products and services competitive with our own;(vi) challenges inherent in developing, manufacturing,and launching new products and services, including
expanding or modifying manufacturing operations andreliance on third-party suppliers for critical components;(vii) the impact of recently launched or pre-announced
products and services on existing products and services;(viii) our ability to further develop and commercialize our
instruments and consumables, to deploy new products,
services, and applications, and to expand the markets
for our technology platforms; (ix) our ability to obtainregulatory clearance for our products from government
agencies; (x) our ability to successfully partner withother companies and organizations to develop new
products, expand markets, and grow our business; (xi)
our ability to successfully identify and integrate acquired
technologies, products, or businesses; and (xii) theapplication of generally accepted accounting principles,
which are highly complex and involve many subjective
assumptions, estimates, and judgments, together withother factors detailed in our filings with the Securities andExchange Commission, including our most recent filings
on Forms 10-K and 10-Q, or in information disclosed inpublic conference calls, the date and time of which arereleased beforehand. We undertake no obligation, and do
not intend, to update these forward-looking statements,
to review or confirm analysts’ expectations, or to provide
interim reports or updates on the progress of thecurrent quarter.

Stay up to date on recent news, stories,
and more by connecting with us.

+1.800.809.4566 toll-free (US)+1.858.202.4566 tel
www.illumina.com©2021 Illumina, Inc.
All rights reserved. All other names, logos, and othertrademarks are the property of their respective owners.

Photo Credit: Al Napp
Illumina Employee, Sr. IT Engineer, United Kingdom
Photo Location: Illumina Centre Building